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Abstract 
Haemoglobinopathies represent the commonest single gene defects in the world and are 
found at highest frequency in those countries where malaria is prevalent.  It is now 
recognised that due to the effect of migration they are not confined to specific 
geographical locations but occur at high frequency in local populations throughout many 
parts of the world. Although the haemoglobinopathies are highly heterogeneous at the 
molecular level with more than 1000 mutant alleles described (Hb Variant database), 
within each ethnic population group common subsets of mutations are found, consisting of 
a high frequency of several common mutations with a smaller number of rare mutations. 
 
As part of the existing national Antenatal and Newborn Screening Programme, and in 
order to achieve a high mutation detection rate in the heterogeneous population of the 
North West of England (NW), and Greater Manchester in particular, a comprehensive 
suite of genetic diagnostic methodologies were developed to detect the wide spectrum of 
mutational defects associated with the Haemoglobinopathy disorders. 
 
Between July 2008 and December 2011 a total of 328 referrals from the NW were 
genotyped at Manchester Royal Infirmary. The total number of haemoglobinopathy 
diagnoses comprised of: 34% (n=113) alpha thalassaemia, 33% (n=109) beta 
thalassaemia, 17% (n=55) were compound heterozygous for an alpha and beta 
thalassaemia mutation and/or variants and 3% (n=10) of patients had a mutation resulting 
in HPFH or δβ thalassaemia. In the remaining 13% (n=41) of referrals either no causative 
mutation was detected or the genotype detected was not enough on its own to account for 
the patients‟ phenotype. 
 
A broad spectrum of mutations were detected within our referral population by DNA 
sequencing, resulting in a wide range of genetic interactions between different alpha and 
beta thalassaemia associated alleles, reflecting the complex molecular heterogeneity of 
these disorders. This indicates that a comprehensive mutational screening approach, using 
multiplex Gap-PCR, DNA sequencing and MLPA is appropriate to detect the mutation 
spectrum found within the heterogeneous populations of the North-West of England, or in 
any other ethnically diverse populations. 
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Chapter 1: Introduction 
 
1.1 Haemoglobin 
Haemoglobin (Hb) is a protein that is contained within all red blood cells (RBC) of the 
human body. Its main function is the transportation of oxygen (O2) from the lungs to the 
body tissues and it also helps to maintain the shape of the red blood cells, it is therefore 
essential for life.  
 
The structure of the haemoglobin molecule was first described by Max F. Perutz in 1959, 
it is a tetramer consisting of four polypeptide (globin) chains which are found in pairs; two 
141 amino acids long alpha globin chains (α1, α2), and two 146 amino acids long beta 
globin (β1, β2) chains (Steinberg, M et al 2009). 
 
 
Figure 1.1: Quaternary structure of the haemoglobin A molecule  
 
The four globin chains have a similar secondary and tertiary structure as they can each be 
divided into eight helical segments, designated A to H which then fold up and are held 
together by salt bridges and hydrogen bonds to form the precise three-dimensional 
spherical structure of the haemoglobin molecule which contains four binding sites or 
surface heme pockets to which up to a total of four oxygen molecules can bind. These 
heme groups are held between helices E and F, and contain an iron (Fe) atom and a 
porphyrin ring (comprised of carbon, hydrogen and nitrogen). Subsequent binding or 
Heme group 
containing 
an iron atom  
β1 
A 
E 
B 
F 
H 
G 
C 
D 
β2 
α2 α1 
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unloading of O2 to each of these four iron atoms alters the quaternary structure of the 
haemoglobin molecule so that when it is in the deoxygenated state (deoxyhaemoglobin) 
and no O2 is bound, the Fe atom exists in the ferrous form (Fe2
+
)  and is found out of the 
plane of the porphyrin ring of heme, whereas in the oxygenated state (oxyhaemoglobin) 
the iron becomes oxidised by the binding of O2 and is converted to the ferric form (Fe3
+
) 
causing it to move into the plane of the porphyrin ring. 
 
Additionally the haemoglobin molecule is responsible for the transportation of up to 10% 
of carbon dioxide (CO2) from the respiring tissues to the lungs, so it can be expired (Bain, 
B: 2006). Unlike oxygen, carbon dioxide directly binds to the amino group of the 
polypeptide chains of haemoglobin to form carbaminohaemoglobin. In the deoxygentated 
state the haemoglobin molecule has a higher affinity for CO2 unlike oxyhaemoglobin 
which has a higher affinity for O2, facilitating the loading and unloading of respiratory 
gases in the lungs and tissues, forming an efficient gaseous exchange system. 
 
The haemoglobin molecule is an allosteric protein that has more than one shape and as 
mentioned above, is capable of conformatory changes in its quaternary structure by the 
interaction between the four globin chains and the heme groups allowing the haemoglobin 
molecule to reversibly load and unload oxygen and carbon dioxide molecules. The 
haemoglobin molecule is designed to switch between two alternative structures by 
structural rotations of the bonds in the side chains between the alpha and beta polypeptides 
in the F-helix; the deoxy or „tense‟ (T) structure and the oxy or „relaxed‟ (R) causing the 
heme molecules to change their positions within the haemoglobin molecule therefore 
causing the heme molecule to change positions.  
 
The behaviour of the haemoglobin molecule is, to a certain extent, controlled by the partial 
pressures of respiratory gases found within the blood, thus the ability of the haemoglobin 
and deoxyghaemoglobin molecules to efficiently load and release the maximum amount of 
respiratory gases to and from the tissues can be explained by its cooperativity, i.e. its 
unique structure which is capable of transforming between the T and R structures in the 
presence or absence of oxygen.  In a high O2 pressure environment such as the lungs, the 
oxygen binds to deoxyhaemoglobin in the T structure and causes a rotation of the two 
pairs of polypeptides causing the Fe ions to shift out of the plane of the porphyrin ring and 
rendering them more accessible to oxygen binding which then transforms the oxygenated 
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haemoglobin to the R state, which has a higher affinity for oxygen and continues to 
increase as each successive molecule of oxygen binds. 
 
Conversely, the transformation from the R to the T structure, which happens under 
conditions of low oxygen pressure such as that found in the tissues, results in the O2 being 
released and causes the polypeptides to rotate back and shift the iron atoms so that they 
become less accessible to oxygen binding, this structural change prevents the irreversible 
binding of oxygen by allowing the iron atom to form loose bonds, allowing it to be readily 
released it into the tissues without it becoming permanently oxidised. 
 
The strength by which haemoglobin binds to oxygen is affected by several factors and the 
haemoglobin molecule is capable of adapting its role of delivery of respiratory gases in 
response to changes in various physiological conditions, for example ensuring enhanced 
oxygen delivery to tissues under anaerobic conditions such as hypoxia, fever or as a result 
of an increase in metabolic rate by bought about by exercising muscle. The change in 
cooperativity of the globin chains makes it possible for the haemoglobin to alter its affinity 
for oxygen. Some physiological factors cause a shift in the oxyhaemoglobin dissociation 
curve to the right, for example a reduction in the pH of the blood caused by increased 
levels of CO2 production from respiring tissues causes the haemoglobin molecule to 
interact with 2,3-diphosphoglycerate (2,3-DPG) which subsequently enhances O2 delivery 
by favouring unloading of oxygen. The converse is true in conditions where the pH level 
is raised such as the lungs in which the haemoglobin molecule has an increased affinity for 
oxygen, therefore shifting the oxygen dissociation curve to the left. 
 
1.2 Developmental regulation of haemoglobin synthesis 
At the molecular level, haemoglobin synthesis is controlled by two multigene clusters on 
chromosome 16 and chromosome 11, from which a series of structurally distinct globin 
chains are synthesised at different rates throughout embryonic, fetal and adult life during 
normal developmental regulation. The genes are arranged on chromosome 11 and 16 in 
the order in which they are expressed during this development: 
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Figure 1.2: Location of the alpha and beta gene clusters. 
(Derived from: http://www.ncbi.nlm.nih.gov/books/NBK10023/). 
 
Figure 1.2 shows the alpha (α) gene cluster located on chromosome 16, made up of one 
embryonic δ-globin and two highly homologous α-globin genes (in cis) 5‟-δ2- α2- α1-3‟. 
The beta (β) gene cluster is located on chromosome 11, and is made up of 5‟-ε-Gγ- Aγ-δ-β-
3‟. Therefore the genotypes αα/αα and β/β would be designated for a normal adult alpha 
and beta chain synthesis, respectively. 
 
During the transition between fetal development, the neonatal period and beyond, different 
globin chains are synthesised and subsequently different haemoglobin tetramers are 
formed. These different types of haemoglobins found in the red cells at these different 
stages reflect the different sites at which erythropoiesis occurs; in the early embryonic 
stage (3-4 weeks gestation) erythropoiesis first occurs in the yolk sac, where specific 
Gower (δ2ε2) (α2ε2) and Portland (δ2γ2) haemoglobins are synthesised. From 10-12 weeks 
gestation the liver and spleen take over as synthesis sites for a large proportion of fetal or 
haemoglobin F (α2γ2) and a small proportion of adult or haemoglobin A (α2β2), then later 
in fetal life and from birth into adulthood the bone marrow is the main site for 
erythropoiesis in which the predominant adult haemoglobin, haemoglobin A is synthesised 
together with a small portion of the minor haemoglobin, haemoglobin A2 (α2δ2). 
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The developmental synthesis of different haemoglobin types between embryonic, fetal and 
adult life reflects the need for sufficient oxygen delivery from the mother to the fetus 
across the placental barrier, therefore embryonic and fetal haemoglobins tend to have a 
higher oxygen affinity than haemoglobin A. This regulatory expression of haemoglobins 
helps to explain why genetic abnormalities affecting the alpha chains present clinically in 
early fetal life, whereas abnormalities associated with the beta chain do not present until 
later in life and can often be difficult to diagnose in the early neonatal period because it is 
difficult to obtain a reliable quantification of HbA2 (See Section 1.4.2.) (Bain, B: 2006, 
Steinberg, M et al: 2009, Ryan, K et al 2010). 
 
1.3 Haemoglobinopathies 
This inherited group of haemoglobin disorders result from a quantitative reduction in the 
rate of synthesis or absence of constituent globin chains (alpha or beta thalassaemia) or a 
qualitative structural change of one or more of the globin chains that combine to form 
haemoglobin resulting in a variant haemoglobin (haemoglobinopathy). 
Haemoglobinopathy disorders represent the commonest single gene defect in the world 
(Henderson, S et al: 2009, Bain, B: 2006, Clarke, B,E and Thein, S.L: 2004) with the 
World Health Organisation (WHO) estimating that approximately 7% of the world 
population are carriers of these disorders.  
The thalassaemia syndromes were initially thought to be limited to the Mediterranean and 
South East Asian regions as the first clinical description was by Thomas B. Cooley in 
1925 in infants living in the Mediterranean, but as the number of cases reported across the 
world increased it became evident that these thalassaemic disorders are were not confined 
to a specific geographical location and they now occur widely at high frequency 
throughout many parts of the world including many areas of Europe such as Italy, Spain, 
Greece and Portugal and also affect individuals within Middle Eastern areas such as Iran 
and Pakistan as well as those populations in southern China, Thailand, Malaysia and 
Indonesia.  They are also the commonest inherited haemoglobin disorders on the Indian 
subcontinent (Weatherall, D.J and Clegg, J.B: 2001). The high prevalence of these 
disorders in some geographical locations reflects the protection these disorders offer 
against P.falciparum malaria (Weatherall, D.J and Clegg, J.B: 2001 and Bain, B:2006), for 
example in Africa where malaria is endemic, up to one-quarter of individuals are 
heterozygous for the alpha plus thalassaemia 3.7kb deletion (Bain, B.2006) and sickle cell 
anaemia is rife. Other factors that contribute to the high frequency and heterogeneity of 
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these disorders worldwide include general population growth, consanguinity which is 
common in those regions where thalassaemia is prevalent (Weatherall, D.J: 2011: BSH) 
and increasing population migration and inter-racial marriages. 
 
 
Figure 1.3: Global distribution of haemoglobin disorders (based on the number of 
births of affected infants per 1000 births).  
(Source: http://www.who.int/genomics/public/Maphaemoglobin.pdf) 
 
The incidence at which the two subgroups of thalassaemia (alpha and beta) occur differ 
within discrete geographical clusters around the world; alpha thalassaemia is found at 
highest prevalence in African, Southeast Asian and Chinese populations and it rarely 
occurs in British Caucasian populations, whereas beta thalassaemia occurs mainly within 
the Mediterranean, Greece and Turkey as well as Italy and the Indian and African 
subcontinents, and throughout the Middle East. 
 
The haemoglobin disorders present with a broad spectrum of clinical symptoms with 
varying clinical effects which is governed by which of the globin chain(s) are involved, 
but many have major implications for those individuals and families that are affected. 
Different interactions of these genetic disorders can result in death in utero if there is a 
complete abolition of alpha-globin chain synthesis, or severe transfusion dependant 
haemolytic anaemia if there is a complete absence of beta-globin chain synthesis. This 
imbalance of globin chain synthesis caused by the thalassaemia syndromes contributes via 
ineffective erythropoiesis to a range of pathological effects including haemolytic anaemia 
with excess, unpaired globin chains precipitating in red cell precursors in the marrow 
(Bain, B. 2006). 
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The impact of human immigration across the world has led to a major increase in the 
heterogeneity of these disorders by distributing these alleles outside of the tropical belt and 
throughout the world (Weatherall, D: 2011). Haemoglobinopathy disorders are common 
now in the United Kingdom (U.K) and constitute a significant public health problem and 
present a diagnostic challenge for healthcare professionals. To date more than 1,000 
haemoglobin disorders have been reported (NHS Sickle Cell and Thalassaemia Screening 
Programme: 2009, Old, J.M: 2003), but only a small proportion of these disorders result in 
a severe disease phenotype and it is only clinical relevant to detect those disorders as 
identified by the Antenatal screening programme in which Prenatal diagnosis (PND) may 
be indicated and the offer of termination of pregnancy, where appropriate. For example, 
haemoglobin Bart‟s hydrops fetalis syndrome which is incompatible with fetal life and can 
result in further obstetric complications for the mother. 
  
1.4 Classification of haemoglobinopathies  
As discussed in section 1.3, the genetic disorders of haemoglobin are divided into those in 
which there is either a reduction in the rate of synthesis or absence of constituent globin 
chains (Thalassaemia) or those in which there is a structural change in the α or non α 
globin chains that combine to form a variant haemoglobin (Haemoglobinopathy). 
Thalassaemia syndromes can be further sub-classified based on the gene involved i.e. 
alpha (α) or beta (β) thalassaemia and on their severity i.e. how much the causative 
mutation down regulates the amount of protein produced. Alpha or beta plus (α+, β+) 
indicates there is some functional globin protein produced whereas alpha or beta zero (αo, 
βo) indicates that no respective globin protein is produced. 
 
1.4.1 Alpha thalassaemia 
Alpha thalassaemia results in a reduced rate of synthesis of alpha globin chains and is 
associated with anaemia with a variable degree of microcytosis and hypochromia. The 
normal complement of alpha-globin genes is four (αα/αα) as two alpha genes are inherited 
on each chromosome 16, therefore this disorder can be classified according to the number 
of alpha globin genes that are missing or inactive which also dictates the clinically severity 
of the condition, which can vary from an asymptomatic clinical picture in which one alpha 
gene is removed or inactivated to a lethal haemolytic anaemia where all four alpha gene 
are affected (Harteveld, C.L and Higgs, D.R: 2010). 
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Loss or inactivation of one alpha globin gene (-α/αα) often results in a „silent‟ 
asymptomatic carrier status therefore individuals with this genotype may present with a 
completely normal red blood cell indices on a Full Blood Count (FBC). Loss of two alpha 
globin genes from either the same chromosome 16, in cis (αα/--) or one from each 
chromosome, in trans (-α/-α) causes a mild to moderate microcytic anaemia. Loss of three 
genes (-α/αα) results in Haemoglobin H disease, which is associated with marked 
haemolytic anaemia caused by the excess of unpaired β-chains, that combine to form 
abnormal haemoglobin tetramers of Hb H (β4) in adult life or Hb Barts (γ4) in fetal life. 
Hb H disease is a clinical syndrome which is associated with a very variable phenotype, 
depending on the underlying genetic lesion, the most common genotype being compound 
heterozygosity for deletional α+ and α0 thalassaemia. Loss of all four genes (--/--), in 
which there is a complete absence of functional alpha-globin chains is incompatible with 
life and leads to intrauterine death as synthesis of haemoglobins F, A or A2 cannot occur, 
the clinical syndrome is called haemoglobin Barts hydrops fetalis (Bain, B: 2006 and 
Weatherall, D: 2001) in which the only haemoglobin present is haemoglobin Barts. 
 
Alpha thalassaemia is predominately caused by large deletions in one or both of the alpha 
genes (HBA1 and HBA2) on the chromosome, in which more 95% of recognised cases are 
caused by a deletion (Chong, S et al: 2000). Alpha zero thalassaemia is most commonly 
caused by large deletions that completely or partially remove both of the alpha globin 
genes. 
Figure 1.4 shows a diagrammatic representation of the extent of the five most common 
deletions (and the British deletion) along the alpha gene cluster that are associated with 
alpha zero thalassaemia, they are designated --SEA, --FIL, --THAI, --MED and -(α)20.5 
and –BRIT. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Extent of the deletions that cause α0 thalassaemia 
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The extent to which the above deletions span the alpha gene cluster vary, but they all 
remove or inactivate both of the alpha globin genes on one chromosome therefore no 
alpha globin chains are synthesised, with the larger deletions also removing the δ and ψ 
genes, therefore these genotypes are of major clinical significance as homozygotes or 
compound heterozygotes for these deletions will exhibit Hb Barts Hydrops Fetalis 
syndrome. 
 
Detection and quantification of the abnormal haemoglobins associated with alpha 
thalassaemia (Hb H and Hb Barts) by High Performance Chromatography (HPLC) can be 
helpful in predicting severe alpha thalassaemia genotypes in newborns, with a cut off of 
more than 25% Hb Barts being chosen by the Newborn Screening programme to highlight 
those babies at risk of developing Hb H disease (Sickle Cell and Thalassaemia Handbook 
for laboratories: http://sct.screening.nhs.uk/policy). 
 
Alpha plus thalassaemia is most commonly caused by the -α3.7 and –α4.2 deletions, in 
which 3.7 kb and 4.2 kb of genomic DNA respectively, are removed from within the alpha 
gene cluster (Embury, S.H et al: 1980 and Baysal, E and Huisman, T:1994). It is thought 
that these are a result of a recombination event that happens during meiosis causing 
unequal crossing over of genetic material, this happens because each of the alpha globin 
genes are located within a highly homologous 4 kb area. This can be further subdivided 
into three homologous subsegments on each alpha-globin gene which are designated X, Y 
and Z boxes. 
Rightward crossover (Z-box): 
 
 
 
 
 
 
Leftward crossover (X-box): 
 
 
 
 
 
 
 
Figure 1.5: Diagrammatic representation of the mutational mechanisms associated 
with the –α3.7 and –α4.2 deletions associated with α+ thalassaemia. (Derived from 
Harteveld, C.L. and Higgs, D.R: 2010). 
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The -α3.7 kb deletion is a caused by the unequal cross over between the mispaired Z-boxes 
(which are 3.7 kb apart) and results in a chromosome with only one functional alpha gene 
(rightward -α3.7 kb deletion) and a chromosome with three alpha genes (αααanti3.7 
triplication), causing α+ thalassaemia. 
 
Similarly, the –α4.2 kb deletion is caused by a non-reciprocal cross over event between the 
X-boxes (which are 4.2 kb apart) which also gives rise to a chromosome with only one 
functional alpha gene (leftward –α4.2 kb deletion) and a chromosome with three alpha 
genes (αααanti4.2 triplication), causing α+ thalassaemia. 
 
Because both these mutational mechanisms only remove all or part of the HBA2 gene it 
does not cause a clinically significant disorder, even when inherited in the homozygous 
state (-α/-α) it does not cause a severe disease phenotype, subsequently alpha plus 
thalassaemia presents no risk to the fetus and would therefore not warrant PND analysis 
(http://sct.screening.nhs.uk/policy).  
 
This cross-over event can also result in a duplication of an alpha globin gene, in which 
there may be three alpha genes on a single chromosome, known as triple alpha (ααα) 
(Trent, R.J et al: 1981 and Lie-Injo, L.E et al:1981), leading to an increased rate of 
synthesis of that globin chain. Duplication of this gene does not cause a significant clinical 
disorder and may actually normalise the globin chain imbalance when it co-exists with a 
deletion of an alpha globin chain in trans, the converse is true when the ααα genotype co-
exists with beta thalassaemia in which case it can aggravate the condition. 
 
Co-inheritance of deletional alpha thalassaemia with other genotypes can module the 
clinical severity of the phenotype, especially in the homozygous state, when found in 
combination with beta thalassaemia the globin chain imbalance is normalised therefore 
alleviating the clinical phenotype. However, this can pose a diagnostic challenge in 
identifying alpha thalassaemia trait because the red cell indices are „normalised‟ on a FBC, 
additionally in the compound heterozygote state with a beta chain variants such as Hb S or 
Hb E, it lessens proportion of the variant detected by phenotypic tests such as High 
Performance Liquid Chromatography. 
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Less commonly α+ thalassaemia can be caused by a non-deletional mutational mechanism, 
in which a single-point mutation affects either one of the alpha globin genes and is 
denoted (αT) (Weatherall, D.J and Clegg, J.B: 2001). In comparison with the deletional 
types this group of thalassaemias tend to have a more pronounced effect on the expression 
and synthesis of the alpha globin chains resulting in a more severe phenotype, this is partly 
because the majority of these point mutations tend to affect the alpha-2 gene which is 
responsible for about 70% of alpha chain production (Bain, B: 2006, Weatherall, D.J and 
Clegg, J.B: 2001, Aguilar-Martinez and Gulbis: 2010, Harteveld, C.L and Higgs, D.R: 
2010) and there is no compensatory increase in the expression of the alpha-1 gene, as there 
is in the deletional types. 
 
Non-deletional forms of alpha thalassaemia are considered to be of clinical significance as 
in the homozygous or compound heterozygous state with α0 thalassaemia they can cause 
particularly severe forms of Haemoglobin H disease or even Hb H hydrops fetalis 
syndrome (Viprakasit, V et al 2002). The mutational mechanism by which they affect the 
gene varies;  those that that commonly affect the polyadenylation signal such as the 
αPA6:A>G and αTSaudi mutations, reported within Saudi Arabian populations, cause an 
extension of the alpha globin gene transcripts and interestingly they have been reported to 
down regulate the synthesis of alpha chains on both of the alpha genes on the same 
chromosome (Weatherall, D.J and Clegg, J.B: 2001), whereas other mutations such as 
αIVS1(-5nt) and αIVS1-117(G>A), often found in Mediterranean and some Indian populations 
affect RNA splicing. Other non-deletional mutations cause alterations to the tertiary 
structure of the haemoglobin molecule and subsequently result in the formation of highly 
unstable haemoglobin variants, for example Hb Constant Spring (αCSα) (End, L.I et al: 
1973, Kan, Y.W et al: 1974), Hb Seal Rock (αSRα) and Hb Quong Sze (αQSα) which are 
reported at highest prevalence within the Middle East, Mediterranean, South East Asia, 
China and Cyprus can cause chronic haemolytic anaemia due to the secondary damage to 
the red cells caused by these unstable variants, which are often undetectable by HPLC. 
As outlined earlier in section 1.3, alpha thalassaemia is found at highest frequencies in all 
tropical and subtropical populations were malaria is prevalent (Harteveld, C.L and Higgs, 
D.R: 2010, Aguilar-Martinez, P and Gulbis, B.:2010) although the spectrum of α+ and α0 
thalassaemia mutations varies throughout the world. Alpha plus thalassaemia is found at 
highest prevalence in individuals from Africa, with a carrier frequency of between 10-30% 
(Ryan, K et al: 2010) but it is also found in other ethnic groups such as in South Asia, 
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Pakistan, India and some Middle Eastern populations such as Iran, Yemen and Kuwait. 
Alpha zero thalassaemia is most commonly found in those individuals indigenous to the 
South-Eastern areas of the world including China, Thailand, Malaysia and the Philippines 
and the Mediterranean regions such as Greece, Turkey and Cyprus (Bain, B: 2006), 
although at a much lower frequency. 
                 
Figure 1.6: Worldwide geographical distribution and frequency of alpha 
thalassaemia alleles (Derived from Weatherall, D.J: 2001). 
 
Traditionally the distribution of alpha thalassaemia is that as represented in Figure 1.6, 
with it rarely reported outside of African and South East Asian populations. Over the last 
few decades the effects of immigration (Henderson et al: 2009) has led to demographic 
changes therefore increasing the „incidence of alpha thalassaemia in Northern European 
countries, Northern America (Harteveld, C.L and Higgs, D.R: 2010) and other previously 
non-endemic areas, including the UK in which a number of cases of alpha zero 
thalassaemia, caused by the British deletion (--BRIT) have been reported in several 
families from Wigan (Eng: 2009, Higgs and Bowden: 2001, Higgs et al: 1985). Results 
from a study by Henderson et al (2009) highlights the complex ethnic diversity 
populations within the UK and the great molecular heterogeneity found; out of the total of 
67 known non-deletional α+ mutations described on the Hb Variant Database over 30 of 
these mutations have been identified within the UK population. The molecular 
heterogeneity of these disorders highlights the potential for interactions between the 
different alpha thalassaemia alleles. 
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1.4.2 Beta thalassaemia  
Beta thalassaemia results in a reduced rate of synthesis of beta globin chains and is also 
associated with a variable degree of microcytosis and hypochromia, resulting a reduction 
in the red cell indices and a characteristic increase in the haemoglobin HbA2 percentage.  
 
Unlike alpha thalassaemia, beta thalassaemia is most commonly caused by point 
mutations, small insertions or deletions within the beta globin gene (HBB) or its 
immediate flanking sequences, in which the underlying genetic lesion causes a reduction 
in the synthesis of beta globin chains which comprises adult haemoglobin. This leads to an 
excess of unpaired alpha-globin chains which then precipitate in the erythroblasts and 
mature red cells causing severe haemolysis, therefore the greater the excess of α-chains the 
more pronounced the anaemia. 
 
Beta thalassaemia often presents at around 6 months of age when the expression of the 
major adult haemoglobin profile develops and β-globin chain synthesis replaces γ-chain 
synthesis, although more severe haematological abnormalities can emerge as early as 3 
months of age (Weatherall, D and Clegg, J.B:2001). This group of haemoglobin disorders 
are extremely heterogeneous at the genetic level, with more than 200 causative mutations 
described in a wide range of ethnic groups (Weatherall, D.J and Clegg, J.B: 2001, Bain, B: 
2006). Beta thalassaemia can be subdivided into different categories based on the varying 
levels of Hb F and Hb A2, detected by HPLC and the severity of the clinical presentation. 
 
Normal or silent beta thalassaemia (β++), as the name suggests is a clinically silent 
haematological clinical condition which is often only identified in those individuals when 
it is co-inherited with a more severe beta thalassaemia allele. These milder phenotypes are 
often associated with mutations within the promoter regions of HBB for example -101 
(C>T), -92 (C>T) -88 (C>T) and -29 (A>G) mutations and are normally associated with 
normal red cell indices, normal HbA2 levels but are often associated with increased Hb F 
percentages of up to 4% (http://globin.bx.psu.edu/hbvar/). 
 
Beta plus (minor) thalassaemia (β+) is also considered to be a mild clinical condition as it 
does not result in significant haematological changes in the heterozygous state but 
nevertheless can cause a clinically significant disease in compound heterozygotes and 
homozygotes. Described beta plus mutations include IVS1-6 (T>C), CAP+1 (A>C) and 
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IVS 1-5 (G>A).  The resultant degree of globin chain imbalance is slightly more 
pronounced than in the above silent forms with a slight reduction in the red cell indices 
and the HbA2 levels are often elevated between 3.6 and 4.2% (Bain, B: 2006). 
 
Even though these milder forms of beta thalassaemia are not considered to be clinically 
significant they can be difficult to diagnose as the haemoglobin A2 and haemoglobin F 
levels are often borderline or even normal, additionally co-inheritance of either alpha zero 
or homozygous alpha plus thalassaemia can make it even more likely that the diagnosis of 
β-thalassaemia could be missed as this can result in normal red cell indices. 
 
Furthermore there is a subgroup of β+ thalassaemia conditions which are associated with a 
particularly severe clinical course, even in the heterozygous state. These are classified as 
severe β+ thalassaemia and are commonly associated with mutations within the 3‟ end of 
exon 2 or 3 of HBB and splice site junctions such as the IVS1-5 (G>C) and IVSII-654 
(C>T) (http://globin.bx.psu.edu/hbvar/) which give rise to elongated unstable β-globin 
chains that form inclusion bodies within the red cell precursors, subsequently shortening 
their survival. These mutations are associated with higher HbA2 levels of between 4 to 5% 
in heterozygotes which are comparable to those found in beta zero thalassaemia, discussed 
below.  Additionally, in contrast to the above mild recessive forms of the disease, these 
conditions are inherited in an autosomal dominant manner; therefore patients with 
dominant beta thalassaemia may require occasional blood transfusions. 
 
Beta zero (β0) thalassaemia trait, in contrast to β+ thalassaemia, is caused by a variety of 
mutational mechanisms for example Codon 30 (G>C), Codon 8/9 (+G) and Codon 39 
(C>T) that result in a significant reduction or even complete absence of beta globin chain 
synthesis which is evident by a marked microcytosis, hypochromia and raised 
haemoglobin A2 and F levels. Beta zero thalassaemia is important to identify as in the 
homozygous or compound heterozygous state it can result in beta thalassaemia major 
(β0β0), a clinical condition in which there is no Hb A (only haemoglobins F and A2 are 
present) as there is a complete absence of beta globin chain synthesis, resulting in a severe 
transfusion dependant haemolytic anaemia. 
 
Furthermore, beta thalassaemia can be further sub-classified to include those patients 
whose clinical phenotype presents in-between that of mild beta thalassaemia and the 
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transfusion dependent conditions; these are referred to as beta thalassaemia intermedia and 
often presents at a later age of between 6-7 years. There are a wide range of genotype 
combinations that can cause beta thalassaemia intermedia, including homozygosity for β+ 
thalassaemia (β+β+), compound heterozygosity for β+ and β0 thalassaemia (β+/β0) and 
homozygosity for severe β+ thalassaemia. The combinations in which these beta 
thalassaemia alleles are inherited dictates the clinical severity, for example, in the milder 
compound heterozygous states (β+β+) Hb A may still be detectable. This group of 
disorders also encompasses those cases in which the α/β globin chain imbalance in cases 
of beta thalassaemia is further aggravated by the co-inheritance of triplicated alpha 
thalassaemia (ααα) or ameliorated by the coinheritance of deletional alpha thalassaemia, 
particularly α0 thalassaemia. 
 
Rarer forms of beta zero thalassaemia are caused by deletional mutational mechanisms 
which remove the portions of the beta globin gene (HBB). A small number (n=14) of 
deletions affecting only HBB have been described (http://globin.bx.psu.edu/hbvar/) with 
the most commonly reported deletion being the 619 bp deletion which is isolated to 
mainly Indian and Pakistani populations, a study by Colah et al (2010) reported this 
deletion was the second common β-thalassaemia mutation found in Gujarat, India. Other 
deletional types, although are extremely rare are of phenotypic interest as they tend to be 
associated with unusually high levels of HbA2 of between 4.6% to 9% in heterozygotes 
(Weatherall, D.J and Clegg, J.B: 2001). 
 
It is evident that the beta thalassaemia disorders are highly heterogeneous at the molecular 
level and therefore often presentation with a wide range of clinical manifestations. The 
large spectrum of beta thalassaemia mutations reported and the diverse range of possible 
gene-gene interactions makes it challenging for clinicians to predict clinical severity, 
especially in those cases of beta thalassaemia intermedia, as the condition varies greatly in 
severity and the severity of the phenotype associated with a specific genotype is not 
always predictable (Bain, B: 2006, Ho et al: 1998). Furthermore the clinical severity of β-
thalassaemia is also influenced by other factors including those affecting the α- and γ-
globin gene expression (Ho et al: 1998) 
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Beta thalassaemia occurs in a wide range of ethnic groups and each population has its own 
range of mutations which usually account for most of the thalassaemia in that area, as 
shown in Figure 1.7 below: 
 
Figure 1.7: Worldwide geographical distribution of beta thalassaemia alleles. 
(Derived from Weatherall, D.J: 2001). 
 
The prevalence of beta thalassaemia is widespread throughout the Mediterranean regions, 
India, South-East Asia and African countries in which there are particular mutations 
clustered around specific geographical locations. The distribution map above shows that 
Africa has an extremely high prevalence of mild beta thalassaemia mutations in which the 
promoter gene mutations -29 (A>G) and -88 (C>T) account for over three quarters of the 
cases of beta thalassaemia (Weatherall, D.J and Clegg, J.B: 2001). β+ thalassaemia is 
reported at high prevalence amongst Turkish and Greek Cypriots in which the causative 
mutation is most commonly IVS1-110 (G>A), this is also commonly reported in the 
Middle East. The severe β+ mutation IVS1-5 (G>C) is most commonly found in the 
Mediterranean, Middle Eastern regions and also India and Sri Lanka (Fisher, C.A et al: 
2003, Colah, R et al: 2010) whereas in South East Asian regions the mutation IVS2-654 
(C>T) accounts for a large proportion of thalassaemia. In India most of the mutations 
causing β thalassaemia are β0 alleles such as codon 8/9 (+G), codon 41/42(-TTCT) and the 
619bp deletion, which accounts for 16% of the thalassaemia there (Weatherall, D.J and 
Clegg, J.B: 2001), whereas in Spain and Portugal the β0 mutation IVS1-1 (G>A) mutation 
is very common. 
 
As a result of recent migration, beta thalassaemia has become a genetically heterogeneous 
disorder, which is now prevalent worldwide. It is not uncommon to find these disorders in 
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other white populations living in Northern Europe and the UK (Hickman, M et al: 1998). 
A study by Henderson et al (2009) found that the UK had the largest number of different 
β-thalassaemia mutations (68) in comparison to other countries. Another study by Fisher et 
al (2003) further highlights the considerable heterogeneity of the beta thalassaemia 
disorders observed in Sri Lanka, even within populations who live in close proximity, 
which is caused by the migration of various ethnic groups to and from the island. A later 
study by Colah et al (2010) also revealed molecular heterogeneity in Indian sub-groups, in 
which there was a large number of rare mutations reported which may be a result of 
several invasions throughout history and migration of populations between countries due 
to commercial trading, leading to mixing of the gene pool. 
 
1.4.3 Hereditary Persistence of Fetal Haemoglobin disorders 
In adult life the proportion of haemoglobin F is usually very low (around less than 1% of 
the total haemoglobin) but this broad spectrum of disorders is used to describe those 
conditions in which there is a persistence of raised fetal haemoglobin beyond infancy and 
in adulthood and arises at around 6 months of age when the switch from fetal to adult 
haemoglobin normally occurs (Weatherall, D.J and Clegg, J.B: 2001, Bain, B: 2006). 
 
These disorders can be subdivided into Hereditary Persistence of Fetal Haemoglobin 
(HPFH) disorders and delta-beta (δβ) thalassaemia and Gamma delta beta thalassaemia 
(γδβ) all of which are caused by genetic defects within the β- and δ-gene clusters and are 
compensated by the up-regulation of γ-chain synthesis and consequently fetal 
haemoglobin, the degree to which depends on the underlying mutational mechanism, with 
the deletional forms being the most common. 
 
The HPFH disorders have been described in a variety of ethnic groups but are most 
commonly found in African, Mediterranean, Chinese and Indian populations and are 
relatively benign in the heterozygous state as they are associated with a balanced α/β chain 
synthesis ratio and normal HbA2 levels.  Even in the homozygous or compound 
heterozygous state with β-thalassaemia they result in a very mild clinical picture due to a 
compensatory increase in synthesis of the γ-chains in response to the deletion of the β-
gene on the affected chromosome, resulting in relatively high Hb F levels of between 15-
30%. Furthermore the high proportion of haemoglobin F associated with these disorders 
may help to alleviate the clinical severity of some beta haemoglobin variants if they are 
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co-inherited with deletional forms of HPFH, for example the symptoms of sickle cell 
anaemia may be alleviated to a very mild sickling disorder. 
 
In contrast, the δβ disorders are associated with a more severe clinical picture even though 
they are also a result of deletions of both the δ- and β-genes and Aγ gene in the γδβ 
disorders. They result in an imbalanced ratio of α/β globin synthesis and are associated 
with slightly lower elevated Hb F levels than HPFH disorders of between 5-15% and the 
phenotype often resembles that of beta thalassaemia trait, except the HbA2 percentage is 
often normal or decreased.  Therefore in the heterozygous state it may result in 
thalassaemia intermedia and thalassaemia major in the homozygous or compound 
heterozygous state. It is therefore clinically important to distinguish between these 
subgroups of disorders.  
 
Known non-deletional forms of HPFH are caused by point mutations and polymorphisms 
within the promoter regions of either the 
Gγ- or Aγ-genes and as in the deletional types, 
these mechanisms are associated with a persistently raised haemoglobin F level into 
adulthood, however in the non deletional types haemoglobin A and A2 continue to be 
synthesised at a reduced rate. The sites at which these polymorphisms and/or mutations 
are found within the two gamma gene loci (HBG2 and HBG1) may either alter the binding 
of regulatory factors that affect HBG expression or are in linkage disequilibrium with 
these functional sites (Akinsheye, I et al : 2011, Wilber, A et al: 2011). 
A further interesting group of non-deletional HPFH disorders which are caused by 
polymorphic changes within the regulatory sequences of the 
Gγ- or Aγ-genes have also 
been reported to further influence the percentage of haemoglobin F. A common sequence 
polymorphism known as the Xmn1 (C>T) restriction site polymorphism at position -158 
upstream of the 
Gγ gene has been reported to increase the synthesis of Hb F by a similar 
mechanism to that described above, although its exact mechanism is unclear. Evidence 
shows that it has the greatest effect on increasing the Hb F levels in those individuals 
whose genotypes cause erythropoietic stress, for example β-thalassaemia or sickle cell 
anaemia, but it has minimal effect in normal individuals, therefore the presence of this 
polymorphism is likely to have an indirect effect which is also related to the amount of Hb 
F produced by individual F cells (Sampietro, M et al: 1992). 
It has been recognised that the production of fetal haemoglobin in individuals may be 
linked to a large number of other gene variants that are in linkage disequilibrium and 
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affect the binding of transcription factors within the beta globin cluster, but there are also 
other genetic loci that have been reported outside of the β-globin gene cluster, that have 
been shown to influence the production of fetal haemoglobin, including sequence variants 
in the BCL11A gene, on chromosome 2, which encodes a repressor of γ-globin gene 
expression and is an important regulator of γ-globin gene silencing, additionally mutations 
in the erythroid-specific transcription factor, Kruppel-like factor (KLF1) and SOX-6 have 
shown to play a significant role in the fetal to adult haemoglobin switch, furthermore the 
two proteins SOX-6 and BCL11A have been reported to cooperate together to silence γ-
gene expression, and finally gene variants in the intergenic regions between the HBS1L 
and MYB genes on chromosome 6, further influences the expression of the γ-globin gene 
by the altered expression of the MYB gene (Donze, D et al:1995, Craig et al:1996, Thein, 
S.L et al:2007, Thein, S.L and Menzel, S: 2009, Galarneau G, et al: 2010, Akinsheye, I et 
al :2011, Wilber, A et al:2011). As a consequence the discovery of these variants has 
become a large area of research, mainly for the therapeutic purpose of ameliorating the 
clinical manifestations of certain thalassaemic conditions such as beta thalassaemia and 
sickle cell disease. 
 
1.4.4 Haemoglobin Variants (Haemoglobinopathies) 
In contrast to the thalassaemia conditions the haemoglobinopathies (or haemoglobin 
variants) are caused by a qualitative structural changes in either the alpha, beta, gamma or 
delta globin chains and are most commonly a result of a substitution of a single amino acid 
within the candidate gene, but rarer mutational mechanisms have also been reported 
including deletions, in which one or more amino acids are deleted, for example the beta 
chain variant Hb Leiden, fusion of haemoglobin chains or extensions of the amino acid 
chain. 
 
The normal complement of globin chains reflects the corresponding percentage at which a 
variant is found, for example a variant affecting the beta globin chain usually comprises 
around 12-40% of the total haemoglobin, whereas an alpha chain variant comprises up to 
25%, although the actual percentage at which the variant is detected can be altered by a 
variety of factors; if a variant haemoglobin is highly unstable it may be detected at a much 
lower percentage or may even go undetected if the variant is rapidly broken down. 
Additionally the co-inheritance of deletional alpha thalassaemia may proportionally reduce 
the percentage of a variant on the beta chain, conversely it would increase the percentage 
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of an alpha chain variant, for example Hb G Philadelphia (HBA2 or HBA1:c.207C>G or 
C>A) normally comprises between 20-25%, but in 80% of cases, this variant occurs with a 
chromosome that carries the 3.7 kb deletion (Bain, B: 2006) further increasing the 
proportion of the variant to 30-35% and even higher percentages of ~45% if co-inherited 
in trans. Furthermore the proportion of alpha chain variants may vary due to the 
differences in transcription rates between the alpha 1- and 2-globin genes with the alpha-2 
gene being responsible for a larger proportion of globin chain synthesis, therefore an alpha 
chain variant may actually comprise anywhere between 12.5% and 37.5% (Bain, B: 2006). 
To date there are over 1000 variant haemoglobins reported on the Hb variant database 
(http://globin.bx.psu.edu/hbvar/) the majority of which are rare or clinically benign as they 
present with normal red blood indices.  However some of the structural variants can result 
in a thalassaemic phenotype which is dependent on the underlying mutational mechanism 
often referred to as thalassaemic haemoglobinopathies which will be explored below. It is 
important to identify those clinically significant structural variants which occur at high 
frequencies in those areas where thalassaemia is also prevalent as their co-inheritance is 
relatively common since they often occur in the same population groups (Weatherall, D.J 
and Clegg, J.B: 2001) and result in a wide spectrum of disorders of varying clinical 
severity. 
 
The structural haemoglobin variants that cause thalassaemic phenotypes are often so 
unstable they are unable to form the normal tetramers of haemoglobin and subsequently 
cannot transport oxygen efficiently. (Bain, B: 2006, Steinberg, M et al: 2009, Steinberg, M 
and Adams: 1983). They are often caused by a genetic lesion within the intervening/splice 
site regions of the globin gene which is therefore likely to promote alternative splicing, for 
example the beta chain variant Hb E (HBB:c.79G>A) is considered a thalassaemic 
haemoglobinopathy as it creates an alternative splice site for messenger RNA (mRNA) 
which is 5' to the normal splice site at IVS-I.  Subsequently the aberrantly spliced mRNA 
is so unstable that the βE chain is synthesised at a lesser rate than Hb A and the variant 
haemoglobin comprises 25-30% in the heterozygote which is less than expected for a beta 
chain variant. The Hb E variant is associated with a β-thalassaemia phenotype, therefore, 
if co-inherited with another β-thalassaemia mutation it is likely to result in a severe form 
of thalassaemia intermedia or major. These conditions form one of the commonest severe 
forms of thalassaemia in South East Asia and India, but studies have highlighted the varied 
clinical expression associated with this variant as it tends to present with a diverse range of 
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clinical symptoms which can be attributable to the degree of globin chain imbalance 
(Tubsuwan, A et al: 2011). 
 
Other variants that result in a similar thalassaemic expression due to the production of 
aberrantly spliced mRNA can be found on the alpha globin genes, such as Hb Evanston 
(HBA2:c.43T>A) or (HBA1:c.43T>C and Hb Fort Worth (HBA2:c.83A>G (or HBA1), 
both of these variants are ineffectively synthesised and their instability may account for 
their low abundance which may give rise to an α+ phenotype with mild microcytosis and 
hypochromia. Other alpha chain haemoglobin variants such as Hb Suan Dok 
(HBA2:c.329T>G), Hb Quong Sze (HBA2:c.377T>C) and Hb Constant Spring 
(HBA2:c.427T>C) result in hyper-unstable variant globin chains which are unable to form 
haemoglobin tetramers for a variety of reasons, depending on the underlying genetic 
mutation. A single base substitution within the termination codon can cause an elongated 
alpha globin chain, as found in the alpha chain variants Hb Seal Rock (HBA2:c.427T>G) 
and Hb Constant Spring. In this case the alpha globin chain is extended by 31 amino acid 
residues, comparable to the beta chain variant Hb Florida (HBB:c.424delC) in which the 
beta globin chain is elongated. Other mutational mechanisms may interfere with the α and 
β polypeptide contact points, as in the Hb Quong Sze variant in which the amino acid 
substitution disrupts the quaternary structure of the haemoglobin protein. These highly 
unstable alpha chain variants are also associated with haematological features similar to α+ 
thalassaemia, in the heterozygous state. Although alpha plus thalassaemia is considered 
not to be of any clinical significance, it appears that a “dysfunctional” globin gene (that 
carries a non-deletional mutation) results in a more severe form of thalassaemia than does 
a deleted gene. Therefore compound heterozygosity for these unstable variants with 
deletional α+ or α0 thalassaemia may cause Hb H disease, and homozygosity can result in a 
particularly severe form of Hb H disease as they tend to be inherited in a dominant 
negative fashion. Interestingly these variants commonly occur in those populations where 
deletional alpha thalassaemia is also prevalent, for example South East Asia.  
 
Another thalassaemic variant which is found at low frequencies in a variety of ethnic 
groups and is associated with production of unstable mRNA is Hb Lepore, in which there 
is a non-homologous cross over event between the δ and β genes, resulting in the 
formation of a fusion chain that is missing a portion of the normal β-globin gene. It is 
synthesised at a lesser rate causing haematological features similar to β-thalassaemia trait 
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and homozygosity or compound heterozygosity with β-thalassaemia can result in beta 
thalassaemia major or intermedia. 
 
There are further subgroups of rare but clinically significant haemoglobin variants, in 
which the underlying mutational mechanism results in a haemoglobin variant with an 
increased oxygen affinity, compared to the normal haemoglobin molecule. These variants 
are of clinical interest as they can subsequently lead to polycythaemia (Bain, B: 2006) or a 
raised haemoglobin concentration, for example, Hb Malmo (HBB:c.294 C>A or 294 
C>G), which can be found in those ethnic groups where consanguinity is not uncommon, 
in which case homozygosity may cause severe erythrocytosis. 
 
Other haemoglobin variants that are found at highest frequency are Hb S (HBB:c.20A>T), 
Hb C (HBB:c.19G>A), Hb D-Punjab (HBB:c.364G>C) and Hb E (HBB:c.79G>A) which 
has already been discussed above, all of which are found within HBB. These variants are 
considered to be of clinical significance and must be detected as part of the antenatal and 
newborn screening programme as their co-inheritance with one another or with β-
thalassaemia can cause a variety of haematological abnormalities ranging from mild to 
moderately severe anaemia through to thalassaemia major depending of the nature of the 
variant.  
 
The haemoglobin S variant is caused by a Glutamic acid to Valine amino acid substitution 
at codon 6 and can cause sickle cell anaemia, in which the red cells become deformed in 
shape and sickle, and polymerisation of the sickle haemoglobin occurs under conditions of 
deoxygenation, therefore preventing the delivery of blood flow through the capillaries and 
therefore delivery of oxygen to the body tissues. 
 
Compound heterozygosity for this variant with β-thalassaemia results in a highly variable 
clinical phenotype, depending on whether the variant haemoglobin is co-inherited with a 
β+ or β0 mutation and the resultant amount of Hb A present. In the former case the clinical 
phenotype is a mild to moderate sickle cell anaemia whereas in the latter case there is no 
haemoglobin A present which results in a clinical course similar to homozygosity for this 
variant βsβs (sickle cell anaemia). 
Furthermore the clinical severity of sickle cell anaemia is related to the proportional 
percentage of haemoglobin F. There is a clear relationship in individuals with this 
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genotype between the Hb F percentage and the haplotype of the chromosome carrying the 
βS variant. The beta globin haplotype found in parts of Saudi Arabia and India is 
associated with unusually high levels of fetal haemoglobin of between 10-25% in adults, 
whereas those haplotypes found in the Senegal area are associated with relatively high 
levels of Hb F expression of between 7-10%. Whereas those haplotypes found within the 
Benin, Bantu, and the Cameroon regions of Africa are associated with lower levels of Hb 
F of between 6-7%. (Thomas, J.J.et al: 1998, Bain, B: 2006, Thein, S.L and Menzel, S: 
2009, Akinsheye, I et al : 2011). These variations of Hb F percentages observed in the 
sickle genotype may be due to the association of these haplotypes with non-deletional 
HPFH variants, as described previously in Section 1.4.3. These are important to consider 
as the haemoglobin F percentage in sickle cell anaemia can be a useful prognostic factor in 
predicting the response to hydroxycarbamide therapy.   
 
Haemoglobin C, which is caused by a Glutamic acid to Lysine amino acid substitution at 
Codon 26 is of very little clinical significance by itself in the heterozygous or homozygous 
state, but its coinheritance with haemoglobin S lead to a sickling disorder comparable to 
sickle cell anaemia or when co-inherited another β-thalassaemia mutation, especially β0, it 
can lead to thalassaemia intermedia, although it is most commonly found in combination 
with β+ mutations as they tend to occur in the same ethnic groups. 
 
Again, these disorders are very heterogeneous as there are a large number of different 
structural haemoglobin variants reported, all of which have different functional properties 
that can interact with one another or with thalassaemia, resulting in a diverse range of 
phenotypes, which therefore makes the potential for predicting individual patient 
outcomes difficult, especially in those countries where compound heterozygous states are 
common such as Thailand, Sri Lanka and Africa.  
 
1.5 Guidelines for referral 
Population screening and pre-natal diagnosis for the haemoglobinopathy disorders is only 
cost effective when directed at those ethnic groups which are at highest risk, rather than to 
the general population. Following the implementation of the national NHS Sickle Cell and 
Thalassaemia (SCT) Screening Programme in England in 2001, the linked Antenatal and 
Newborn Screening programme aims to offer timely screening to all antenatal women, 
couples and newborn babies affected by sickle cell, thalassaemia and other haemoglobin 
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variants to achieve the lowest possible childhood mortality rates for sickle cell disorders in 
the newborn period. 
 
The UK antenatal screening programme aims to identify those women deemed to be at 
„highest risk‟ of having an affected pregnancy i.e. offspring with a clinically significant 
haemoglobinopathy, by offering phenotypic screening to women between 8-10 weeks of 
pregnancy and, if relevant, to their partners, so the couple can make an informed choice 
regarding their reproduction i.e. offer of prenatal diagnosis or a termination if the offspring 
affected. It is worth noting that the screening programme(s) are not designed to diagnose 
all genotypes associated with the haemoglobinopathy disorders, but only to detect those 
parental carrier state combinations as listed in Appendix 1 that give rise to significant 
sickle cell disease or β-thalassaemia in the fetus, these include Hb SS, Hb SC, Hb S/O-
Arab, Hb S/D-Punjab, Hb S/β thalassaemia, δβ-thalassaemia, Hb Lepore, Hb E/β 
thalassaemia, β thalassaemia major and Hb Hydrops Fetalis (Ryan, K: 2010). The 
antenatal screening programme also aims to detect those who are carriers of alpha zero 
thalassaemia, as this carries the potential risk of having a fetus with the clinically 
significant disorder, Hb Barts hydrops fetalis.  
 
Indications for testing as part of the antenatal screening programme 
(http://sct.screening.nhs.uk/policy) are governed by whether the individual lives in a high 
or a low prevalence area, which is determined by the fetal prevalence of sickle cell 
disorders: in high prevalence trusts, such as those found within Manchester, there are more 
than 1.5 babies born with a sickle cell disorder per 10,000 births (Ryan, K. et al. 2010). 
All antenatal women will be offered screening, (See Appendix 2: Testing algorithm for 
laboratory screening in high prevalence trusts), whereas individuals in low prevalence 
areas will be screened based on an assessment of individual risk, determined by use of a 
Family Origin Questionnaire (FOQ) which asks patients about their family origin. This 
strategy ensures that a large number of people are not unnecessarily tested, in an attempt 
to identify a very small proportion of patients with a significant abnormality. 
 
Haemoglobinopathy disorders are predominantly inherited in an autosomal recessive 
manner, therefore offspring of couples who both carry mutations associated with severe 
alpha or beta thalassaemia have a one in four chance that their children could be affected 
by a clinically significant haemoglobinopathy disorder, for example if both parents are 
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carriers of alpha zero thalassaemia, pre-natal diagnosis is recommended to asses the risk of 
offspring having Hb Barts hydrops fetalis syndrome. 
 
Recommendations for DNA analysis include definitive diagnosis of the main genetic risk 
combinations as recommended by the antenatal screening algorithm (Appendix 2) and the 
BCSH guidelines for the diagnosis of significant haemoglobinopathies (Ryan, K et al: 
2010). Some cases may need to be assessed on an individual basis, for example where 
there is a family history of a rare abnormality such a particularly severe form of non-
deletional Hb H disease resulting in hydrops fetalis syndrome, or a highly unstable variant. 
 
The molecular heterogeneity of these disorders together with the wide range of gene-gene 
interactions makes accurate interpretation of the clinical phenotypic screen difficult, for 
example β-thalassaemia can mask co-existing 0 thalassaemia by normalising the red cell 
indices.  It is therefore important to test those individuals from high risk ethnic groups 
such as South East Asia for possible underlying alpha thalassaemia, therefore DNA 
analysis can be used to clarify the diagnosis and accurately asses the risk to the fetus. 
Additionally, apart from mass spectrometry, DNA analysis is also the only way a 
definitive identification of an abnormal haemoglobin variant can be achieved. 
 
1.6 Laboratory methods for diagnosis of haemoglobinopathy disorders 
A haemoglobinopathy phenotypic screen is often requested as part of a routine antenatal 
booking or can form part of an investigation for underlying anaemia, haemolysis or 
microcytosis, alternatively „screening may also be preoperative, neonatal, antenatal, pre 
conceptual, pre-marriage or targeted at specific groups perceived to be at risk‟ (Bain, B: 
2011). A haemoglobinopathy screen includes a Full Blood Count (FBC) followed by 
Haemoglobin electrophoresis by two independent methods; High Performance Liquid 
Chromatography (HPLC) and Isoelectric Focusing (IEF). 
 
The resultant imbalance of globin chains in the thalassaemia syndromes causes a form of 
haemolytic anaemia which is reflected in the FBC by a reduced level of Haemoglobin 
(Hb), Mean Corpuscular Volume (MCV) and Mean Cell Haemoglobin (MCH) with the 
degree of microcytosis being proportional to the number of genes affected, the red blood 
cell count (RBC) may also be increased. Cut-off values indicating heterozygosity for 
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thalassaemia are an MCV <78 fL and MCH <27 pg, an MCH value below 25 pg is used 
by the antenatal and newborn screening programme to indicate heterozygosity for α0 
thalassaemia. 
 
HPLC is a chromatographic technique which is used to separate out the different 
components of haemoglobin within a column under high pressure. The analyte (the blood 
sample) is contained within a liquid (mobile phase) and is forced through a column which 
is packed with negatively charged small particles (stationary phase) to which the 
positively charged components of the haemoglobin are absorbed. The individual 
components of the haemoglobin molecules elute from the column at different times 
according to their charge and affinity for the stationary phase, they then can then be 
detected optically. The variant haemoglobins can then be subsequently identified by their 
characteristic retention time and quantified by measuring the area under the corresponding  
peak in the chromatogram. 
 
HPLC is used to accurately quantify the percentage of primary haemoglobins A, Hb A2 
and F, and is used to diagnose cases of β-thalassaemia in which there is a characteristic 
raised Hb A2 level of above 3.5%. It can also be used to identify those cases in which there 
is a raised level of Hb F, in which case HPFH, δβ or thalassaemia major may be suspected. 
 
HPLC is also used for the provisional identification of variant haemoglobins, in which the 
globin chains produced are abnormal in structure but the α/β globin synthesis ratio is often 
normal leading to normal MCV and MCH values. The common clinically significant 
haemoglobin variants such as haemoglobin S, C, D
Punjab
, E, O
Arab
 and Lepore are easily 
separated and identified using HPLC, although other variants may have similar retention 
times and may not be identifiable, therefore only haemoglobin variants that alter the 
charge relative to the normal haemoglobin molecule can be detected by HPLC (Clarke and 
Thein: 2004) and those which result in a highly unstable haemoglobin variant may go 
undetected.  
 
Abnormal results should always be confirmed by an independent technique, such as 
Isoelectric focusing (IEF) or Sickle solubility testing. In those cases where a variant 
haemoglobin is suspected, DNA studies may be used for a definitive diagnosis. 
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HPLC forms an important screening tool used by the Newborn and Antenatal screening 
programme to quantify the haemoglobin fractions Hb H and Hb Barts, shown below as 
detected by Bio-Rad Variant V-II HPLC instrumentation: 
                
Figure 1.8: Chromatograms showing Hb Bart‟s and Hb H variants 
 
The newborn screening programme uses a cut-off value of 25% Hb Barts, below which 
haemoglobin H disease would not be suspected, whereas a baby with Hb Barts hydrops 
fetalis would usually have no Hb F or A, only Hb Barts.  
In reference laboratories within the UK two types of analysis are recommended for the 
antenatal screening of the haemoglobinopathy disorders. Therefore a second line test must 
be used in order to validate and confirm the presumed identity of an abnormal variant. 
Sickle solubility testing may be used for the confirmation of an initial screen suggesting 
the presence of sickle haemoglobin, alternatively IEF may be used for the confirmation of 
other common haemoglobin variants. Isoelectric focusing (IEF) is an electrophoretic 
technique which is used for the identification of haemoglobin variants on an agarose gel, 
whereby their separation is achieved based on the characteristic Isoelectric point (pl) of 
each variant i.e. they separate according to their differences in net charge, at a specific pH 
of solution, when an electrical charge is applied. The various haemoglobin variants form 
discrete bands that are then visualised by staining and their patterns of migration can be 
used for the presumptive identification of haemoglobin variants. If this technique is used 
as a confirmatory technique, then control haemoglobins must also be run on each gel. 
 
Further biochemical tests may be warranted in order to evaluate the patients iron status, 
including Serum Ferritin, Serum Iron and Zinc Protoporphyrin (ZPP) which are important 
in order to exclude underlying iron deficiency, as the haematological parameters for 
thalassaemia and iron deficiency are quite similar (Harteveld, C.L and Higgs, D.R: 2010) 
and iron studies are important for a differential diagnosis. 
Hb Bart‟s 
Hb H 
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Peripheral blood film examination is indicated when an abnormality of globin synthesis is 
suspected and can be very useful when an initial screening test detects an abnormality. A 
thalassaemic blood smear usually shows a variable degree of microcytosis and 
hypochromia, nucleated red blood cells and basophilic stippling in cases of β-
thalassaemia. Other characteristic cells may also be observed if the individual has a 
haemoglobin variant, such as sickled or crescent cells in sickle cell disease, target cells 
with haemoglobin C variant and basophilic stippling in those with the haemoglobin 
Constant Spring variant.  
 
Further staining the peripheral blood cells with 1% Brilliant Cresyl Blue can help visualise 
inclusion bodies that have attached and precipitate into the circulating red blood cells of 
patients with Hb H disease, this causes damage to the red cell membrane giving them a 
typical „golf-ball‟ appearance (Bain, B: 2006, Aguilar-Martinez and Gulbis: 2010, 
Harteveld, C.L and Higgs, D.R: 2010). 
 
1.7 Project summary 
In those cases where a haemoglobinopathy disorder is suspected, the initial investigation is 
based on haematological and biochemical analysis methods which aim to identify the 
thalassaemia syndrome or variant(s) present. However, interpretation of this phenotypic 
screening data can often be ambiguous where there is scope for complex interactions 
between genotypes. Providing antenatal couples with an accurate genetic risk assessment 
for their offspring on a phenotypic basis alone can be difficult. DNA analysis should 
permit a definitive characterisation of the complex genetic interactions commonly found in 
these disorders. 
 
Although the haemoglobinopathies are heterogeneous at the molecular level, there are 
common subsets of mutations associated with geographical regions and ethnic groupings, 
categorised as the Mediterranean, Asian Indian, Southeast Asian and African populations. 
Sub populations within each of these areas have their own spectrum of abnormal variants 
and mutations, as well as a number of rarer mutations found at much lower gene 
frequencies.  
 
Traditionally the strategy for genetic identification of alpha or beta thalassaemia mutations 
within a diagnostic DNA laboratory has been „ethnic-led‟ i.e. targeted diagnosis by allele-
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specific Polymerase Chain Reaction (PCR) according to the individuals‟ ethnicity. The 
increased racial heterogeneity of the UK population has significantly increased the 
spectrum of haemoglobinopathy mutations present, resulting in a higher number of α- and 
β- thalassaemia defects than in any other of the 60 countries with a published spectrum of 
mutations (Henderson, S. et al. 2009). This increases the number of different mutations 
and possible interactions which a genetic diagnostic service needs to detect and the 
„ethnic-led‟ screening approach becomes less effective, as it means that rarer or previously 
uncharacterised mutations may be missed. To illustrate: a study by Fisher et al (2003) 
highlights the importance of detecting underlying ααα alpha thalassaemia in those 
individuals with beta thalassaemia and the implications of having only a targeted 
mutational screening approach in complex ethnic populations, in which a screening 
programme in Sri Lanka, if based on the detection of the three most common mutations 
would leave „up to 25% of alleles unidentified‟ (Fisher et al: 2003).  
 
In order to achieve a high mutation detection rate in the heterogeneous population of the 
North West of England, and Greater Manchester in particular, a comprehensive range of 
laboratory assays are required to ensure that a wide spectrum of defects can be detected, 
ranging from large deletions to point mutations. In this study, a range of PCR based 
methods were employed for the detection of large deletions associated with alpha 
thalassaemia or the HPFH and δβ disorders. Direct DNA sequencing of the alpha and beta 
globin genes will also be developed for the detection of point mutations associated with 
thalassaemia and haemoglobin variants, eliminating the need for lengthy targeted mutation 
screening protocols. 
 
1.8 Project aim and hypothesis 
To develop a comprehensive range of laboratory methodologies to detect different classes 
of mutations associated with alpha and beta thalassaemia, as part of a haemoglobinopathy 
genetic diagnostic service, in the heterogeneous population of the North West of England. 
The spectrum of mutations detected within the referral population will then be analysed in 
order to determine their frequency and distribution to produce a data set for this group. 
 
The frequency and range of the mutations detected, in those referrals where the ethnicity is 
known, will then be compared to published data on expected mutation frequencies. The 
genotypes detected will also be analysed in terms of phenotype and genotype correlations 
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in order to identify those cases that are not fully explained with a view to suggesting 
further possible service development. The true genetic heterogeneity of the referral 
population can then be accurately evaluated and the effectiveness of our more 
comprehensive first pass screening approach assessed in relation to an alternative, ethnic 
led, screening strategy. 
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Chapter 2: Materials and Methods 
2.1 Patient selection and Phenotypic Screening 
Between July 2008 and December 2011 a range of diagnostic samples, referred as part of 
the existing national antenatal haemoglobinopathy screening programme were analysed at 
the Molecular Diagnostics Centre (MDC) within Manchester Royal Infirmary which is 
CPA accredited. Appropriate consent for genetic analysis was obtained for all patient 
specimens included as part of the diagnostic service provided for this disorder. 
 
All of the patients within this group had haemoglobinopathy phenotypic screening 
performed, which included a full blood count (FBC) performed internally at MRI on a 
Sysmex XE2100 analyser and HPLC on a BioRad Variant II Haemoglobin testing system, 
run on the β-thal short programme (Variant/Variant II Beta thalassaemia short program 
kit) or by the external referral centre performed on different instrumentation. Patients were 
suspected to have a haemoglobinopathy disorder if either a haemoglobin variant was 
detected by HPLC and/or FBC analysis revealed an MCH of less than 27 pg (normal 
reference range 27-32 fL) and an MCV of less than 80 fl (normal reference range 80-97 
fL). An MCH level of below <25 pg would be indicative for alpha zero thalassaemia. The 
above red cell changes may also be accompanied by a characteristic increase of Hb A2 to 
3.5% or above (normal reference range 2.3-3.3%) detected by HPLC, in which case beta 
thalassaemia would be suspected, and in the HPFH and δβ disorders, a persistently raised 
Hb F level to 4% and above. Where appropriate, in order to accurately assess a patients‟ 
phenotype, their iron status was assessed by measurement of their Serum Protein level, in 
order to exclude iron deficiency anaemia. Further genetic analysis was only carried out on 
those patients in whom a haemoglobinopathy disorder was suspected and in those that met 
the criteria as outlined by the SCT testing algorithm in high prevalence areas (see 
Appendix 2), although exceptions were made in some instances where DNA studies were 
used to clarify a patient‟s clinical diagnosis.  
 
2.2 Sample processing for genetic testing 
The investigations in this project were carried out on twenty mL of whole blood collected 
from each adult patient in 4x5 mL Vacutainer tubes (Becton Dickenson, UK) containing 
7.2mg of EDTA in each 4 mL tube. For young children and babies only 1mL of whole 
blood was collected. All samples met the minimum labelling requirements as outlined by 
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the national screening programme and CMFT trust protocols, including a Family Origin 
Questionnaire and appropriate consent for further genetic investigation.  
 
2.3 Extraction of genomic DNA 
Genomic DNA was extracted from 400µL of whole blood using the semi-automated 
Promega Maxwell®16 DNA system (Promega, UK). The Maxwell® platform uses 
individual reagent cartridges and purification plungers that extract DNA by utilising 
paramagnetic-bead based technology. Firstly the cells were lysed in the presence of 
chaotropic and detergent agents and then the nucleic acids bind to magnetic silica 
particles.  Then through a series of wash steps the lysed cellular components are removed, 
along with any other bound particles or contaminants before the nucleic acids are finally 
eluted into 200µL sterile water. The Maxwell® 16 system was suitable for the rapid (30-
40 minutes) semi-automated extraction of DNA from up to 16 whole blood samples at a 
time. It produced a high quality yield of up to 150ng/µL of DNA, suitable for downstream 
applications such as those used in this study. For the purpose of this study, when prompted 
by the machine the protocol selected was “Blood”, and the sample type selected was 
“DNA”. 
 
3.0 Deletion analysis by Gap-PCR protocols 
Gap-PCR (amplification across the breakpoints of a deletion) provided a simple diagnostic 
test for the identification of deletions, provided the breakpoint sequences were known such 
as those associated with thalassaemia including common alpha thalassaemia deletion 
mutations, alpha gene duplications and other globin gene deletions, such as those 
associated with the HPFH disorders.  
 
Two primers complementary to the sense and antisense strands regions of the DNA were 
used that flank the extent of the deletion; amplifying a deletion-specific fragment. The 
normal allele was detected by amplifying across one of the breakpoints, using one primer 
complementary to part of the deleted sequence and one complementary to the flanking 
sequence. For small deletions, typically less than one kilobase in size, the primer pairs 
generated two products, with the smaller fragment arising from the deletion allele. For 
larger deletions, the distances between the two flanking primers were too great to amplify 
the normal DNA fragment and the only product obtained was from the flanking/internal 
primer combination, representing the deleted fragment. Heterozygosity was detected by 
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the presence of both the normal and deleted products in a single reaction (See figure 2.2). 
The different sized bands were visualised by agarose gel electrophoresis.  
 
3.1 Multiplex Gap-PCR for the detection of deletional forms of alpha thalassaemia 
Multiplex Gap-PCR provided an essential screening tool for the rapid detection of a range 
of alpha thalassaemia deletions in the heterogeneous referral population found within the 
North West of England. 
 
Primers specific for the seven most common alpha thalassaemia deletions were 
multiplexed so they could be simultaneously detected in a single Gap-PCR reaction. The 
two methods employed within the MDC were based on adapted protocols derived from 
Chong, S.S et al: 2000 and Liu, Y.T et al: 2000. They were capable of detecting 
heterozygosity, homozygosity and compound heterozygosity for the most common forms 
of deletional alpha thalassaemia including the alpha plus thalassaemia α-3.7 and α-4.2 
deletions, the alpha zero thalassaemia (α)-20.5, --SEA, --MED, --THAI and --FIL deletions 
(Arnold, S et al: 2001, Baysal, E. and Huisman, T.H.J: 1994, Dodѐ, C et al: 1992, Chong, 
S.S et al: 2000, Bowden, D.K et al: 1992). Furthermore these assays encompassed the 
detection of the British α0 deletion (--BRIT), which is prevalent in our referral population 
(Eng, B et al: 2009). Additionally the alpha globin gene duplication (ααα) could also be 
detected using the Liu, Y.T et al (2000) methodology. 
 
Two independent multiplex Gap-PCR assays were used in our genetic screening service so 
one assay could be used as a confirmatory technique if a deletion is detected by the other. 
 
3.2 Method Validation 
Methods adopted were confirmed by the analysis of known control samples carrying 
relevant deletions obtained from the John Radcliffe Oxford University, Kings College and 
University College London hospitals. The alpha zero -α20.5 deletion could not be 
independently validated due to a lack of DNA control sample. 
 
3.3 Multiplex Gap-PCR assay based on Liu, Y.T et al: 2000 protocol 
This protocol was used for the detection of the seven most common forms of deletional 
alpha thalassaemia and the α-globin gene triplication. Three separate multiplexes were 
utilised; the first multiplex detected the five most common alpha zero deletions: -(α)20.5, --
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SEA
, --
MED
, --
THAI
 and –FIL. The second multiplex detected the alpha plus α-3.7 deletion and 
the α-globin gene triplication. The third multiplex detected the alpha plus α-4.2 deletion. 
This protocol helped to overcome the inherent problems associated with the amplification 
of the GC-rich α-globin gene cluster, by the use of the enhancing agents Betaine and 
Dimethyl Sulphoxide (DMSO), producing a reliable and reproducible PCR assay suitable 
for diagnostic use. 
 
Figure 2.1 summarises the positions of the multiplexed primers used in this protocol used 
for the amplification of specific deletions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Location of the multiplexed PCR primers in the α-globin gene cluster (the 
genes are represented as grey boxes, derived from Liu, Y.T et al:2000). 
 
Table 2.1 (a to c), below summarises the sequence of the primers, used in each of the three 
multiplex PCR reactions, and their corresponding final concentrations.  
(a) Multiplex-1 Primers: 
Primer 
Name 
Description Primer Sequence 5‟ to 3‟ 
Final 
Conc. 
(µM) 
1 20.5-F GGGCAAGCTGGTGGTGGTGTTACACAGCAACTC 0.1 
2 20.5-R CCACGCCCATGCCTGGCACGTTTGCTGAGG 0.1 
3 alpha SEA-F CTCTGTGTTCTCAGTATTGGAGGGAAGGAG 0.3 
4 alpha-R TGAAGAGCCTGCAGGACCAGGTCAGTGACCG 0.15 
5 MED-F CGATGAGAACATAGTGAGCAGAATTGCAGG 0.15 
6 MED-R ACGCCGACGTTGCTGCCCAGCTTCTTCCAC 0.15 
7 SEA-R ATATATGGGTCTGGAAGTGTATCCCTCCCA 0.15 
8 FIL-F AAGAGAATAAACCACCCAATTTTTAAATGGGCA 1.6 
9 FIL-R GAGATAATAACCTTTATCTGCCACATGTAGCAA 1.6 
10 Thai-F CACGAGTAAAACATCAAGTACACTCCAGCC 0.1 
11 Thai-R TGGATCTGCACCTCTGGGTAGGTTCTGTACC 0.1 
 
 
4.2(F)                 4.2(R1)                                              4.2(R2) 
3  HVR 
3.7(F)                          3.7(R1)           3.7(F)                            3.7(R2) 
                          THAI(R) 
               FIL(R) 
MED(R) 
20.5(R) 
Inter 
HVR 
THAI(F)  
   FIL(F)      20.5(F) 
ζ2 ψζ1 Ψα2 ψα1 
 
α2 α1 θ1 
MED(F) 
α/SEA(F)   α(R) 
Ψα1 α2 α1 
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(b) Multiplex-2 Primers: 
Primer Description Sequence 5‟ to 3‟ Final 
Conc. 
 (µM) 
12 3.7-F AAGTCCACCCCTTCCTTCCTCACC 0.3 
13 3.7-R1 ATGAGAGAAATGTTCTGGCACCTGCACTTG  0.1 
14 3.7-R2 TCCATCCCCTCCTCCCGCCCCTGCCTTTTC 0.1 
 
(c) Multiplex-3 Primers 
Primer Description Sequence 5‟ to 3‟ Final 
Conc. 
 (µM) 
15 4.2-F TCCTGATCTTTGAATGAAGTCCGAGTAGGC 0.8 
16 4.2-R1  TGGGGGTGGGTGTGAGGAGACAGGAAAGA
GAGA 
0.4 
17 4.2-R2 ATCACTGATAAGTCATTTCCTGGGGGTCTG 0.4 
Tables 2.1 (a-c): Sequence of the primers used in: (a) Multiplex-1, (b) Multiplex-2 
and (c) Multiplex-3. 
 
3.3a: Multiplex PCR Amplification 
1. A separate PCR amplification was performed for each of the three multiplexes using 
0.5mL thin-walled PCR tubes (Peqlab, UK).  
2. 100-200ng of genomic DNA was added to each reaction. 
3. A “no DNA” (blank control) was always included in the PCR to indicate if cross 
contamination had occurred. 
4. A known deletion control (positive control) was included in the PCR if a mutation from 
a patient sample was being confirmed.  
5. A master mix was made for each of the individual multiplex reactions, each containing 
different reagents, primer concentrations and volumes of water. 
 
Detailed below in Tables 2.2 (a-d) are the reagents used their corresponding volumes for 
each multiplex: 
 
Multiplex-1 (α0) PCR: 
A total reaction volume of 25µL comprised of:  
Reagent Volume per 
reaction (µL) 
10x PCR Buffer (Life Technologies, UK) 2.5 
MgCl2 (Life Technologies, UK) 1.5 
Betaine (Sigma, UK) 3.75 
DMSO (Sigma, UK) 1.25 
AmpliTaq Gold DNA Polymerase (Life 
Technologies) 
0.25 
dNTP‟s (Bioline, UK) 0.5 
Primers: (total multiplex volume): 10.5 
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Table 2.2a: Components of the Multiplex-1 PCR reaction master mix. 
 
Multiplex-2 (α-3.7) PCR: 
The different reagents used for Multiplex 2 reflect the changes made from the original 
protocol and subsequent assay optimisation needed for the successful amplification of both 
the –α3.7 deletional and normal DNA fragments. Initially an Extensor Hi-Fidelity PCR 
Enzyme Mix (Thermo Scientific, UK) was used, but the assay reliability was improved by 
use of a KAPA 2G Robust PCR kit (Kapa Biosystems, Africa). A total reaction volume of 
25µL comprised of:  
 
 
 
 
 
 
 
 
 
 
Table 2.2b: Components of the Multiplex-2 (α-3.7) PCR reaction master mix. 
 
Multiplex-2 (ααα) PCR: 
Multiplex 2 was further optimised in order to overcome the failure of the multiplex to 
detect the alpha gene duplication (ααα). Therefore a separate PCR methodology was 
devised using only the two primers specific for this gene duplication.  
(Eurofins, Germany) 
20.5-F (5µM) 0.5 
20.5-R (5µM) 0.5 
alpha SEA-F (5µM) 1.5 
alpha-R (5µM) 0.75 
MED-F (5µM) 0.75 
MED-R (5µM) 0.75 
SEA-R (5µM) 0.75 
FIL-F (20µM) 2 
FIL-R (20µM) 2 
Thai-F (5µM) 0.5 
Thai-R (5µM) 0.5 
Sterile H2O 3.75 
DNA 1 
Reagent Volume per 
reaction (µL) 
5X KAPA (2G) GC Buffer  
(Kapa Biosystems, Africa) 
5.0 
KAPA2G Robust DNA polymerase 
(Kapa Biosystems, Africa) 
0.5 
dNTP Mix (10mM each dNTP)  
(Kapa Biosystems, Africa) 
0.5 
Primers: (total multiplex volume) 
(Eurofins, Germany) 
2.5 
3.7-F (5µM) 1.5 
3.7-R1 (5µM) 0.5 
3.7-R2 (5µM) 0.5 
Sterile H2O 14.5 
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A total reaction volume of 50µL comprised of: 
 
 
 
 
 
 
 
 
 
Table 2.2c: Components of the Multiplex-2 (ααα) PCR reaction master mix 
 
Multiplex-3 (α-4.2) PCR: 
This multiplex was optimised using the same Qiagen reagents as above for detection of the 
triplicated alpha genotype (Table 2.2c), due to consistent failure to amplify products 
within the PCR reaction when the original protocol was used. A total reaction volume of 
50µL comprised of: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2d: Components 
of the Multiplex-3 (α-4.2) PCR reaction master mix 
 
Each of the multiplex PCR reactions were then transferred to a Techne TC-3000 
(Bibby Scientific, UK) thermal cycler in order to perform the PCR amplification step. The 
thermal cycling conditions for each of the reactions are shown below. 
 
Multiplex-1 and Multiplex-3 were run under the same thermal cycling conditions 
consisting of: Initial 15-minute denaturation at 95°C, followed by 35 cycles of 95°C 
denaturation for 60 seconds, 65°C annealing for 60 seconds and 72°C extension for 150 
seconds. A final 10-minute extension at 72°C completed the reaction. 
Reagent Volume per 
reaction (µL) 
10x PCR Buffer (Qiagen, UK) 5.0 
Q-Solution (Qiagen, UK) 10 
HotStar Taq Plus (Qiagen, UK) 0.25 
dNTP‟s (Bioline, UK) 4.0 
Primers: (Eurofins, Germany)  
3.7-F (5µM) 1.5 
3.7-R1(5µM) 1.5 
Sterile H2O 25.75 
DNA 2.0 
Reagent Volume per 
reaction (µL) 
10x PCR Buffer  5.0 
Q-Solution 10 
HotStar Taq Plus 0.25 
dNTP‟s 4.0 
Primers:  
4.2-F (5µM) 8.0 
4.2-R1 (5µM) 4.0 
4.2-R2 (5µM) 4.0 
Sterile H2O 12.75 
DNA 2.0 
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Multiplex-2 (for the detection of α-3.7 deletion) was run by preheating the block to 94°C 
before inserting the reaction tubes. Then an initial 3-minute denaturation at 94°C was 
performed, followed by 35 cycles of 94°C denaturation for 60 seconds, 65°C annealing for 
60 seconds, and 72°C extension for 150 seconds. A final 10-minute extension at 72°C 
completed the reaction. 
 
Modified Multiplex-2 (for the detection of ααα alpha) was run by preheating the block to 
96°C before inserting the reaction tubes. Then an initial 15-minute denaturation at 96°C, 
followed by 30 cycles of 98°C denaturation for 45 seconds, 60°C annealing for 90 
seconds, and 72°C extension for 135 seconds. A final 5-minute extension at 72°C 
completed the reaction. 
 
3.3b Agarose gel electrophoresis: 
A 1.0% agarose gel (w/v) was prepared by adding 1.0g of molecular grade agarose 
(Peqlab, UK) to 100mL of 0.6 x TBE buffer in a conical flask and mixed. It was then 
heated in the microwave on full power for 3 minutes. Three µL of 10mg/mL ethidium 
bromide was then added to the gel and left to cool to approximately 60°C. A gel tray was 
prepared with a 1mm 16 well comb and the gel was then poured into the tray and allowed 
to cool for a minimum of 30 minutes or until it had set. 
 
Once the thermal cycler had finished, the PCR amplification products were prepared for 
loading on to the gel by addition of 4µL of PCR product to 2µL of loading dye in a 
separate 0.5 mL tube. A total of 6µL of each sample was loaded into individual wells of 
the gel and a 1kb UltraRanger DNA ladder (Norgen Biotek, Canada) was added to the 
wells either side of the PCR product loading. The gel was left to run at 110 volts for a 
minimum of 1.5 hours. The banding pattern on the gel was then visualised and 
photographed on a Gene Genius gel documentation system (Syngene, UK). The banding 
patterns observed for this Gap-PCR assay are shown below. 
 
3.3 c: Interpretation of Banding Patterns Observed 
PCR Fragment sizes obtained from the alpha globin gene in Multiplex-1, 2 and 3 are 
shown below in Figure 2.2 (a-c): 
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Multiplex-1 (α0): 
 
 
 
Figure 2.2a: Banding pattern observed for Multiplex-1 (for the detection of α0 
thalassaemia deletions) Run with UltraRanger 1kb DNA ladder (labelled „L‟). 
 
The presence of a single band at 1010 bp (for the specific α2 fragment) indicated that the 
individual tested negative for the five alpha zero deletions and was therefore was 
considered normal for these genotypes (as in Lane 4). In the presence of an additional 
specific deletional fragment, this indicated heterozygosity for that particular deletion, 
occurring at either of the following positions: 660 bp (--
SEA
) as in lane 1, 875 bp (--
MED
) as 
in lane 2, 411 bp (--
THAI
), 550 bp (--
FIL
) as in lane 3 and 1187 bp (-α20.5) which is not 
shown in Figure 2.2a above. Lane 5 is a blank „no DNA‟ control. 
 
Conversely, the absence of the α2 fragment and the presence of a single deletion fragment 
indicated the individual was homozygous or compound heterozygous for deletional alpha 
thalassaemia. 
 
 
 
 
 
 
 
 
L        1         2         3        4        5        L 
1187bp (-α20.5) 
1010bp (Normal-α2) 
875bp (--
MED
) 
660bp (--
SEA
) 
550bp (--
FIL
) 
411bp (--
THAI
) 
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Multiplex-2 (α-3.7): 
                                            
Figure 2.2b: Banding pattern observed for Multiplex-2 (for the detection of the α-3.7 
deletion). Run with UltraRanger 1kb DNA ladder (labelled „L‟) 
 
A single band at 2217bp indicated that the –α3.7 deletion was not present, and the 
individual was normal for this genotype (as in Lane 4).  
 
A band at 1963bp indicated that the deletion was present, and in the presence of the 
normal band at 2217bp indicated heterozygosity for this deletion (as in Lane 2). When the 
normal band at 2217bp was absent, this indicated homozygosity for this deletion (as in 
Lanes 1 and 3). Lane 5 is a blank „no DNA‟ control 
 
Multiplex-2 (ααα): 
The banding pattern observed for the triplicated alpha genotype is shown below: 
 
 
Figure 2.2c: Banding pattern observed for Multiplex-2 (for the detection of ααα 
alpha). Run with UltraRanger 1kb DNA ladder (labelled „L‟) 
L      1        2        3       4       5       L     
2217 bp 
1963 bp (-α3.7) 
L         1         2         3         4         5        L     
2440 bp (ααα) 
2217 bp 
56 
 
As in Figure 2.2c a single band at 2217 bp indicated that the gene triplication was not 
present, and the individual was normal for this genotype (as in Lanes 1, 2 and 4).  
 
A band at 2440 bp indicated the alpha gene triplication was present and when found in the 
presence of the normal band at 2217 bp this indicated heterozygosity for this genotype (as 
in Lane 3). When the normal band at 2217 bp was absent, this indicated homozygosity for 
the alpha gene triplication (not shown). Lane 5 is a blank „no DNA‟ control. 
Multiplex-3 (α-4.2):  
                                          
Figure 2.2d: Banding pattern observed for Multiplex-3 (for the detection of the α-4.2 
deletion). Run with UltraRanger 1kb DNA ladder (labelled „L‟). 
 
A single band at 1510 bp indicated the –α4.2 deletion was not present, and the individual 
was normal for this genotype (as in Lanes 1, 2, 3 and 5). 
 
A band at 1725 bp indicated that the –α4.2 deletion was present and when found in the 
presence of the normal band at 1510 bp this indicated heterozygosity for this deletion (as 
in Lane 4). When the normal band at 1510 bp was absent this indicates homozygosity for 
this deletion (not shown). Lane 6 is a blank „no DNA‟ control. 
 
The following points were considered when interpreting the above banding patterns. 
The presence of the specific α2 fragment indicated at least one intact α2 gene and thus in 
the presence of an additional deletional fragment indicated heterozygosity for that specific 
deletion. Conversely, the absence of the α2 fragment and the presence of a single 
deletional fragment indicated that the individual was homozygous for that α-thalassaemia 
deletion. The presence of two deletional fragments of different size indicated compound 
1725 bp (-α4.2) 
1510 bp 
L     1      2      3      4      5      6     L     
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heterozygosity for deletional alpha thalassaemia. The patient was considered negative for 
the above deletions when the α2 fragment was present and there were no additional 
deletional fragments, although this does not entirely exclude alpha thalassaemia as a rare 
alpha thalassaemia deletion or a non deletional form of alpha thalassaemia may still be 
present. It is important that these results were interpreted alongside an individual‟s 
phenotypic and clinical data. 
 
3.3 d Limitations of the Liu, Y.T et al: 2000 protocol 
The Liu based protocol did not provide a truly multiplexed assay which was capable of 
detecting the seven common forms of deletional alpha thalassaemia in a single reaction. 
All of the three individual multiplex reactions required optimisation and different running 
conditions. Subsequently the Chong based protocol, discussed below was developed in 
order to improve and streamline the analysis for alpha thalassaemia. 
 
3.4 Multiplex Gap-PCR assay based on Chong, S.S et al: 2000 protocol 
This protocol utilised one multiplex reaction for the detection of the seven most common 
forms of deletional alpha thalassaemia. 
 
As above, this protocol overcomes the difficulties associated with amplification of the 
alpha globin genes by PCR such as sequence homology and high GC content by use of a 
Qiagen HotStar Taq plus DNA polymerase PCR kit (Qiagen, UK) that contains PCR 
additives, such as a proprietary “Q-solution” which facilitates the amplification of difficult 
templates by destabilising secondary structures and reducing the energy required to melt 
the GC-rich alpha globin region. 
In this protocol a multiplex of 16 different primers were used in a single PCR reaction, 
their sequences and final concentrations are detailed below in Table 2.3: 
Primer 
Name 
Primer Sequence (5‟-3‟) Final 
Conc. 
(µM) 
LISI-F ATACCATGGTTACCCCATTGAGC 0.5 
LISI-R AGGGCTCATTACATGTGGACCC 0.5 
α2/3.7-F CCCCTCGCCAAGTCCACCC 0.2 
α2-R AGACCAGGAAGGGCCGGTG 0.2 
20.5-F GCCCAACATCCGGAGTACATG 0.2 
3.7/20.5-R AAAGCACTCTAGGGTCCAGCG 0.2 
4.2-F GGTTTACCCATGTGGTGCCTC 0.5 
4.2-R CCCGTTGGATCTTCTCATTTCCC 0.5 
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SEA-F CGATCTGGGCTCTGTGTTCTC 0.2 
SEA-R AGCCCACGTTGTGTTCATGGC 0.2 
FIL-F TTTAAATGGGCAAAACAGGCCAGG 1.0 
FIL-R ATAACCTTTATCTGCCACATGTAGC 1.0 
MED-F TACCCTTTGCAAGCACACGTAC 0.2 
MED-R TCAATCTCCGACAGCTCCGAC 0.2 
THAI-F GACCATTCCTCAGCGTGGGTG 0.3 
THAI-R CAAGTGGGCTGAGCCCTTGAG  0.3 
Table 2.3: Multiplex primer sequences and final concentrations for the Chong 
Gap-PCR protocol. 
 
3.4a Multiplex PCR Amplification 
A PCR reaction was set up (as detailed in steps 1-5 in Section 3.3a). Detailed in Table 2.4 
below are the reagents used their corresponding volumes for this multiplex.  
A total reaction volume of 50µL comprised of: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4: Components of the “Chong” PCR reaction master mix. 
 
The multiplex PCR reactions were then transferred to a Techne TC3000 thermal cycler 
(Bibby Scientific, UK) in order to perform the PCR amplification step. The thermal 
cycling conditions selected started with an initial 15-minute denaturation at 96°C, 
Reagent Volume per 
reaction (µL) 
10xPCR Buffer (Qiagen, UK) 5.0 
Q-Solution (Qiagen, UK) 10 
HotStar Taq Plus (Qiagen, UK) 0.25 
dNTP‟s (Bioline, UK) 4.0 
Primers (10µm) (total multiplex volume) 
(Eurofins, Germany) 
31 
LIS1-F 2.5 
LIS1-R 2.5 
α2/3.7-F 1.0 
α 2-R 1.0 
20.5-F 1.0 
3.7/20.5-R 1.0 
4.2-F 2.5 
4.2-R 2.5 
SEA-F 1.0 
SEA-R 1.0 
FIL-F 5.0 
FIL-R 5.0 
MED-F 1.0 
MED-R 1.0 
THAI-F 1.5 
THAI-R 1.5 
DNA 2.0 
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followed by 30 cycles of 98°C denaturation for 45 seconds, 60°C annealing for 90 
seconds, and 72°C extension for 135 seconds. A final 5-minute extension at 72°C 
completed the reaction. 
Agarose gel electrophoresis was carried out as detailed in step 3.3b. 
 
3.4b Interpretation of Banding Patterns Observed 
PCR Fragment sizes observed for the alpha globin gene using the Chong based protocol 
are shown below in Figure 2.3: 
                                       
 
Figure 2.3: Banding pattern observed for „Chong‟ PCR. Run with UltraRanger 1kb 
DNA ladder (labelled „L‟) 
 
An individual testing negative for the above 7 deletions will showed two bands: one at 
2350bp one at 1800bp (as in Lane 1). In the presence of an additional specific deletional 
fragment, this indicates heterozygosity for that particular deletion, occurring at either of 
the following positions: 1349bp (--
SEA
) as in lane 2, 1153bp (--
THAI
) as in lane 3, 1007bp (-
α20.5) as in lane 4, 2202bp (-α3.7) as in lane 5, 1628bp (-α4.2) as in lane 6 and 546bp (--FIL) 
(not shown in Figure 3 above). Lane 9 is a blank „no DNA‟ control. 
 
The following points were considered when interpreting the above banding patterns.  
Unlike the Liu based protocols (discussed in Section 3.3c) this protocol is based on the 
amplification of the α2 gene which may be totally or partially removed by any of the 7 
deletions being tested for. Therefore the presence of the α2 gene fragment (represented by 
a band at 1800bp) is used to indicate heterozygosity when any deletion allele is present. 
Conversely its absence indicates the α2 globin gene is absent from both chromosomes 16 
L    1      2     3     4      5     6      7      8     9     L     
2350bp (LIS1) 
2202bp (-α3.7) 
1800bp (α2) 
1628bp (-α4.2) 
1349bp (--
SEA
)  
1153bp (--
THAI
) 
1007bp (-α20.5) 
807bp (--
MED
) 
546bp (--
FIL
) 
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and can indicate homozygosity or compound heterozygosity for either of the 7 forms of 
deletional alpha thalassaemia tested for, as in Lane 7 (-α3.7/-α4.2) and Lane 8 (-α3.7/--MED). 
Furthermore independent control primers on the LIS1 gene act as a control for quality of 
amplification within each individual PCR reaction, and is represented by a band at 2350 
bp. 
 
3.5 Gap-PCR assay for the detection of the British (--BRIT) alpha zero deletion 
based on Eng, B et al: 2009 protocol. 
This protocol utilised a Gap-PCR reaction for the detection of the --BRIT alpha zero 
deletion, using the Qiagen HotStar Taq plus DNA polymerase PCR kit (as in Section 3.4). 
Two different primer pairs were used in one reaction: one which spanned the --
BRIT
 
breakpoint and amplified the deletion specific fragment and the second which serves a 
control and amplified a larger fragment from the PAFAH1B1 gene on chromosome 17.  
Their sequence and final concentrations are detailed below in Table 2.5: 
Primer 
Name 
Primer Sequence (5‟-3‟) Final Conc. 
(µM) 
LIS-1F ATACCATGGTTACCCCATTGAGC 0.4 
LIS1-R BRIT TTATGTAATGCACATTGCACATCCC 0.4 
BRIT-F CAGGTGTCCATCATCAGGACTAAC 0.4 
BRIT-R CCTTCACCACCACCTGTGTAGG 0.4 
Table 2.5: Primer sequences and final concentrations for the British alpha Gap-PCR 
3.5 a: Gap-PCR amplification 
A PCR reaction was set up (as detailed in steps 1-5 in Section 3.3a).  
Table 2.6 below details the reagents used and their corresponding volumes for this assay. 
A total reaction volume of 50µL comprised of: 
Reagent Volume per 
reaction (µL) 
10xPCR Buffer (Qiagen, UK) 5.0 
Q-Solution (Qiagen, UK) 10 
HotStar Taq Plus (Qiagen, UK) 0.25 
dNTP‟s (Bioline, UK) 4.0 
Primers: (10µm)  
(Eurofins, Germany) 
 
LIS1-F 2.0 
LIS1R-BRIT 2.0 
BRIT-F 2.0 
BRIT-R 2.0 
Sterile H2O 20.75 
Table 2.6: Components of the British alpha deletion PCR reaction master mix. 
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The PCR reaction was then transferred to a Techne TC3000 thermal cycler (Bibby 
Scientific, UK) in order to perform the PCR amplification step. The thermal cycling 
conditions selected started with an initial 15-minute denaturation at 96°C, followed by 30 
cycles of 98°C denaturation for 45 seconds, 60°C annealing for 90 seconds, and 72°C 
extension for 135 seconds. A final 5-minute extension at 72°C completed the reaction. 
Agarose gel electrophoresis was carried out as detailed in step 3.3b. 
 
3.5b Interpretation of Banding Patterns Observed 
PCR Fragment sizes observed for the alpha globin gene using the Eng et al based protocol 
are shown below in Figure 2.4: 
 
Figure 2.4: Gel image of banding patterns observed for British alpha deletion Gap-
PCR.  
 
An individual testing negative for the --
BRIT
 deletion will one band at 850 bp (as in Lane 
3). A heterozygote for this deletion will show an additional deletional specific fragment at 
439 bp (--
BRIT
) (as in Lanes 1 and 2). Lane 4 is a blank „no DNA‟ control. 
 
Gap-PCR methodology was also used for the detection of the nine most common deletions 
that involve the β-globin gene complex on chromosome 11 and are associated with clinical 
manifestations of HPFH and δβ-thalassaemia disorders (Craig, R.A et al: 1994). 
 
4.0 Gap-PCR for the detection of deletional forms of HPFH and δβ-thalassaemia 
A protocol described by Craig, R.A et al: 1994 was used for the rapid molecular detection 
of the nine known deletions associated with the HPFH and δβ-thalassaemia disorders. This 
was based on Gap-PCR methodology (as described in Section 2.3) in which each specific 
deletion is detected by amplification products generated by combinations of three specific 
primers within the same reaction, leading to the production of a unique deletion-specific 
product in the presence of a deletion and a normal control band of a different size in the 
        850 bp  
 
 
439 bp (--
BRIT
) 
L         1         2        3        4         L 
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presence of the normal allele. This protocol can detect the following deletions: HPFH-1, 
HPFH-2, HPFH-3, Spanish (δβ)0, Haemoglobin Lepore, Sicilian (δβ)0, Chinese Gγ(Aγδβ)0, 
Asian-Indian inversion deletion 
Gγ(Aγδβ)0 and  the Turkish inversion deletion (δβ)0. 
 
Figure 2.5 summarises the PCR primers used in this protocol and their relative positions 
along the β-globin gene cluster. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Location of the PCR primers along the β-globin gene cluster, showing the 
location of the primers and extent of deletions detected in the Craig, R.A et al Gap-
PCR protocol (Derived from Craig, R.A et al: 1994). 
 
Table 2.7 below summarises the sequence of the primers used in this protocol. 
Primer 
Name 
Sequence (5‟-3‟) 
A1 AGAATGTCACACTTAGAATCTG 
A2 CACTTTAATTCTGGTCTACCTGAA 
A3 ACTGTGATGTTGGAAATGGAC 
B1 GACATGGACTATTGTTCAATGA 
B2 TGCTATGCCAACTCACTACC 
B3 TTTATATATGAAATGCTACTGATT 
C1 CTTTGCTGTTCAGGCTTAATTT 
C2 GACACAGAGCAGTGATTGGTGCA 
D1 AGCCCGCCACTGCACTGTG 
E1 GACACACATGACAGAACAGCCAAT 
E2 CGATCTTCAATATGCTTACCAAG 
E3 CATTCGTCTGTTTCCCATTCTA 
F1 TTGGGTTTCTGATAGGCACTG 
F2 GTGTCACCCATTAATGCCTTGTAC 
F3 TAGATCCCTTTGCCATTATG 
A1                                                        114kb 
                           A2                                                D1 
 
G1                                                                    100kb 
                                G2                                                                   G3 
 
E1           11.5kb                         J3       J4 
 
                J1      J2   J5 
 
     ε                           
G
γ      
A
γ          ψβ               δ                β 
                  5’                        3’ 
     
HPFH-1 
HPFH-2 
HPFH-3 
Spanish (δβ)
0
 
Hb Lepore 
Sicilian (δβ)
0
 
Chinese 
G
γ(
A
γδβ)
0
 
Asian-Indian 
G
γ(
A
γδβ)
0
 
Turkish (δβ)
0
 
B1                                                        105kb 
                           B2                                  B3 
 B1                                                        48.5kb 
                          C1                                        C2 
 
 E1       7.4kb       E2 
                           E3 
 F1             13.4kb 
                     F2  F3 
 
    H1                15.2kb                       H3  7.4kb          H4 
            H2     H5 
 
INVERSION 
A1                                                        106kb 
                         A2                      A3 
 
INVERSIO
N 
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G1 GGCATATATTGGCTCAGTCA 
G2 CTTGCAGAATAAAGCCTATC 
G3 TCAACAAUATCAACATTACACC 
H1 ATGCCATAAAGCACCTGGATG 
H2 GAGCTGAAGAAAATCATGTGTGA 
H3 TAACCATATGCATGTATTGCC 
H4 CAATGTATCATGCCTCTTTGCAC 
H5 GCAGCCTCACCTTCTTTCATGG 
J1 GAAGAGCAGGTAGGTAAAAGAACC 
J2 TTCCACTATCTTACTTACACAT 
J3 CAAAGCAGCAATACTAAACAGGAG 
J4 TGCTGAGGATTGTTTTAGGTC 
J5 GAATAGCAGTGGTGAGAGAG 
Table 2.7: Primer sequences used in the Craig et al: 1994 Gap-PCR protocol. 
 
4.1 Gap-PCR amplification 
All PCR reactions were performed using the KAPA2G (GC) robust DNA polymerase 
PCR kit (Kapa Biosystems, South Africa), which contains a highly robust and sensitive 
second-generation enzyme and a GC buffer which has been specifically designed for the 
amplification of difficult templates, therefore providing a reliable assay for the detection 
of the deletions in Figure 2.5.  
 
1. Separate PCR amplification reactions were performed for each specific deletion being 
tested for, using 0.5mL thin-walled PCR tubes (Peqlab, UK).  
2. 100-200ng of genomic DNA was added to each reaction. 
3. A “no DNA” (blank control) was always included in the PCR to indicate if cross 
contamination had occurred 
4. A known deletion control (positive control) was included where possible. 
5. A master mix was made for each of the individual multiplex reactions, each containing 
different reagents, primer concentrations and volumes of water. 
 
All separate PCR reactions were set up in a 25µL total reaction volume containing: 5µL of 
5X KAPA (2G) GC Buffer, 0.5µL of KAPA2G DNA polymerase, 0.5µL of dNTP mix 
(10mM each dNTP), 1.5µL of each of the three deletion specific primers (at a 
concentration of 5µM, with the exception of the HPFH-2 deletion control primer B2 which 
was used at a concentration of 1µM). Volumes of MgCl2 and subsequent volumes of 
sterile water were optimised for each of the individual reactions, as detailed below in 
Table 2.8a. 
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PCR Reagents Volume (µL per reaction) 
Deletion 
MgCl2 
(25mM) 
Deletion 
specific 
primers 
sH20 
HPFH-1 0.5 A1, A2, A3 12 
HPFH-2 1.5 B1, B2, B3 11 
HPFH-3 2 B1, C1, C2 10.5 
Spanish (δβ)o 2.5 A1,A2, D1 10 
Hb Lepore 1.5 E1, E2, E3 11 
Sicilian (δβ)o  1.5 F1, F2, F3 11 
Chinese 
Gγ(Aγδβ)0 1.5 G1, G2, G3 11 
Asian-Indian Inv/Del 
A
 Gγ(Aγδβ)0  
1.5 H1, H2, H3 11 
Asian-Indian Inv/Del 
B 
Gγ(Aγδβ)0 
1.5 H2, H4, H5 11 
Turkish Inv/Del A
 
(δβ)o 
1.5 E1, J1, J3 11 
Turkish Inv/Del B
 
(δβ)o 
1.5 J2, J4, J5 11 
Table 2.8a: Component volumes for each of the PCR master mix reaction.  
 
Each PCR reaction was then transferred to a Techne TC3000 thermal cycler (Bibby 
Scientific, UK) in order to perform the PCR amplification step. The thermal cycling 
conditions for each of the reactions were then optimised. All reactions commenced with an 
initial denaturation for 2 minutes, followed by 30 cycles of denaturation, annealing and 
extension at varying temperatures for each PCR reaction, the details of which are given 
below in Table 2.8b. 
 PCR thermal Cycler Conditions 
PCR 
product 
size (bp) 
Denaturation Annealing Extension Final Ext. 
Deletion 
Temp 
(°C) 
Time 
(sec) 
Temp 
(°C) 
Time 
(sec) 
Temp 
(°C) 
Time 
(min) 
Temp 
(°C) 
Time 
(min) 
HPFH-1 1,193 
(mutant) 
1,616 
(normal) 
95 20 54 20 72 1 72 1 
HPFH-2 1,950 
(mutant) 
2,206 
(normal) 
95 20 55 20 72 1 72 1 
HPFH-3 607 
(mutant) 
841 
(normal) 
95 20 58 20 72 1 72 1 
Spanish 
(δβ)o 
1,281 
(mutant) 
1,616 
(normal) 
95 60 58 60 72 1 72 10 
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Hb 
Lepore 
777 
(mutant) 
915 
(normal) 
95 60 58 60 72 2 72 2 
Sicilian 
(δβ)o  
1,150 
(mutant) 
1,585 
(normal) 
95 20 60 20 72 1 72 1 
Chinese 
Gγ(Aγδβ)0 
508 
(mutant) 
682 
(normal) 
95 60 58 60 72 2 72 2 
Asian-
Indian 
Inv/Del A
 
Gγ(Aγδβ)0  
327 
(mutant) 
1,195(nor
mal) 
95 60 58 60 72 1 72 10 
Asian-
Indian 
Inv/Del 
 
Gγ(Aγδβ)0 
B 
371 
(mutant) 
665 
(normal) 
95 60 58 60 72 1 72 10 
Turkish  
Inv/Del A
 
(δβ)o 
432 
(mutant) 
742 
(normal) 
95 20 65 20 72 1 72 1 
Turkish  
Inv/Del B
 
(δβ)o 
489 
(mutant) 
700 
(normal) 
95 20 57 20 72 1 72 1 
Table 2.8b: Details of PCR thermal cycler running conditions for each deletion. 
 
The PCR products from each reaction were separated by agarose gel electrophoresis as 
detailed in step 3.3b. 
 
4.2 Interpretation of Banding Patterns Observed 
The PCR fragment sizes observed for each specific deletion are detailed in Table 2.8b 
above, and illustrated for the HPFH-1, HPFH-2, HPFH-3, Hb Lepore and Chinese 
Gγ(Aγδβ)0 deletions below in figures 2.6a to 2.6e:  
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2,206(normal) 
1,950(mutant) 
 
1,616 (normal) 
 
1,193 (mutant) 
                               
            Figure 2.6a: Gel image of banding            Figure 2.6b: Gel image of banding                          
 pattern observed for HPFH-1 deletion.    pattern observed for HPFH-2 deletion. 
  
                              
             Figure 2.6c: Gel image of banding          Figure 2.6d: Gel image of banding            
  pattern observed for HPFH-3 deletion.  pattern observed for Hb Lepore deletion 
 
 
                 Figure 2.6e: Gel image of banding pattern observed for Chinese
 Gγ(Aγδβ)0  
      deletion. 
  L       1         2        3       4       5     L 
  L        1       2       3       4      L 
915 (normal) 
777 (mutant) 
 
  L       1       2      3      4       5      6      L 
682 (normal) 
508 (mutant) 
 
841 (normal) 
 
607 (mutant) 
 
  1       2       3       4      L 
  L       1        2       3       4        5       L 
67 
 
5.0 DNA sequencing for the detection of point mutations and small deletions 
associated with thalassaemia and haemoglobin variants. 
DNA sequencing allows the analysis of the exact nucleotide sequence of the gene under 
study. Direct DNA sequencing of the alpha and beta globin genes represents the “gold 
standard” for mutation analysis, allowing a single-pass detection method for most of the 
point mutations associated with thalassaemia and haemoglobin variants, eliminating the 
need for lengthy targeted mutation screening protocols. 
 
5.1a PCR Amplification for the generation of HBB gene specific products 
This protocol identified mutations by full DNA sequence analysis of the essential regions 
of HBB, which was amplified in three overlapping fragments using three sets of primer 
pairs.   
As figure 2.7 shows; the 5‟ promoter region, exon 1, intron 1, exon 2 and the 5‟ end of 
intron 2 were amplified in one amplicon (referred to as Product 1). Most of intron 2 were 
amplified in another amplicon (referred to as Product 2) and the remaining 3‟ end of intron 
2, exon 3 and the 3‟ UTR were amplified in another amplicon (referred to as Product 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Location of PCR primer pairs along the beta-globin gene. 
 
5.1b Primer Design 
Three overlapping primers sets were designed using the online Primer 3 software 
(http://frodo.wi.mit.edu/) to conform to the following parameters: an annealing 
temperature of between 55-60°C, absence of significant hairpin loop formation, lack of 
secondary priming sites and low specific binding at the 3‟ end of each prime pair in order 
to avoid mispriming.  
The picked primers were then checked for underlying SNP‟s using the online software 
SNPcheck, Version 2 (http://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck).  
Exon 
1 
Exon 3 Exon 2 
5’ 3’ 
782 bp 
Product 1 
 
595 bp 
Product 2 
850 bp 
Product 3 
HBB1-R    HBB1-F  
Hb2-F 
Hb3-R 
Hb2-R 
Hb3-F 
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The primers were tailed with N13 (modified from M13 universal primer sequences) 
forward or reverse sequences respectively so that one set of forward and reverse primers 
could be used in subsequent cycle sequencing reactions.  
Their sequences are detailed below in Table 2.9. 
HBB 
Frag. 
No. 
Primer sequence 
5‟ to 3‟ 
Annealing 
Temp. (ºC) 
Product size 
(inc. N13 
tails) (bp) 
1 
Hb1F: 
gtagcgcgacggccagtACTCCTAAGCCAGTGCCAGA 
Hb1R: 
cagggcgcagcgatgacAAAACGATCCTGAGACTTCCA 
60 782 
2 
Hb2F: 
gtagcgcgacggccagtTTTCTTTCCCCTTCTTTTCTATGG 
Hb2R: 
cagggcgcagcgatgacAATGGTGCAAAGAGGCATGA 
60 595 
3 
Hb3F: 
gtagcgcgacggccagtTGGAATATATGTGTGCTTATTTG
CAT 
Hb3R:cagggcgcagcgatgacTCTTTATGTTTTAAATGCA
CTGACCTC 
60 850 
Table 2.9: Primer sequences for the amplification of HBB and their corresponding 
annealing temperatures. Common N13F and N13R tailed sequences are shown in italics. 
 
Primer Name 5‟ to 3‟ primer sequence 
N13F gtagcgcgacggccagt 
N13R cagggcgcagcgatgac 
Table 2.10: N13 forward (N13F) and N13 reverse (N13R) primer sequences for use in 
cycle sequencing reactions. 
 
See Appendix 3 for HBB genomic DNA sequence with primer locations. 
 
5.1.c Full sequence HBB PCR set up 
A 25 µL PCR reaction was set up using Invitrogen Taq DNA polymerase kit (Invitrogen 
by Life Technologies, UK) in 0.5mL thin-walled PCR tubes to which 2.0µL of patient 
DNA (100-200ng) was added, except in the “no DNA” (blank control) to which 2.0 µL of 
sterile H2O was added. 
 
Three individual master mixes were prepared, for each of three overlapping fragments of 
the HBB gene. Each contained the following: 2.5µL of 10X Invitrogen PCR Buffer, 
0.75µL of 50mM MgCl2, 2.0µL of 10mM dNTP mix, 0.1µL Invitrogen Taq polymerase, 
2.0µL each of forward and reverse primer and 13.65µL of sterile H2O. 
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Each of the PCR reactions were then transferred to a Techne TC-3000 thermal cycler 
(Bibby Scientific, UK) and the „Beta.cyc‟ amplification programme was selected. The 
thermal cycling conditions consisted of an initial 3-minute denaturation at 94°C followed 
by 30 cycles of 94°C denaturation for 60 seconds, 60°C annealing for 45 seconds, and 
72°C extension for 1 minute and a final 5-minute extension at 72°C. 
 
5.1d Agarose gel electrophoresis 
Prior to DNA sequencing 4 µL of each PCR product was added to 2µL of loading dye, 
then analysed on a 1.0% agarose gel (w/v), to check that the amplification had been 
successful (See Section 3.3b). 
 
5.1e Purification of the PCR products by Microclean 
The amplification products, representing the essential regions of HBB sequence were then 
purified using microCLEAN (WebScientific, UK). MicroCLEAN is a one-tube DNA 
clean-up reagent which is used to purify double stranded DNA from reaction buffers, 
enzymes, dNTPs and primers.  
 
20µL of microCLEAN was added to each PCR DNA product then mixed by vortexing, 
and left at room temperature for 5 minutes. The tubes were then spun (Jouan SA 
microcentrifuge) at 70g for 5 minutes. All the supernatant was removed using a pipette 
and then the tubes were spun down again at 12000 rpm for 2 minutes. The dregs were 
removed using a pipette and the pellets were re-suspended in 20µL of sterile H2O and left 
for a minimum of 5 minutes in order to allow the DNA to rehydrate before proceeding to 
the next cycle sequencing step. 
 
5.1f Cycle sequencing 
Dye terminator cycle sequencing uses dideoxy chain termination chemistry in order to 
generate terminated DNA strands needed for sequence determination from single stranded 
DNA templates (Sanger, et al: 1977). 
 
During the cycle sequencing reaction the PCR template is terminated at every point along 
the strand due the random incorporation of a matching dideoxy nucleotide triphosphates 
(ddNTP). These are A, T, G and C base analogues containing base specific flurophores 
which are capable of emitting light at distinct wavelengths. These ddNTPs have a hydroxy 
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(OH) group missing at the 3' position (the location where one nucleotide would normally 
attach to another to form a chain) therefore in the absence of this OH group additional 
nucleotides cannot be added to the chain, thus interrupting chain elongation. The Big-
Dye® Terminator v3.1 Cycle sequencing Kit (Life Technologies, UK) contains all the 
components required for cycle sequencing, including ddNTPs, dNTPs, Amlitaq DNA 
polymerase FS, MgCl2  and reaction buffer. N13 forward and reverse primers were used 
(Table 2.10) in the appropriate cycle sequencing reactions in order to sequence the PCR 
product containing the N13 tails, allowing the PCR products to be sequenced using 
utilising only one sequencing primer set (forward and reverse). 
 
Cycle sequencing reaction set up 
The cycle sequencing reaction was carried out in a 96-well microtitre plate (Thermo 
Scientific, UK). On ice 4µL of each PCR product was aliquotted from the individual PCR 
tubes (representing each amplified segment of the gene), into each corresponding well of 
the plate.  
 
Two separate cycle sequencing reaction master mixes were prepared for each of the 
forward and reverse cycle sequencing reactions, for the appropriate number of reactions 
using the 1x reaction mix, to make up a total volume of 11µL (as detailed in Table 2.11).  
Reagent Volume per reaction 
(µL) 
Big Dye Terminator v3.1 
(Life Technologies, UK) 
1.0 
5x Cycle Sequencing Buffer 
(Life Technologies, UK) 
2.5 
N13F or N13R primer (2μM)  1.5 
sH20 6.0 
Table 2.11: Cycle sequencing reaction mix  
11µL of the N13 forward master mix was added to each forward reaction in the plate, 
containing the DNA templates, similarly 11µL of the N13 reverse master mix was added 
to each reverse reaction in the plate. The plate was sealed with a silicone septum, briefly 
centrifuged then transferred to an Primus 96 thermal cycler (MWG Biotech, Germany) run 
on the „B.Buffer‟ cycle, which consisted of an initial 3-minute denaturation at 96°C, 
followed by 25 cycles of: 96°C denaturation for 15 seconds, 50°C annealing for 10 
seconds, and 60°C extension for 2 minutes, then a final hold at 8°C. The samples were 
then stored, in the fridge at 4°C, until ready to proceed to the next purification step. 
71 
 
5.1g Purification of cycle sequencing products by ethanol precipitation 
Purification of the cycle sequencing reaction products was essential prior to sequencing 
analysis in order to remove unincorporated dye terminators. This was achieved by 
precipitating the cycle sequencing reactions directly in the 96 well plate using EDTA and 
ethanol precipitation. 
 
The plate (from step 3.1d) was removed from either the thermal cycler or the fridge and 
briefly spun at 40g for 30 seconds. Then, using a multi-channel pipette, 5µL of 125mM 
EDTA (Sigma-Aldrich, UK) (pH 8) and 70µL of 95% ethanol (Severn Biotech, UK) was 
added to each well. The plate was then sealed with a septum (Life Technologies, UK) then 
briefly vortexed and then incubated at room temperature for 15 minutes. The plate was 
then centrifuged (Thermo Jouan BR4i, UK) at 2600g for 30 minutes to precipitate the 
sequencing products. The seal was then removed and the plate inverted on to a paper towel 
and centrifuged at 170g for 1 minute to remove the supernatant. The purified products 
were then washed as follows: 60µL of 70% ethanol (Severn Biotech, UK) was added to 
each well, the plate was resealed with the septum then centrifuged for 15 minutes at 
1600g. 
 
The plate was then again inverted on to a paper towel and centrifuged at 170g for 1 minute 
to ensure all the supernatant was removed. The plate containing the purified cycle 
sequencing product was then wrapped in aluminium foil and incubated at room 
temperature for 15 minutes to ensure all the ethanol had evaporated, leaving only the DNA 
pellet. The plate was then re-sealed with the silicon septum and stored at -20°C or until 
ready for sequencing analysis. 
 
5.2 DNA sequencing analysis by Capillary Electrophoresis  
The samples were prepared for DNA sequencing by re-suspension of the purified 
sequencing pellets in "Hi-Di" Formamide (Life Technologies, UK). 15µL of Hi-Di was 
added to each well containing purified cycle sequencing products and the plate sealed with 
a septum and then briefly centrifuged at 40g for 30 seconds. The plate was then placed on 
a thermal cycler in order to denature the sequencing products by performing a 5-minute 
incubation at 94°C.  Immediately after the programme had finished the plate was placed 
on ice in order to prevent the formation of single stranded DNA secondary structures, then 
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the plate was briefly centrifuged again at 40g for 30 seconds, ensuring the Formamide was 
at the bottom of each well and that no bubbles were present. 
 
The 96 well plate containing the denatured cycle sequencing products was loaded onto the 
3130xl DNA Sequencer (Life Technologies, UK) and the appropriate patient details for the 
plate were entered in the „Plate Editor‟ window. The relevant parameters were selected: 
Instrument protocol: „FastSeq_POP7‟ and analysis method „Sequence analysis‟. During 
electrophoresis, the dye-labelled DNA fragments are injected into the 16 channel 50cm 
capillary array by electro-kinetic injection. When an electrical current is applied they 
move through the capillary, containing POP-7 liquid polymer (Life Technologies, UK) 
and are separated according to their size. As the terminated cycle sequencing fragments, 
each containing one of the four base-specific flurophores at the end of their terminated 
sequence pass through a fixed point in the electrophoretic capillary they are excited by a 
laser, the detector then records the florescent signal i.e. the characteristic wavelength at 
which each fluorophore emits light and a base name is assigned accordingly (A,T,G or C) 
to that point in the DNA sequence. As a result the DNA sequence data from the gene of 
interest is stored as an electropherogram from which further analysis can be performed. 
 
5.3 DNA Sequence data analysis 
Once the sequencing had been completed, the sequencing traces were provisionally 
reviewed and cropped appropriately using Applied Biosystems DNA sequencing Analysis 
Software version 5.2 (Life Technologies, UK). These .ab1 data files were then transferred 
to another computer for further mutation analysis using Mutation Surveyor software 
(SoftGenetics, USA). 
 
5.4 Analysis of sequencing data using Mutation Surveyor Software 
Further mutation detection analysis was performed using Mutation Surveyor version 3.97 
software (http://www.softgenetics.com/mutationSurveyor.html). This software was used to 
simultaneously perform variant analysis and mutation detection from Sanger sequencing 
.ab1files, generated by the ABI Capillary DNA Sequencer. It employs a range of 
algorithms to align and compare both the forward and reverse electropherograms, 
generated from the GenBank reference files against the patient traces, checking for 
dissimilar and similar peaks that are present. When the software detects a difference in 
sequence between the reference and patient sequences i.e. a heterozygote or homozygote 
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mutation(s), it is indicated by a peak in the comparison window, as shown in figure 2.8 
below: 
                                    
 
Figure 2.8: Mutation detected using the Mutation Surveyor software  
 
Figure 2.8 illustrates a patient DNA sequence trace compared against a reference DNA 
sequence trace. The middle rows show the comparison window highlighting the difference 
between the reference and patient sequence traces, indicating the presence of a 
heterozygous point mutation.  
 
See Section 5.8 for details of the HBB GenBank reference sequence used. 
 
5.5 PCR Amplification for the generation of HBG2 (
Gγ
) gene specific products 
This protocol was used to identify non-deletional HPFH mutations and the Xmn1
 Gγ -158 
(C>T) restriction site polymorphism, by full DNA sequence analysis of the essential 
regions of the HBG2 gene, which was amplified in a single fragment using one primer 
pair.  
See Section 5.8 for details of the HBG2 GenBank reference sequence used. 
 
5.5a Primer Design 
One primer pair (forward and reverse) was designed to amplify the following regions of 
HBG2, the primers were tailed with N13 (modified from M13 universal primer sequences) 
Patient reverse trace 
HBB GenBank reference reverse trace 
HBB GenBank reference forward trace 
Patient forward trace 
Difference between 
reference and patient 
sequence trace detected in 
the forward and reverse 
comparison window. 
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forward or reverse sequences respectively (as detailed previously in Table 2.10). Their 
sequences are detailed below in Table 2.12. 
 
 
 
 
 
 
 
Table 2.12: Primer sequences for the amplification of HBG2 and their corresponding 
annealing temperatures. Common N13F and N13R tailed sequences are shown in italics.  
 
See Appendix 4 for HBG2 genomic DNA sequence with primer locations. 
 
5.5b Full sequence HBG2 PCR set up 
A 25µL PCR reaction was set up using Invitrogen Taq DNA polymerase kit (Invitrogen by 
Life Technologies, UK) in 0.5mL thin-walled PCR tubes to which 2.0µL of patient DNA 
(100-200ng) was added, except in the “no DNA” (blank control) to which 2µL of sterile 
H2O was added. 
 
One master mix was prepared, each containing: 2.5µL of 10X Invitrogen PCR Buffer, 
0.75µL of 50mM MgCl2, 2.0µL of 10mM dNTP mix, 0.1µL Invitrogen Taq polymerase, 
2.0µL each of Xmn forward and reverse primer and 13.65µL of sterile H2O. 
 
Each of the PCR reactions were then transferred to a Techne TC-3000 thermal cycler 
(Bibby Scientific, UK) and the „Beta.cyc‟ amplification programme was selected. The 
thermal cycling conditions consisted of an initial 3-minute denaturation at 94°C followed 
by 30 cycles of 94°C denaturation for 60 seconds, 60°C annealing for 45 seconds, and 
72°C extension for 1 minute and a final 5-minute extension at 72°C. 
 
Agarose gel electrophoresis was then carried (as detailed in Section 3.3b) in order to check 
that the amplification had been successful, the PCR products were then purified by 
microCLEAN (as detailed earlier in Section 5.1e). Cycle sequencing, purification of the 
cycle sequencing products by ethanol precipitation and then DNA sequencing analysis by 
Capillary Electrophoresis and DNA Sequence data analysis using Mutation Surveyor 
Software was carried out as detailed in sections 5.1f to 5.4 above. 
 
HBG2 
Primer 
Primer sequence 5‟ to 3‟ Annealing 
Temp. (ºC) 
Product size (inc. 
N13 tails) (bp) 
XmnF 
gtagcgcgacggccagt 
GAACTTAAGAGATAATGGCCTAA 
60 655 
XmnR 
cagggcgcagcgatgac 
TAGTCCAGACGCCATGGGTCA 
60 655 
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See Section 5.8 for details of the HBG2 GenBank reference sequence used and the primer 
locations. 
 
5.6 PCR Amplification for the generation of HBA1 and HBA2 gene specific products 
This protocol identified mutations by full DNA sequence analysis of the essential regions 
of the HBA1 and HBA2 genes. This enabled the identification of non-deletional forms of 
alpha thalassaemia and alpha globin chain variants. HBA1 and HBA2 were amplified as 
single amplicons using a common 5‟ forward primer in combination with a specific 3‟ 
alpha-1 or alpha-2 reverse primer. Due to the high sequence homology between HBA1 and 
HBA2, it was essential to check the design of the specific reverse primers to ensure that the 
correct alpha globin gene was amplified. 
The size of the HBA1 and HBA2 gene PCR products are shown below in Figure 2.9.  
 
 
 
 
 
 
Figure 2.9: Location of PCR primer pairs along the HBA1 and HBA2 genes. 
 
The sequences of the primers used are detailed below in Table 2.13. 
 
PCR Primer 
 
Primer sequence 5‟ to 3‟ 
Annealing 
Temperature (ºC) 
Common α-F 
gtagcgcgacggccagtGTGGAGGGT
GGAGACGTCCTG 
66.5 
Specific α1-R 
cagggcgcagcgatgacGAGAGGTTC
TAGCCATGTGTG 
57.4 
Specific α2-R 
cagggcgcagcgatgacCCATTGTTGG
CACATTCCGG 
66.6 
Table 2.13: Primer sequences and their corresponding annealing temperatures, used 
for the amplification of HBA1 and HBA2 (the common N13 sequences are shown in 
italics). 
 
This PCR protocol was optimised based on a protocol used by King‟s College Hospital 
NHS Trust. Initially a Thermo Scientific Reddymix PCR kit (Thermo Fisher Scientific, 
UK) was used that combined of all the essential components needed for a PCR including a 
gel-loading dye, into one single master mix. This allowed the completed PCR sample to be 
directly loaded onto an agarose gel therefore eliminating many pre- and post- PCR steps. 
HBA2 HBA1 
Ex 1 Ex 2 Ex 3 Ex 1 Ex 2 Ex 3 
Com -F 2 sp-R 
1168bp 1121bp 
5‟ 3‟ 
Com -F 1 sp-R 
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Due to manufacturing problems encountered with this PCR kit, limiting its supply this 
assay was adapted using a KAPA 2G Robust PCR Kit (Kapa Biosystems, Africa), as 
described above for the HPFH and Multiplex-2 assays.  
 
5.6 a Full sequence HBA1 and HBA2 PCR set up 
Separate PCR reaction mixes for the amplification of the alpha 1 and 2 genes was 
required, with each master mix containing either the -1 or -2 specific primers, along 
with the common forward primer. 
 
25µL PCR reactions were performed using 0.5mL thin-walled PCR tubes (Peqlab, UK), to 
which 2.0µL of patient DNA (100-200ng) was added, except in the “no DNA” (blank 
control) to which 2µL of sterile H2O was added. Two master mix reactions were made for 
each of alpha globin gene reactions and for the appropriate number of sample required, 
each containing: 5µL of 5x KAPA2G GC PCR Buffer (with MgCl2), 0.5µL of KAPA 
10mM dNTP mix, 0.3µL of KAPA2G Robust DNA polymerase, 1.0µL of (5µM) common 
alpha forward primer and 1.0µL of either and α-1 or α-2 specific reverse primer and 
15.2µL of sterile H2O. 
 
Each of the PCR reactions were then transferred to a PeqStar 96 Universal Gradient 
thermal cycler (Peqlab, UK) and either the „ALPHA-1.Kappa.cyc‟ or „ALPHA-
2.Kappa.cyc‟ amplification programme was selected. Each thermal cycler programme 
consisted of a touchdown PCR protocol, detailed below, in which different starting 
annealing temperatures were used for the alpha-1 and alpha-2 globin genes. 
„ALPHA-1.Kappa‟    „ALPHA-2.Kappa‟ 
  Initial Denaturation: 95 C for 3mins   95 C for 3mins 
 5 Cycles of:       
 95 C for 30 sec (Denature)    95 C for 30 sec 
   62 C for 30 sec (Anneal)   66 C for 30 sec 
  72 C for 1 min (Extension)   72 C for 1min 
  5 Cycles of:       
 95 C for 30 sec   95 C for 30 sec 
    60 C for 30 sec   64 C for 30 sec 
   72 C for 1min    72 C for 1min 
   25 Cycles of:  
  95 C for 30 sec    95 C for 30 sec 
  58 C for 30 sec    62 C for 1min 
  72 C for 1min     72 C for 1min 
   72 C for 1min (Final Extension) 72 C for 1 min 
 8 C Hold Forever     8 C Hold Forever 
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Agarose gel electrophoresis was then carried (as detailed in Section 3.3b) in order to check 
that the amplification had been successful.  
 
The PCR products were then purified by microCLEAN, as detailed earlier in Section 
(5.1e). 
 
5.6 b Internal quality control 
Most genomic DNA samples will generate an -1 PCR product but for those individuals 
who are homozygous for the alpha 3.7 kb or 4.2 kb deletion will not produce an -2 PCR 
product, therefore prior to alpha sequencing, alpha Gap-PCR analysis was carried out so 
the alpha deletion status of the individual is known. 
 
5.6 c Cycle Sequencing 
The alpha 1 and 2 gene specific PCR products (from step 5.5a) were used as individual 
templates for the Big Dye Terminator cycle sequencing reaction (as discussed in Section 
5.1f). Cycle sequencing of each of the HBA1 and HBA2 gene-specific PCR products was 
performed using four primers; N13F and N13R primers (as previously detailed in Table 
2.10) and two internal forward and reverse exon primers. (Sequences detailed below in 
Table 2.14).  
 
These primers provided a good coverage of each of the alpha globin genes as they 
provided an overlapping sequence read, their respective product sizes are shown below in 
Figure 2.10:  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Cycle sequencing of HBA1 and HBA2. 
 
 
691 bp 
706 bp 
 
 N13F 
N13R  
Exon 2 - 3'  
Exon 2 - 5'  
   
Exon1 Exon2 
GCGGC
GGGCC
GGGAG
CGATCT
GGGTC
GAGGG
GCGAG
ATGGCG
CCTTCC
TCTCAG
GGCAG
AGGATC
ACGCGG
GTTGCG
GGAGG
TGTAGC
GCAGGC
GGCGG
CTGCGG
Exon3 
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Internal exon cycle 
sequencing primers 
Primer sequence 5‟ to 3‟ 
αEx2-5‟F ACCCCTCACTCTGCTTCTC 
αEx2-3‟R CCTCGACCCAGATCGCT 
Table 2.14: Details of the internal exon cycle sequencing primers used for cycle 
sequencing. 
 
See Appendix 5 for HBA1 and HBA2 genomic DNA sequence with primer locations 
 
Cycle sequencing reaction set up 
The cycle sequencing reactions were carried out directly in a 96-well plate (Thermo 
Scientific, UK) format. On ice, 2 µL of purified PCR product (template DNA), 
representing each fragment of the alpha 1 or alpha 2 gene as appropriate, was aliquotted 
from the individual PCR tubes into each corresponding well of the plate. 
 
For the sequencing of both alpha genes for a single patient, a total of 8 different PCR 
product and primer combinations are present, but as the master mixes for the α1 and α2 re-
sequencing  
are the same, only four different sequencing master mixes were required. 
 
Four separate cycle sequencing reaction master mixes were prepared for each of the four 
different primer (N13F, N13R, αEx2-5‟ common F, αEx2-3‟ specific R) cycle sequencing 
reactions, for the appropriate number of reactions using the 1x reaction mix, to make up a 
total volume of 13µL, detailed below in Table 2.15: 
Reagent Volume per 
reaction (µL) 
Big Dye Terminator v3.1  
(Life Technologies, UK) 
1.0 
5x Cycle Sequencing Buffer 
(Life Technologies, UK) 
2.5 
N13 forward primer (3.3μM)  1.0 
N13 reverse primer (3.3μM)  
αEx2-5‟ common F primer 1.0 
αEx2-3‟ specific R primer 1.0 
sH20 8.5 
Table 2.15: Master mix volumes for HBB cycle sequencing reaction. 
13µL from each of the four master mix reactions were added separately to each 
appropriate well in the microtitre plate, containing the DNA template. The plate was then 
sealed with a septum, briefly centrifuged then transferred to a Primus 96 thermal cycler 
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(MWG Biotech, Germany) and run on the „Alpha.SEQ.cyc‟ programme, which consisted 
of an initial 3-minute denaturation at 96°C, followed by 25 cycles of 96°C denaturation for 
15 seconds, 55°C annealing for 10 seconds, and 60°C extension for 2 minutes, then a final 
hold at 8°C. 
The cycle sequencing products were then purified by ethanol precipitation (Section 5.1g) 
and sequencing analysis was carried out on the ABI Prism 3130xl Capillary DNA 
Sequencer (Life Technologies, UK) (Section 5.2) and then analysed using Mutation 
Surveyor Software (Sections: 5.3 and 5.4). 
See Section 5.8 for details of the HBA1 and HBA2 reference sequences used and the 
primer locations. 
 
5.7 Confirmation of results 
When a point mutation had been detected in either HBA1, HBA2 or HBB, it was confirmed 
by repeat PCR amplification of the appropriate portion of the gene, using the original 
patients DNA sample, as described in either Sections 5.1c (HBB) or 5.5a (HBA), and then 
sequenced and analysed as detailed in Sections: 5.1d-g, 5.2 to 5.4. 
 
5.8 Online Resources and mutation nomenclature 
A list of reported causative alpha and beta thalassaemia mutations are contained within an 
online repository known as the database of human variants and thalassaemias 
(http://globin.psu.edu). This locus specific database (LSD) was consulted to determine if a 
change detected had been previously reported and to assess its pathogenic nature and 
clinical manifestations. The base and amino acid numbering of each mutation found was 
determined by referring to this haemoglobinopathy database and published HBA1, HBA2 
and HBB sequences. Each mutation described at the amino acid level was numbered as +1 
from the initiator methionine, as per the LSD. Mutations were also described at the cDNA 
level according to guidance issued by the Human Genome Variation Society 
(http://www.hgvs.org/). Note that the LSD does not use HGVS numbering at the protein 
level.  Any unclassified changes that had not been previously reported were assessed by 
unclassified variant in silico analysis tools including Almaut (Interactive Biosoftware, 
France). 
 
Reference sequences for HBB, HBG2, HBA1 and HBA2 were obtained from Ensemble 
database (http://www.ensembl.org/index.html). Their respective GenBank reference 
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sequences are: HBB: NM_000518.4, HBG2: NM_000184.2, HBA1: NM_000558.3 and 
HBA2: NM_000517.4. 
 
6.0 Multiplex Ligation Probe Amplification (MLPA) 
Multiplex Ligation Probe Amplification (MLPA) (MRC-Holland, the Netherlands) is a 
sensitive laboratory method for the relative quantification of copy number or dosage of 
many nucleic acid sequences in a single reaction containing, requiring only 200ng of 
genomic DNA.  
 
It is useful for the detection of rare or previously uncharacterised deletions or duplications 
affecting the alpha or beta globin gene clusters and unlike other diagnostic assays such as 
sequencing, it is capable of detecting copy number changes of complete exons. 
 
In this project MLPA was used for the identification of unknown deletions when a 
causative mutation could not be identified using the assays described above.  
 
MLPA is based on the hybridisation or binding of one MLPA probe (consisting of two 
oligonucleotides directly flanking the DNA target sequence). The two parts of each probe 
hybridize to adjacent target sequences and are ligated by a thermostable ligase. All of the 
ligated probes are subsequently amplified in a single PCR reaction, using only one primer 
pair. The resulting amplification products of each probe have a unique length of between 
130-480 nucleotides which are then separated and analysed by capillary electrophoresis. 
The relative amounts of probe amplification products, as compared to a control DNA 
sample, reflect the relative copy number of target sequences. In the presence of a 
heterozygous gene deletion, fewer MLPA probes will hybridise, resulting in a 
characteristic reduction in probe height by up to 50%. 
 
Two separate SALSA MLPA kits were used in this project; P140 (version B2) for analysis 
of the alpha globin gene cluster and P102 (version B1) for analysis of the beta globin gene 
cluster. Each kit comprises the same reagents needed for ligation and PCR, but each with a 
unique probemix. The P140-B2 HBA SALSA MLPA kit contains 38 individual probes, 
including one probe that is specific for the detection of the Constant Spring point 
mutation, with amplification products of between 130 and 409 nucleotides and is designed 
to detect copy number changes of 24 different sequences within the alpha globin gene 
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cluster. The P102-B1 HBB SALSA MLPA kit contains 43 probes, including one probe 
that is specific for the sickle-cell point mutation, with amplification products of between 
130 and 481 nucleotides and is designed to detect deletions/duplications within the beta 
globin gene cluster. 
 
In addition, both of these kits contain nine control fragments generating amplification 
products smaller than 120 nucleotides, including: four DNA Quantity fragments (Q-
fragments) at 64, 70, 76 and 82 nucleotides, which are only visible when the DNA sample 
quality is less than 100ng, three DNA denaturation control fragments (D-fragments) at 88, 
92 and 96 nucleotides, which when found at a low signal indicate incomplete denaturation, 
one X-fragment at 100 nucleotides, specific for the X chromosome and one Y-fragment at 
105 nucleotides, specific for the Y chromosome. 
 
Figures 2.11 below show a schematic representation of the location of the probes in the 
P140-B2 HBA and P102-B1 HBB MLPA kits, where the numbers above the arrows 
represent the amplification size of the respective probe in nucleotides: 
 
Figure 2.11a:                      
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Figure 2.11b:                         
 
Figure 2.11: Schematic representation of the location of the probes in the (a)P140-B2 
HBA MLPA kit (Description version 22; 24/12/2011) and the (b) P102-B1 HBB 
MLPA kit (Description version 14; 24/08/2011) (Obtained from MRC-Holland: 
www.mlpa.com). 
 
See Appendix 6 and 7 for details of SALSA MLPA P140-B2 HBA and P102-B1 HBB 
probemix, with their corresponding chromosomal positions.    
 
Figures 2.12 below shows the actual capillary electrophoresis pattern of the amplified 
probe profile across the alpha and beta globin gene clusters: 
                                                                      
 
 
 
Figure 2.12a: Capillary electrophoresis pattern from a female control DNA sample of 
analysed with SALSA MLPA kit P140-B2 HBA (lot 0508). 
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Figure 2.12b: Capillary electrophoresis pattern from a male control DNA sample of 
analysed with SALSA MLPA kit P102-B1 HBB (lot 0508). 
 
 
6.1 Method 
MLPA was performed in a single reaction and can be divided into three main steps: 
 
6.1a DNA Denaturation and hybridisation of the SALSA MLPA probes 
1. The DNA was diluted with TE buffer, at least 24 hours beforehand, to a concentration 
of 40ng/µL. 
2. 5µL of diluted DNA was added to appropriately labelled 0.2µL dome cap, thin-walled 
strip tubes (Alpha laboratories, UK). At least seven „normal‟ controls and one blank was 
included on each run. 
3. The sample strips were then loaded onto an Applied Biosystems 2720 thermal cycler 
(Life Technologies, UK) and denatured at 98°C for 5 minutes then left to cool to 25°C. 
4. Once the samples had cooled to 25°C, using a multi-channel pipette, 1.5µL of MLPA 
buffer and 1.5µL of Probemix (MRC Holland) was added to each of the samples whilst sat 
on the thermal cycler.  
5. The samples were left to hybridise overnight by selecting the „Hybrid+Ligate‟ 
programme on the Applied Biosystems 2720 thermal cycler which consisted of: 1 minute 
initial incubation at 95°C followed by 18 hours at 60°C. 
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6.1b Ligation reaction 
It was crucial at this stage the samples are not removed from the thermal cycler block 
1. A ligase buffer mastermix master of the following was prepared: 
 
Reaction Component Volume/per reaction 
(µL) 
Ligase Buffer A 3.0 
Ligase Buffer B 3.0 
Sterile H2O 25 
Ligase-65 1.0 
2. 32µL of the above mastermix was transferred to each of the samples on the thermal 
cycler held at 54:C. 
3. The „Hybrid+Ligate‟ program was then resumed to the next step, which consisted of: 15 
minute incubation at 54:C, followed by 5 minutes at 98:C then final hold at 4:C. 
 
6.1c MLPA PCR reaction 
1. A master mix consisting of: 4µL of SALSA PCR buffer and 26µL sterile H2O was 
prepared. 
2. 30µL of this master mix was aliquotted into a set of new 0.2µL thin-walled, flat-cap 
strip tubes (Starlab, UK), that were labelled with the same corresponding sample numbers 
at is in step 2 (Section 6.1a). 
3. 10µL of the ligation product (from Section 6.1b) was transferred into the tubes 
containing the SALSA PCR master mix. 
4. The tubes were then loaded onto the thermal cycler and the „MLPA-PCR‟ programme, 
the samples were initially held the 60:C hold step. 
5. Meanwhile, a PCR master mix of the following reagents was prepared: 
 
Reaction Component Volume/per reaction 
(µL) 
SALSA primers 2.0 
SALSA enzyme dilution 
buffer 
2.0 
Sterile H2O 5.5 
SALSA polymerase 0.5 
6. Using a multi channel pipette, 10µL of the above PCR polymerase master mix was 
added to each tube sitting on the thermal cycler. 
7. The „MLPA PCR‟ program was resumed, and the thermal cycle conditions consisted of 
33 cycles of: 95°C denaturation for 30 seconds, 60°C annealing for 30 seconds, and 72°C 
85 
 
extension for 1 minute, followed by a final 20 minute extension at 72°C, then a hold step 
at 4°C. 
 
6.2 Separation of amplification products by capillary electrophoresis 
1. This step is carried out directly into a 96-well plate format (Thermo Scientific, UK). 
2. A master mix of 9µL of Formamide and 0.3µL of ROX-500 size standard was prepared 
for the appropriate number of samples. 
3. 9.3µL of the above master mix was aliquotted into each sample well of the plate. 
4. 1µL of the MLPA PCR product, (from Section 6.1c) was added to each corresponding 
well of the plate, containing the master mix.  
5. The plate was sealed with a septum and briefly centrifuged. 
6. The plate was then placed on the thermal cycler and denatured for 2 minutes at 94°C. 
7. The plate was then placed on ice to „snap-chill‟ for two minutes, to ensure the DNA 
products remain single stranded. 
8. The plate was then loaded onto the ABI Prism 3130xl Capillary DNA Sequencer (Life 
Technologies, UK) in order to carry out the fragment analysis, entering the following 
specific parameters in Life Technologies Genemapper plate editor: 
 
Sample Type: Sample 
Size Standard: GS500(-35) 
Panel: HBB or HBA panel, as appropriate 
Instrument protocol: Fragment Analysis _POP7 
Analysis method: HBB  or HBA_ANALYSIS 
 
6.3 MLPA Data analysis using Genemapper Software (Life Technologies, UK) 
Once the fragment analysis had been completed, the relevant sample files (.fsa) were 
imported and analysed in Genemapper software (version 4). Provisional analysis of the 
morphology and designations of the size standard was done, and the MLPA probe data 
was inspected, ensuring all the appropriate control probes were present and that there was 
no unexplainable loss in the signal of the probes. The raw result table was then exported in 
a .txt which was then imported to an Excel spreadsheet, below, for further analysis. 
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6.4 MLPA Data analysis using manual Excel spreadsheet 
Further fragment analysis and visualisation of the probes was performed using the 
appropriate Excel based interpretation macro (http://www.ngrl.org.uk/Manchester/ 
publications/ MLPA) for either HBA (P140-B2HBA-v18) or HBB (P102-B1HBA-v12). 
This macro normalised the electrophoresis results by comparing the relative probe signals 
from all the samples to each other and to the control probes, which was essential for 
obtaining accurate MLPA data (www.mlpa.com).  From this intra assay analysis a 
„Sample quality‟s score was produced, and each sample must pass this score i.e the 
standard deviation must be less than 0.1. Samples with a quality value exceeding 0.1 were 
rejected.  
 
Once the reliability of the data has been established a deletion in one copy of a probe 
target sequence (a deletion in either the alpha or beta globin gene clusters) was apparent 
by a reduction in relative probe peak height for that probe amplification product of 35-
55%. 
 
Figures 2.13 below show the diagrammatic representation of the MLPA probe data as a 
histogram, produced from the Excel spreadsheet
 
Figure 2.13a: Histogram showing HBA MLPA probe data from a patient DNA 
sample with a homozygous alpha plus deletion, showing probes missing. 
 
C
1
 5
q
3
1
 
C
2
 9
q
2
2
 
C
3
 1
5
q
1
1
 
C
4
 1
7
q
2
1
 
C
5
 1
p
2
1
 
C
6
 5
p
1
5
 
C
7
 5
q
2
2
 
C
8
 1
1
p
1
3
 
C
9
 1
1
q
2
2
 
C
1
0
 5
q
2
2
 
C
1
1
 3
q
2
9
 
P
O
L
R
3
K
 
H
S
-4
0
(i
) 
H
S
-4
0
(i
i)
 
9
.3
k
b
+
H
B
Z
 
3
.5
k
b
+
H
B
Z
 
H
B
Z
_
H
B
Z
P
(i
) 
H
B
Z
_
H
B
Z
P
(i
i)
 
H
B
A
2
P
_
H
B
A
1
P
 
H
B
A
1
P
_
H
B
A
2
(i
) 
H
B
A
1
P
_
H
B
A
2
(i
i)
 
H
B
A
1
P
_
H
B
A
2
(i
ii)
 
H
B
A
1
P
_
H
B
A
2
(i
v
) 
H
B
A
1
/2
 E
x
1
 
H
B
A
2
 i
2
(i
) 
H
B
A
2
i2
(i
i)
 
H
B
A
1
/2
 E
x
3
 
H
B
A
2
 E
x
3
 
H
B
A
2
_
H
B
A
1
(i
) 
H
B
A
2
_
H
B
A
1
(i
ii)
 
H
B
A
2
_
H
B
A
1
(i
v
) 
H
B
A
1
+
0
.2
k
b
 
H
B
A
1
+
0
.5
k
b
 
H
B
A
1
+
2
.4
k
b
 
H
B
A
1
+
3
.7
k
b
 
H
B
A
1
+
2
.6
M
b
 
C
 S
p
ri
n
g
 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
P
a
ti
e
n
t.
2
  
87 
 
           
 
Figure 2.13b: Histogram showing HBA MLPA probe data from a control DNA 
sample. 
 
6.5 Quality control 
Mutations or polymorphisms within the sequence detected by a probe may also result in a 
reduced relative peak area due to failure to bind a probe.  Therefore apparent deletions 
detected by a single probe must always be confirmed by an alternative method. 
Furthermore, due to the number of alpha globin genes the relevant probes will only show a 
relative decrease in signal of between 20-25%. 
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Chapter 3: Results 
 
All patient data discussed in this chapter is derived from the raw information contained 
within Appendix 8. 
 
3.0 Sample referral 
Between July 2008 and December 2011, 328 referrals from the NW were genotyped at 
Manchester Royal Infirmary as part of the national Antenatal and Newborn Screening 
Programme. A range of genetic analysis was carried out on each sample, including Gap-
PCR, full gene sequencing and MLPA, as described in chapter 2. 
 
3.1 Proportion of all haemoglobinopathy diagnoses 
The total number of haemoglobinopathy diagnoses (Table 3.1) comprised of: 34% 
(n=113) alpha thalassaemia, 33% (n=109) beta thalassaemia, 17% (n=55) were compound 
heterozygous for an alpha and beta thalassaemia mutation and/or variants and 3% (n=10) 
of patients had a mutation resulting in HPFH or δβ thalassaemia. In the remaining 13% 
(n=41) of referrals either no causative mutation was detected or the genotype detected was 
not enough on its own to account for the patients‟ phenotype. 
 
Globin chain/disorder Number 
of patients 
Percentage of total 
referrals (%) 
Alpha thalassaemia 113 34 
Beta thalassaemia 109 33 
Compound 
heterozygous (α and β- 
chain mutations) 
55 17 
No causative mutation 
detected 
41 13 
HPFH/δβ disorder 10 3 
Table 3.1:  Breakdown of the total number of haemoglobinopathy diagnoses 
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Figure 3.1: Total haemoglobinopathy diagnoses 
Figure 3.1 shows that the largest proportion of patient diagnoses was either alpha or beta 
thalassaemia which comprised 34% (n=113) and 33% (n=109) of all patient referrals 
respectively. A total of 17% (n=55) of patients had a compound heterozygous genotype 
i.e. a mutation within both of the beta and alpha globin genes, these cases are discussed 
further in Section 7.0. A further 3% (n=10) of patients had a HPFH or δβ disorder, and in 
the remaining 13% (n=41) of patient cases genetic testing within the Molecular 
Diagnostics Centre did not detect a causative mutational mechanism, or the genotype 
detected was not enough on its own to account for the patients phenotype (these are 
discussed further in Section 11.0). 
 
3.2 Stated ethnicity of all patients referrals 
The ethnicity of each patient was recorded either on the Family Origin Questionnaire 
(FOQ), completed by a healthcare professional or on the appropriate paperwork as part of 
the routine antenatal genetic referral process. 
 
The stated ethnic group of each patient was recorded according to the categories outlined 
on the FOQ: „Mixed‟, „White‟, „Mediterranean‟ (MED), „Asian‟, „South East 
Asian‟(SEA), „Black‟, „Arabic‟, „Any other‟ or when this information was not available, 
„Not stated‟. This information was then collated in order to asses the incidence of 
haemoglobinopathy disorders within each ethnic group referred from the North West 
34% 
(n=113) 
33% 
(n=109) 
17% 
(n=55) 
3% 
(n=10) 13% 
(n=41) 
Alpha thalassaemia 
Beta thalassaemia 
Compound Heterozygote 
(α and β mutations) 
HPFH/δβ 
No caustive mutation 
detected 
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population, as shown below in Figure 3.2:           
 
Figure 3.2: Proportion of patient ethnic groups referred 
Figure 3.2 demonstrates ethnic diversity of the North West referral population. The 
incidence of haemoglobinopathies was highest in the Asian (26%) ethnic group, followed 
by South East Asian (21%) and Black (20%) ethnic groups, with the other ethnic groups 
collectively comprising 33% of all referrals. The three ethnic groups that formed the 
largest proportion of patient referrals were further sub-divided into more specific 
ethnicities so that further analysis could be performed.  This is represented graphically 
below in figures 3.3a to 3.3c. 
36 (11%) 
6 (2%) 
86 (26%) 
69 (21%) 
67 (20%) 
15 (5%) 
15 (5%) 
2 (1%) 
32 (10%) 
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MEDITERRANEAN 
ASIAN 
SOUTH EAST ASIAN 
BLACK 
ARABIC 
MIXED 
OTHER 
NOT STATED 
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Figure 3.3a: Proportion of South East Asian ethnic subgroups 
Figure 3.3a shows that from all the diagnoses made in those patients from the South East 
Asia (21%, n=69) ethnic group, a large proportion comprised those from Chinese (59%, 
n=41) and Thailand or Filipino (23%, n=16) ethnic sub-groups. 
           
 
Figure 3.3b: Proportion of Asian ethnic subgroups  
 
Figure 3.3b shows that of the diagnoses made in those patients from the Asian ethnic 
group (26%, n=86), a large proportion comprised those from Pakistani (42%, n=36) and 
Indian (33%, n=28) ethnic groups. 
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Figure 3.3c: Proportion of Black ethnic subgroups 
 
Figure 3.3c shows that from the diagnoses made in those patients from the Black ethnic 
group (20%, n=67), the largest proportion of these patients were those originating from 
the African ethnic group (72%, n=48). 
 
3.3 Mutation data analysis 
In the following sections analysis of all the genotypes encountered with the patient 
referrals was performed in order report the spectrum and frequency of haemoglobinopathy 
mutations found within the MDC. The distribution and frequency of mutations detected in 
each individual was then related to their ethnic group, where known, and assessed in terms 
of whether or not that mutation would be expected in their ethnic group from previous 
population studies. This enabled us to assess the effectiveness of our broader genetic 
screening approach versus ethnic led, targeted mutation screening. 
 
This data is reported below according to the nature of the mutations and the laboratory 
methods used.  
 
4.0 Gap-PCR analysis for the detection of deletional forms of alpha thalassaemia 
A total of 131 patients (40% of the total haemoglobinopathy referrals) had a form of 
deletional alpha thalassaemia (4 patients were not tested for deletional alpha thalassaemia 
due to the limited quantity of DNA available). 
 
36 
6 
86 
69 
15 15 
2 
32 
48 
2 
4 
13 67 
WHITE 
MEDITERRANEAN 
ASIAN 
SOUTH EAST ASIAN 
ARABIC 
MIXED 
OTHER 
NOT STATED 
BLACK: African 
BLACK: Afro-Caribbean 
BLACK: British 
BLACK: Caribbean 
93 
 
All patient referrals were then categorised based on the clinical severity of their genotype 
and then a comparison made to their stated ethnicity. A total of 42% (n=55) of all patients 
identified with a deletional form of alpha thalassaemia had a mild alpha plus genotype (-
α3.7 or –α4.2), whereas 18% (n=24) of patients had homozygous alpha plus thalassaemia 
trait. A total of 32% (n=42) of patients had a clinically severe genotype of alpha zero 
thalassaemia trait, and 4% of patients (n=5) had deletional Hb H disease. Furthermore 4% 
of patients (n=5) had the triplicated alpha genotype. 
                              
 
Figure 3.4: Distribution of deletional alpha thalassaemia genotypes between ethnic 
groups 
 
Figure 3.4 above shows that the majority of severe deletional alpha genotypes were 
reported mainly in patients from the South East Asian group, where alpha zero 
thalassaemia and deletional Hb H disease was most prevalent. The mixed ethnic group, 
although small in number overall (n=6) had a high proportion (n=4) of alpha zero 
thalassaemia. There was also a large proportion (n=5) of alpha zero thalassaemia reported 
in the White ethnic group, mainly accounted for by the north west of England originating -
-BRIT deletion. Furthermore, mild and clinically insignificant genotypes such as alpha 
plus trait and homozygous alpha plus were prevalent in Black, Asian and Arabic ethnic 
groups.  
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The distribution and frequency of all deletional forms of alpha thalassaemia detected were 
then analysed and their frequency determined within each ethnic group, as shown in 
Figures 3.4a and 3.4b.  
                         
 
Figure 3.4a: Distribution of deletional alpha thalassaemia genotypes between ethnic 
groups. 
Figure 3.4a shows that heterozygosity for the alpha plus -α3.7 deletion and alpha zero --SEA 
deletion were the most common deletional genotypes within the referral population, 
comprising 55% (n=72) and 25% (n=33), respectively of all deletional alpha thalassaemia 
genotypes.  
This data has been further modified in Figure 3.4b to exclude the large number of patients 
with –α3.7 and --SEA deletions in order to show the distribution of other deletional alpha 
thalassaemia genotypes more clearly: 
                  
 
Figure 3.4b: Distribution of deletional alpha thalassaemia mutations between ethnic 
groups (excluding heterozygous –α3.7 and --SEA genotypes). 
0 
10 
20 
30 
40 
50 
60 
70 
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
 
Alpha deletion 
Not Stated 
Any Other 
Mixed   
Mediterranean 
Arabic 
White 
Asian 
Black    
SEA 
0 
1 
2 
3 
4 
5 
6 
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
 
Deletional alpha genotype 
Not Stated 
Any Other 
Mixed   
Mediterranean 
Arabic 
White 
Asian 
Black    
SEA 
95 
 
In proportion to the total number of patients referred within each ethnic group, the largest 
incidence of deletional alpha thalassaemia is found in those patients from South East 
Asian, 65% (n=45) and Black, 48% (n=32) ethnic groups. 
 
The proportion of patients with a deletional alpha thalassaemia genotype was then 
correlated according to whether their genotype would be expected within their stated 
ethnicity, shown in Figure 3.5: 
                            
 
Figure 3.5: Proportion of all deletional alpha thalassaemia patient genotypes 
according to expected ethnicity. 
 
Figure 3.5 shows that a large proportion of patients with a deletional alpha thalassaemia 
genotype had a deletion(s) which would be expected in their ethnic group, this shows that 
there was a strong correlation between the patients‟ stated ethnicity and their genotype, for 
example the five reported cases of the alpha zero --BRIT deletion was exclusively found 
in patients from the „White‟ ethnic group, and of the majority (62%, n=5) of patients with 
the alpha plus –α4.2 deletion were, as expected were from the SEA ethnic group. 
Conversely the triplicated alpha genotype was found in a variety of ethnic groups. 
 
5.0 DNA sequencing of HBA1 and HBA2 for the detection of point mutations and 
small deletions associated alpha thalassaemia. 
Of the total number of genetic referrals received (n=328), 265 patients that had their 
HBA1 and HBA2 genes sequenced, the remaining 63 patients did not have their alpha 
globin genes sequenced as it was either deemed unnecessary or the causative genotype had 
already been detected. A causative non-deletional mutation i.e. a point mutation or a small 
deletion/insertion was detected within either of the alpha globin genes by DNA 
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sequencing in 18% (n=59) of all the patient referrals, including both non-deletional alpha 
thalassaemia and alpha chain variants. No causative alpha mutation was detected in 58% 
(n=190) of patients, in the remaining 16 patients a candidate change was detected, but the 
change was not previously unreported on the Hb variant database. Subsequent in silico 
analysis by Alamut software was used to asses the pathogeneicity of these changes, and if 
it the mutation was subsequently deemed to be of significance i.e. a missense or splice site 
mutation it was reported alongside the patients‟ phenotypic data, although in the absence 
of protein expression studies clinical interpretation could not be offered. 
 
Of the 59 causative mutations detected, 30 were found within the HBA1 gene and 29 
within the HBA2 gene. The breakdown of the class of mutations detected as shown in 
Figure 3.6. 
                                
Figure 3.6: Proportion of all non-deletional alpha thalassaemia mutations detected by 
DNA sequencing of HBA1 and HBA2. 
 
Figure 3.6 shows that out of all of the patient cases in which a causative mutational change 
was detected within the alpha globin genes, 10% (n=6) of patient cases were classified as 
non-deletional alpha thalassaemia and 90% (n=53) were classified as an alpha chain 
haemoglobin variant. The clinical significance, or otherwise, of these variants is discussed 
in section 5.2. 
 
5.1 Non-deletional form of alpha thalassaemia 
The distribution of the mutations detected that are associated with non-deletional alpha 
thalassaemia were then correlated according to the patients‟ stated ethnicity, as shown in 
Figure 3.7 below: 
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Figure 3.7 Proportion of non-deletional alpha thalassaemia within each ethnic group 
 
Figure 3.7 shows that a total range of 5 different non-deletional mutations causing alpha 
thalassaemia were found within all patient referrals. The highest incidence of non-
deletional alpha thalassaemia was found in those patients from Asian ethnic groups, 
comprising 67% (n=4) of all non-deletional alpha thalassaemia cases, with the remaining 
two cases reported in one individual from SEA and one from Black ethnicity. 
 
5.2 Alpha chain haemoglobin variants 
Thirty three different alpha chain haemoglobin variants were detected within the referral 
population. Figure 3.8 below shows the total number of individuals within each ethnic 
group with an alpha chain haemoglobin variant: 
                                                                 
Figure 3.8: Proportion of alpha chain haemoglobin variants detected within each 
ethnic group 
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Figure 3.8 shows that 33 different alpha chain haemoglobin variants were detected by 
DNA sequencing, the most common variant being G-Philadelphia followed by Hb Q-India 
and Hb Manitoba (II). The largest proportion of variants was found in those patients from 
Black 25% (n=13) and SEA 21% (n=11) ethnic groups, followed by 15% (n=8) within 
Asian ethnic groups. A further (10%, n=5) cases were reported in White, Mixed and Not 
Stated ethnic groups. Of this broad spectrum of haemoglobin variants identified, four of 
these are classified as clinically significant (according to the Hb variant database) because 
they are associated with a thalassaemic phenotype. These included: Hb Constant Spring, 
Hb Seal Rock, Hb Quong Sze and Hb Evanston, which were detected in 6 patients, in 
which 67% (n=4) of these cases were found in patients from the SEA ethnic group. 
 
In addition to these „thalassaemic‟ variants many other alpha chain variants detected 
within our referral population could also be considered to be of clinical significance due to 
the effect of the causative mutation on the quaternary structure of the protein products.  
These include the following 5 variants that were detected in 6 cases within the referral 
population: Hb Chesapeake, Hb Dunn, Hb Linwood, Hb Toulon and Hb West-One, all of 
which are associated with increased oxygen affinity and may cause erthrocytosis. A 
further 5 haemoglobin variants that were detected within 8 cases (Hb Manitoba (I and II), 
Hb Riccarton, Hb Setif and Hb Spanish Town) are associated with the formation of 
unstable haemoglobin tetramers. Furthermore, two haemoglobin variants; Hb G-
Philadelphia and Hb Q-Thailand which are classified by the Hb variant database as having 
a „normal‟ clinical presentation in the heterozygous state but are most commonly reported 
in the compound heterozygous state in trans with deletional alpha thalassaemia (-α3.7 and –
α4.2 respectively) resulting in a thalassaemic like phenotype.  This clinical presentation was 
found in all of the seven patient cases with these two haemoglobin variants.   
 
5.3 Population genetics of all causative mutations detected within HBA1 and HBA2. 
Of all the patient cases in which a causative point mutation (i.e thalassaemia or 
haemoglobin variant) was identified, 53% (n=31) had an alpha genotype that would be 
expected in their stated ethnic group, 37% (n=22) had an alpha genotype which not be 
expected within their ethnic group and in 10% (n=6) of cases the patient ethnic group was 
not stated, as shown in figure 3.9 below: 
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Figure 3.9: Proportion of all alpha genotypes according to expected ethnicity. 
 
Therefore DNA sequencing of the essential regions of the alpha-globin genes indicates 
that a “first pass” ethnic led mutation screening strategy may miss up to 47% of alpha 
genotype cases analysed. 
 
6.0 DNA sequencing of HBB for the detection of point mutations and small deletions 
associated beta thalassaemia. 
DNA sequencing of the beta-globin gene identified 44 different types of non-deletional 
mutations i.e. a point mutation or a small deletion/insertion within 168 patients. All 
together there were a total of 180 beta mutations reported, including heterozygous and 
compound heterozygous genotypes reported within this group. 
 
Of the total number of genetic referrals received (n=328), 308 patients that had their beta 
globin genes sequenced, the remaining 20 patients did not have their beta globin genes 
sequenced as it was not necessary. A causative mutation was detected within the beta 
globin gene by DNA sequencing in 51% (n=168) of all patient referrals, and no beta 
mutation was detected in the remaining 49% (n=160) of patients. 
 
Of the 160 cases in which a causative beta mutation was not was detected, a candidate 
change was detected within 8 patients, but these changes were either a polymorphism of 
no clinical significance or an unclassified variant in which subsequent in silico analysis 
using Alamut software deemed the change not to be pathogenic in nature. 
 
Out of the 168 patients in whom a causative mutation was detected by DNA sequencing of 
the beta globin gene, the largest proportion of cases 58% (n=96) had a beta chain 
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haemoglobin variant mutation, 37% (n=63) had a beta thalassaemia mutation and 
remaining 5% (n=9) of patients were compound heterozygous for a thalassaemia and a 
haemoglobin variant mutation, as represented in Figure 3.10. 
 
Figure 3.10: Proportion of all causative beta thalassaemia mutations detected by 
DNA sequencing of HBB. 
 
The proportion of beta genotypes (represented above) was then divided according to the 
patients‟ ethnicity:  
 
 
Figure 3.11: Proportion of beta genotypes within each ethnic group. 
 
Figure 3.11 shows that the Asian ethnic group represented the largest proportion of 
patients with beta thalassaemia mutations, comprising 49% (n=31) of all beta thalassaemia 
genotypes diagnosed. Black ethnic groups had the largest number of haemoglobin variant 
genotypes comprising 38% (n=36) of all cases with this genotype. The SEA ethnic group 
had equal proportions of thalassaemia and haemoglobin variant mutations, whereas the 
White ethnic group had a much larger proportion of haemoglobin variant mutations 
(n=10) than thalassaemia mutations (n=5), the majority of which (n=8) were associated 
with a change in the protein behaviour, i.e. unstable or associated with an increased 
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oxygen affinity. The small number of compound heterozygote genotypes was confined to 
the Asian and Black ethnic groups. 
 
6.1 Mutations detected within HBB associated with beta thalassaemia 
Further analysis of the mutations associated with beta thalassaemia is represented in 
Figure 3.12. 
 
Figure 3.12: Range and distribution of beta thalassaemia mutations within each 
ethnic group.  
 
Note: Figure 3.12 represents the total number of beta mutations detected and not the total of patient cases with a beta mutation, as one 
patient was compound heterozygous two beta thalassaemia  mutations. 
 
Figure 3.12 shows that 20 different mutations associated with beta thalassaemia were 
detected within the referral population. The largest number of beta thalassaemia mutations 
detected were in patients from Asian ethnic groups, comprising 49% (n=36) of all beta 
thalassaemia mutations detected, followed by the Black ethnic group 15% (n=11) and 
patients in SEA ethnic groups, which comprised 10% (n=7) of all beta thalassaemia 
mutations detected.  
 
The total number of beta thalassaemia mutations (n=73) found was further categorised 
based on the clinical severity of the mutation and then compared to the patient ethnic 
group. Note that the total number of patient cases with beta thalassaemia (n=72) is not the 
same as the total number of beta thalassaemia mutations found (n=73) because one patient 
was compound heterozygous for the CAP
+1
 and IVS1-5 thalassaemia mutations. 
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Figure 3.13: Clinical severity of all beta thalassaemia mutations detected. 
 
NOTE: In figure 3.13 one patient was compound heterozygous for a beta plus and a severe beta plus mutation and was included in each 
category. 
 
Figure 3.13 shows that a total of 34% (n=25) of patients had a beta plus thalassaemia 
mutation, 21% (n=15) had a severe beta plus thalassaemia mutation and 45% (n=33) had a 
beta zero thalassaemia mutation. 
 
The total number of clinically significant beta mutations (i.e. beta zero thalassaemia) was 
highest in those patients from Asian ethnic groups, comprising 26% (n=19) of all beta 
thalassaemia mutations detected. This ethnic group also had the largest number of severe 
beta plus (10%, n=7) and beta plus thalassaemia mutations (14%, n=10). 
 
Within the „White‟ ethnic group a total of 5 beta thalassaemia mutations were found of 
which 40% (n=2) were clinically significant mutations associated with beta zero 
thalassaemia.  Furthermore, within the „Arabic‟ ethnic group a total of 3 thalassaemia 
mutations were detected, all of which were beta zero thalassaemia mutations.  
 
Screening for beta thalassaemia mutations by DNA sequencing helped to clarify the 
genotype in young children referred for query beta thalassaemia major, in which trace 
amounts of Hb A had been detected on HLPC. In many of these cases genetic analysis 
revealed homozygosity for severe beta plus thalassaemia, often the IVS1-5 (G>C) 
mutation. It also helped to diagnose beta thalassaemia in those patient cases that had been 
referred with borderline HbA2 levels, in which case the CAP
+1
 mutation was the most 
common causative mutation, often found in patient from the Asian ethnic group. 
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6.2 Mutations detected within HBB associated with a haemoglobin variant. 
Figures 3.14a and 3.14b show the range of beta mutations detected that are associated with 
a haemoglobin variant and their distribution within each ethnic group.  
 
 
Figure 3.14a: Total number of clinically significant HBB variants within each ethnic 
group 
 
Figure 3.14a represents the total number of clinically significant variants (as outlined by 
the Antenatal Screening programme) found within the referral population. There was a 
range of 4 such variants detected in a total of 71 patients. Note there were no genetic 
referrals received from patients with the Hb O-Arab genotype. The most prevalent 
clinically significant haemoglobin variant was Hb S which was found in a total of 42 
patient cases, comprising 40% (n=42) of all patient cases in which a beta chain 
haemoglobin variant was found. Hb E was found in a variety of ethnic groups. 
 
Figure 3.14b: Total number of „clinically benign‟ HBB variants within each ethnic 
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Figure 3.14b represents the total number of cases with a „clinically benign‟ HBB 
haemoglobin variant and their distribution within each ethnic group. There were 20 
different beta chain haemoglobin variants detected in 36 individuals within a variety of 
ethnic groups, with those of Asian ethnicity comprising the largest proportion (n=12), 
accounting for 33% of these cases.  
 
The overall incidence of beta haemoglobin variants was highest in individuals from Black 
ethnic groups comprising 36% (n=38) of cases in which a beta chain variant was 
identified, followed by Asian 22% (n=23) and White ethnic groups 10% (n=10). The 
highest incidence of variants reported in patients from Black ethnic groups was accounted 
for by the large number of cases with sickle haemoglobin (Hb S) which comprised 31% 
(n=33) of all beta haemoglobin variant cases detected and 79% (n=33) of all sickle 
haemoglobin cases. 
 
According to the antenatal screening programme, the 20 beta chain haemoglobin variants 
shown in Figure 3.14b are considered not to be of clinical significance, but some of these 
„clinically benign‟ variants may actually be associated with a thalassaemic phenotype. 
Further investigation shows that 10 of these haemoglobin variants, found in 50% (n=18) 
of patients are associated with a completely normal clinical presentation, including Hb 
Alamo, Hb Alperton, Hb Camden, Hb City of Hope and Hb OSU-Christiansborg. 
However, the remaining 10 variants are not completely benign due to their altered protein 
structure, for example Hb Monroe, detected in 8% (n=3) of these patients is classified as a 
thalassaemic haemoglobin variant (according to the Hb variant database) due to its highly 
unstable nature.  
Hb Leiden, Hb Bushwick, Hb Hofu, Hb J-Guantanamo, Hb Köln and Hb Tyne, found in 
22% (n=8) of these patients all have an unstable protein structure which may result in a 
severe haemolytic anaemia crisis when induced by oxidative stress. Furthermore Hb 
Malmö, Hb Old Dominion and Hb Olympia, found in 19% (n=7) of these patients are all 
associated with marked erthrocytosis, which had potential implications for a family 
referred to ourselves, which is discussed further in Chapter 4. The highest incidence of 
these types of variants was found in individuals of Asian ethnic origin followed by White 
ethnic groups. 
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Therefore, the identification of these variants by DNA sequencing may be of clinical 
significance, especially in the antenatal context where such haemoglobin variants may be 
co-inherited with another thalassaemic allele. 
 
6.3 Population genetics of all causative mutations detected within HBB. 
The total number of cases in which a causative mutation was detected within HBB (i.e. 
thalassaemia or haemoglobin variant) was correlated with patients‟ stated ethnicity by 
using previously reported population frequencies of mutations.  
 
Figure 3.15a: Proportion of all beta genotypes according to expected ethnicity. 
 
Figure 3.15a above, shows that 66% of patients (n=111) had a beta genotype that would 
be expected within their ethnic group and 24% (n=40) had a beta genotype that would not 
normally be predicted to be associated with the patients‟ stated ethnicities. In the 
remaining 10% (n=17) of cases the ethnicity was not stated. 
 
The total number of cases in which the beta genotype was expected within their ethnic 
group was further divided into those patients which had mutations commonly found in 
their ethnic group and those which had mutations rarely found, as shown in Figure 3.15b: 
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Figure 3.15b: Proportion of rare and common beta mutations in those patient cases 
with a mutation expected within their ethnic group. 
 
Figure 3.15b shows that out of the 111 cases carrying a beta mutation which was expected 
within their ethnic group, 87% (n=97) had mutations commonly found within the patients‟ 
ethnic group and 13% (n=14) had mutations that are rarely found within the ethnic group 
i.e. these cases which would require more extensive targeted mutation screening in order 
to detect these mutations. 
  
The patients‟ stated ethnicity was then correlated according to their beta genotype and the 
expected ethnicity in which their genotype (i.e. the mutation) would normally be expected. 
 
Figure 3.16: Proportion of beta genotypes according to expected ethnicity.  
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in a beta chain haemoglobin variant, in which 27% (n=26) of these cases had a 
haemoglobin variant which would not be expected within their ethnic group. 
Further analysis of the correlation between the patients stated ethnicity and the beta chain 
haemoglobin variant was done. Those patients with a clinically significant haemoglobin 
variant (as outlined in Figure 3.14a) showed the strongest correlation, in which 75% 
(n=53) of these patients had a variant which would be expected within their ethnic group. 
This correlation was less noticeable in the „clinically benign‟ beta chain haemoglobin 
variants (as outlined in Figure 3.14b) as only 39% (n=14) of these patients had a variant 
that would be expected within their ethnic group, for example all three reported cases of 
Hb Monroe, normally expected in black ethnic groups, was reported in only patients from 
the Asian ethnic group. 
 
Conversely, those patients with a beta thalassaemia genotype showed the strongest 
correlation between the patients ethnic group and the mutation expected, with only 19% 
(n=12) of these patients possessing a mutation which would not be expected with their 
ethnic group. 
 
These results show that DNA sequencing of the essential regions of HBB indicates that a 
“first pass” ethnic led, targeted mutation screening strategy may miss up to 34% (n=57) of 
beta mutations in our referral population. 
 
7.0 Compound heterozygous genotypes 
Compound heterozygosity for either an alpha or beta thalassaemia mutation or 
haemoglobin variant was detected in 17% (n=55) of all patient referrals. A large number 
(n=48) of these patients were compound heterozygous for a deletional form of alpha 
thalassaemia and a beta thalassaemia mutation, which is recognised to modulate the 
clinical severity of the phenotype (as discussed in Chapter 1, section 1.4.2), but it can pose 
a diagnostic challenge as the red cell indices can be „normalised‟. This was encountered in 
a few patients within our referral population, including an individual from the Black ethnic 
group who was referred with a normal FBC, but raised HbA2 level. Further DNA studies 
revealed homozygosity for the minus 88 (C>T) beta plus mutation and –α3.7 deletion. 
Another patient, from the Mediterranean ethnic group had a normal FBC, but with raised 
HbA2 and Hb F levels, DNA studies revealed compound heterozygosity for the IVS1-110 
(G>A) beta plus mutation and –α3.7 deletion.  
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Furthermore, in four patient cases compound heterozygosity for a beta zero thalassaemia 
mutation and the alpha gene duplication aggravated the globin chain imbalance further, 
resulting in a beta thalassaemia intermedia phenotype. 
 
A large proportion (14%, n=47) of all patient referrals were found to be compound 
heterozygous for deletional alpha thalassaemia and a haemoglobin variant on either the 
alpha or beta globin genes.  A large number of these cases co-inherited the –α3.7 deletion 
with the sickle (Hb S) beta chain haemoglobin, these comprised 6% (n=19) of all patients 
referrals and 35% (n=19) of all compound heterozygous patient cases. 
 
8.0 Haemoglobin variants 
As highlighted in earlier sections, a diverse range of alpha and beta chain haemoglobin 
variants were found within the referral population. DNA sequencing was useful in 
identifying variants in those patients who had been referred with unusual HPLC results, 
such as an abnormal Hb A or HbA2 peak morphology, i.e. a shoulder peak or and split 
peak morphology. The variants detected within our referral population associated with 
HPLC anomalies included, Hb Alperton, Hb Tyne, Hb Riccarton, Hb Santa Barnabas, Hb 
Fort Worth, Hb Seal Rock, Hb Spanish Town. Hb City of Hope, which was completely 
silent on HPLC, was only detected by DNA sequencing because the patient also had Hb S. 
Interestingly 6 of these 8 variants may be of clinical significance and therefore it was 
important that their identity was confirmed by DNA studies. 
Additionally, 5 haemoglobin variant referrals were received from IVF patients. The 
variants detected in these patients included Hb Camden, Hb Hofu, Hb J Bangkok, Hb Q-
India and Hb Kurdistan, all of which have a normal clinical presentation. 
 
9.0 DNA sequencing of the 5‟ region of the HBG2 (GGamma) gene for the detection of 
the Xmn I
 
restriction site polymorphism and point mutations associated with non-
deletion forms of HPFH. 
DNA sequencing of the 5‟ region of the HBG2 gene was performed on a total of 37 
patients. Of these, homozygosity for the Xmn I polymorphism was detected in 5 patient 
cases, all of which also had a beta thalassaemia mutation.  In two of these patient cases, 
both from Asian ethnic groups, this polymorphism may have helped to ameliorate their 
beta thalassaemia major genotype to beta thalassaemia intermedia (as discussed Chapter 1, 
Section 1.4.3). Heterozygosity for the Xmn I polymorphism was detected in 20 patient 
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cases, but these were not considered to be of any physiological importance, as this 
genotype is reported to have a minimal effect on the phenotype of the patient. Other 
polymorphisms detected by this screening methodology include those found at minus 309, 
minus 408 and minus 369 nucleotides 5‟ to the HBG2 CAP site, which unlike the Xmn I 
polymorphism do not have any physiological implications. Heterozygosity for the minus 
202 (C>G) non-deletional HPFH mutation (HBG2:c.-255 C>G) (Collins, F, S et al: 1984 
and Huisman, T.H.J et al: 1975) was detected in one patient from the Black ethnic group 
who had been referred for Hb S variant screening with a raised Hb F of 21.7%. 
 
10.0 Deletional forms of beta thalassaemia, including HPFH and δβ disorders 
detected by Gap-PCR. 
A deletional mutation mechanism, associated with either HPFH or δβ thalassaemia was 
detected in 3% (n=9) of all patient diagnoses. The range of deletions found within each 
ethnic group is shown below in Figure 3.17: 
 
Figure 3.17: Proportion of HPFH and δβ mutations detected within each ethnic 
group. 
 
HPFH disorders were most prevalent within Black ethnic groups, comprising 67% (n=6) 
of these genotypes detected within the MDC, with the most commonly reported deletion 
being the HPFH-2 deletion. In four of these patient cases this genotype was co-inherited 
with the –α3.7 deletion. 
 
11.0 Patients in which no causative mutation was detected by the screening 
methodologies employed within MDC. 
In 13% (n=41) of all patient referrals to the MDC either no causative mutation was 
detected using the laboratory screening methods discussed in Chapter 2, or the genotype 
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detected was not enough on its own to account for the patient‟s phenotype. The proportion 
of these cases are represented and discussed further below: 
 
Figure 3.18: Proportion of patients in which no causative mutation was detected by 
the screening methodologies employed within MDC. 
 
11.1 Borderline phenotypic results/Antenatal partner 
Fourteen of these cases had been referred with normal to borderline red cell indices and 
exclusion of thalassaemia was valuable clinical information, or they were part of an „at-
risk‟ antenatal couple and clarification of their genotype was useful. No further genetic 
investigation was performed in these cases.  In several cases, repeat phenotypic screening 
within the MRI of samples referred from an external source revealed normal indices. 
 
11.2 Other underlying clinical conditions 
A further 5 patients were diagnosed with iron deficiency and 2 patients had other 
underlying clinical conditions including a compensation haemolytic anaemia caused by a 
pyruvate kinase deficiency and myelodysplastic syndrome. 
 
11.3 Novel mutation detected 
A novel mutation was detected within the MDC in two patient cases. The first patient was 
of Northern European descent, referred from an external source for an abnormal 
haemoglobin variant of 25.9%, with normal red cell indices. DNA sequencing of their 
HBA2 detected heterozygosity for a novel mutation within codon 11 
(NM_000517.4:c.34A>G). This mutational mechanism that resulted in a haemoglobin 
34% 
(n=14) 
12% 
(n=5) 5% 
(n=2) 
5% 
(n=2) 
10% 
(n=4) 
5% 
(n=2) 
29% 
(n=12) 
Borderline phenotypic results/antenatal 
partner testing 
Iron deficiency  
Other underlying clinical condition 
Novel mutation detected 
Genotype screening inconsistent with 
phenotype 
Suspected εγδβ thalassaemia 
Referred for further genetic testing 
externally  
111 
 
variant was assumed to have a normal clinical presentation, as in a previously described 
change Hb J-Wenchang-Wuming that affects the same location of the gene 
(NM_000517.4:c.34A>C). 
 
The second patient was of Middle Eastern descent with a raised HbA2 of 4.2% and normal 
red cell indices. DNA sequencing of their HBA2 globin gene detected heterozygosity for a 
novel single base change 12 nucleotides into the 3‟ UTR, non-coding region of the alpha-2 
gene (HBA2:c.*12G>A). This change was internally reported to be of unlikely clinical 
significance due to the patient‟s normal red cell indices. 
 
11.4 Genotype screening inconsistent with phenotype 
In 4 patients their normal genotype results were unexplained and were not consistent with 
their phenotype. Further genetic testing of 3 of these patients by the National Reference 
Laboratory for Haemoglobinopathies also failed to detect a causative mutational 
mechanism. The fourth patient, who was male and of unknown ethnicity, had been 
referred for query alpha thalassaemia because of his significantly reduced red cell indices 
and was unresponsive in iron therapy, no further action was taken in this case as his Hb 
level was only 8g/dL and iron deficiency still suspected. 
 
11.5 Suspected εγδβ-thalassaemia cases 
Two interesting patient cases are discussed in this section in which a rare form of εγδβ-
thalassaemia was suspected after initial extensive genetic screening within the MDC failed 
to detect a causative mutation. Further analysis of the β-gene cluster by MLPA was 
subsequently performed once the assay had been established. 
 
The εγδβ-thalassaemia disorders are genetically and phenotypically heterogeneous, caused 
by a variety of deletional mechanisms that either delete all of the genes within the β-gene 
cluster or inactivate them as a result of the upstream LCR regions being deleted. This 
condition presents in the neonatal period with haemolytic anaemia and splenomegaly, with 
the occasional need for blood transfusions during the first six months of life. Data suggests 
that heterozygotes for εγδβ-thalassaemia have a phenotype resembling that of a beta 
thalassaemia carrier, but with more severe microcytosis and hypochromia at birth, and 
normal levels of haemoglobin F and A2.(Driscoll, C.M. et al: 1989, Rooks, H et al: 2005, 
Furuya, C et al: 2008).  
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The first patient was a young white British female who presented as a neonate with severe 
anaemia, cardiac failure, hypertrophy and splenomegaly, with a severely microcytic 
picture (MCV: 54fL, MCH:17.4pg) but normal Hb A and Hb F levels. After extensive 
analysis on this patient, a repeat sample was requested on which beta MLPA analysis was 
performed. The result from this analysis confirmed a diagnosis of εγδβ thalassaemia, due 
to the observation of a large deletion, removing the entire extent of her β-gene cluster. 
This is was evident from a series of reduced probe heights, as shown in the histogram 
below in Figure 3.19: 
 
 
Figure 3.19: Histogram representing the HBB MLPA probe data from the patients‟ 
DNA sample (the red arrows indicate the probes that showed a reduction in height). 
 
Figure 3.18 show that the probes that showed a relative reduction in probe peak height for 
that probe amplification product. This indicates a heterozygous deletion that spans across 
the patient‟s entire β-globin cluster, consistent with group I εγδβ-thalassaemia. The blue 
bars represent control probes showing a normal complement of DNA at these locations. 
 
The second patient was a young Caucasian male who presented with a persistently low 
MCV of 59fl, and an MCH of 18.1 pg, but normal Hb A and Hb F levels. Initial DNA 
analysis within the MDC detected the triplicated alpha genotype. However, this genotype 
on its own was not enough to account for the hypochromic indices. HBB MLPA analysis 
was performed as εγδβ-thalassaemia was suspected. His results are shown below in Figure 
3.20.  
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Figure 3.20: Histogram representing the HBB MLPA probe data from the patients‟ 
DNA sample. 
 
Figure 3.20 shows that the none of the MLPA probes shows a relative reduction in probe 
peak height. This indicates the absence of a deletion within the β-gene cluster, excluding 
εγδβ-thalassaemia. This normal result was also confirmed by external genetic testing by 
King‟s College Hospital NHS Trust. 
 
11.6 Patients referred to the National Reference Laboratory for 
Haemoglobinopathies, Oxford for further genetic testing. 
In the remaining 12 cases, where failure to detect a mutation using our panel of tests was 
suspected, further analysis by the National Reference Laboratory for 
Haemoglobinopathies detected a causative mutational mechanism. These genotypes 
mainly consisted of deletional forms of beta thalassaemia or novel δβ-deletional 
mechanisms that could not be confidently characterised by HBB MLPA. 
 
These 12 cases are broken down as follows: two patients with the Black 12Kb δβ° 
deletion, one patient with the 909bp Afghan β° deletion, one patient with the Indian 32kb 
deletion, and one patient with the Indian 619bp β° deletion. Two further patients were 
reported by Oxford as having a rare, unidentifiable form of deletional HPFH or δβ-
thalassaemia. Three other patients were reported as having an unidentified non-deletional 
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HPFH mutation. One patient was reported by Oxford to have a „probable δ-chain variant‟, 
and the remaining patient was suspected to be either normal or to have some form of εγδβ0 
thalassaemia. 
 
Many of the above patient cases were referred externally for further genetic analysis as 
HBB MLPA was unavailable within the MDC at that time. Such patients were suspected to 
have an underling deletion if DNA sequencing detected a hemizygous change, for example 
the Hb S variant in the absence of any heterozygous polymorphisms. Therefore in many of 
these cases it was not possible to confidently exclude an underlying deletional mechanism 
such as HPFH or δβ, especially in those patients with a family history of persistently 
raised Hb F. 
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Chapter 4.0: Discussion 
4.1 Introduction  
As discussed in the introductory chapter, the haemoglobinopathies represent the 
commonest single gene defects in the world and are found at highest frequency in those 
countries where malaria is prevalent.  It has now been recognised that due to the effect of 
migration they are not confined to specific geographical locations but occur at high 
frequency in local populations throughout many parts of the world. 
 
Although the haemoglobinopathies are highly heterogeneous at the molecular level with 
more than 1000 mutant alleles described (Hb Variant database), within each ethnic 
population group common subsets of mutations are found, consisting of a high frequency 
of several common mutations with a smaller number of rare mutations. 
 
The impact of immigration from endemic areas to non-malarial countries has significantly 
increased the range of haemoglobinopathies that need to be characterised by a diagnostic 
service. Following the implementation of the national NHS Sickle Cell and Thalassaemia 
(SCT) Screening Programme in England in 2001, the front line element of this process is 
the offer of phenotypic screening to all antenatal women in high prevalence areas with 
targeted screening in lower prevalence areas. This screening will identify those individuals 
who are likely to carry a haemoglobinopathy disorder based on their red cell indices and 
HLPC results. Unfortunately, due to the molecular heterogeneity of these disorders and the 
wide range of gene-gene interactions, accurate interpretation of the clinical phenotypic can 
be difficult. Therefore genetic analysis may be requested for a definitive diagnosis of the 
main genetic risk combinations as recommended by the antenatal screening algorithm 
(Appendix 1) in those ethnic groups which are deemed to be at highest risk and permits 
definitive diagnosis of complex genetic interactions prior to genetic counselling. 
 
This study examines the strategy developed in Manchester which aimed to achieve a high 
mutation detection rate in the heterogeneous population by developing a comprehensive 
range of laboratory assays, to ensure that the broad spectrum of genetic defects associated 
with the haemoglobinopathy disorders could be detected. 
 
 
4.2 Aims and development of the study 
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In order to fulfil the study aim of detecting the large spectrum of the mutations likely to be 
found within the North West (NW) referral population, and to assess the true genetic 
heterogeneity, a comprehensive mutational screening approach was employed. This 
included using a variety of PCR based laboratory assays such as multiplex Gap-PCR and 
direct DNA sequencing of the alpha and beta globin genes, in order to eliminate the need 
for lengthy targeted mutation screening protocols.  
 
As the study progressed it was clear that development of further assays was needed in 
order to detect the broad range of different mutational mechanisms encountered within our 
referral population and in order to confidently asses those patients with complex 
phenotype and genotype correlations. This included development of alpha and beta gene 
cluster MLPA analysis for the detection of rarer deletional forms of thalassaemia and the 
adaption of Gap-PCR and sequencing technologies for the detection of HPFH and δβ 
thalassaemia disorders. 
 
The mutation frequency data collected within this study was used to assess the genetic 
heterogeneity of the referral population and the effectiveness of our more comprehensive 
screening approach could be assessed and evaluated against ethnic led, more targeted, 
mutation detection approaches.  
 
4.3 Study population 
In order to assess the range of genetic defects associated with the haemoglobinopathy 
disorders, a total of 328 patient referrals from the NW population were genotyped within 
the Molecular Diagnostics Centre between July 2008 and December 2011. Of these patient 
diagnoses, 113 patients had a mutational mechanism associated with alpha thalassaemia, 
109 patients had a form of beta thalassaemia, 55 were compound heterozygous for an 
alpha and beta thalassaemia mutations and/or variants and 10 patients exhibited a HPFH or 
δβ thalassaemia disorder. In the remaining 41 referrals, either no mutation was found or 
the genotype detected was not enough on its own to account for the patient‟s phenotype. 
These are discussed further in Section 4.13. 
 
4.4 Ethnic composition of the North West referral population and incidence of 
haemoglobinopathies. 
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A wide range of haemoglobinopathy mutations were found in all ethnic groups, as 
identified by the Family Origin Questionnaire (FOQ), reflecting the considerable ethnic 
diversity within the NW referral population (Chapter 3, Figure 3.2). As outlined in 
Chapter 3, the three ethnic groups which comprised the largest incidence of 
haemoglobinopathies were the Asian, Black and South East Asian groups. Within the 
referral population the Asian ethnic group was relatively mixed with different ethnic sub-
groups, the largest proportion of patients within the Asian ethnic group were from 
Pakistani and Indian Asian origin with only a very small proportion of patients of 
Bangladeshi extraction. Within the SEA ethnic group, the largest proportion were patients 
of Chinese origin, followed by Thai or Filipino with only a very small number of patients 
from Indonesian and Malaysian origins. Within the Black ethnic group, nearly all of the 
patients were of African origin and a smaller proportion from Black Caribbean origin. 
 
The significance of the ethnic composition and the range of mutations found within the 
North West population will be discussed further in later sections. 
 
Interestingly, 11% of patient referrals were received from those of White British origin, an 
ethnic group in which haemoglobinopathy disorders are considered rare. Only a small 
number of patient referrals were received from patients of Arabic and Mixed and Other 
origins. The smallest proportion (2%) of patient referrals was from patients of 
Mediterranean origin. Unfortunately the patients‟ ethnic origin was not stated on the FOQ 
in 10% of referrals, this was especially common in those patients who had been referred 
from an external source. The incidence of haemoglobinopathy disorders in relation to their 
ethnicity could therefore not be assessed. This is surprising as prior information on the 
ethnic origin of the patient is an important part of the diagnostic strategy, especially in 
those less heterogeneous populations where patients‟ stated ethnicity enables a quick 
identification of the mutations most likely to be present.  However, as discussed in earlier 
sections, this ethnic led strategy becomes less efficient and reliable in those populations 
such as the North West of England where there is a diverse ethnic mix. 
 
 
 
4.5 Summary of all haemoglobinopathy diagnoses according to ethnicity 
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When the type of haemoglobinopathy disorder was correlated to the patients‟ ethnicity, the 
highest incidence of alpha thalassaemia was found in the SEA ethnic groups, beta 
thalassaemia was found predominantly in patients from Asian origin, and haemoglobin 
chain variants were found at highest prevalence in the Black and SEA ethnic groups, with 
a relatively large proportion, from the small number of total referrals from White ethnic 
groups comprising a haemoglobin variant genotype. Compound heterozygous genotypes 
were most commonly reported in the Black ethnic groups. These findings from within our 
referral population correlate with the reported incidence of these genotypes in general 
literature, although the exact distribution of mutations found within each of these ethnic 
groups do not, as highlighted in the following sections.   
 
Literature reports that beta thalassaemia is common within the Indian subcontinent and in 
South East Asia, which loosely correlates with the ethnic composition of beta thalassaemia 
diagnoses observed in this study. The largest proportion of beta thalassaemia was 
diagnosed in those individuals of Asian ethnicity, although the prevalence of cases in 
those patients of Asian Indian origin was no more than in those patients of Asian Pakistani 
origin. 
 
Variant chain haemoglobins were found at highest prevalence in the Black and SEA ethnic 
groups. This would be expected as the beta chain variant Hb S is found at highest 
frequencies within Black African populations and the alpha chain variants Hb Quong Sze, 
Hb Constant Spring and Hb Q-Thailand are almost exclusively reported in the literature 
and in our referral population in those patients of SEA origin. Interestingly 39% (n=14) of 
all patient referrals within the „White‟ ethnic group comprised haemoglobin chain 
variants. 
 
Despite the largest proportion of patient referrals received being of Asian origin, only a 
small proportion of haemoglobin variants were found within this ethnic group. The beta 
chain variant Hb D-Punjab was almost exclusively found in a small number (n=8) of 
patients within this ethnic group, the other two cases were found in patients of „White‟ 
origin. 
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Compound heterozygous genotypes were found at highest frequency in patients from the 
Black ethnic group. This would be expected due to the co-inheritance of the –α3.7 deletion 
with the sickle (Hb S) beta chain haemoglobin commonly reported in this ethnic group. 
 
A relatively large proportion of haemoglobinopathy diagnoses were made in those 
referrals received from White British patients (n=36), an ethnic group in which the 
haemoglobinopathy disorders are traditionally considered rare. These diagnoses included 5 
cases of beta thalassaemia, 7 cases of alpha thalassaemia and 15 cases of haemoglobin 
chain variants. 
 
Due to the small number of referrals received from the NW population from patients of 
Arabic, Mixed and Mediterranean origin, only a small proportion of haemoglobinopathy 
diagnoses were made, therefore, interpretation of the mutational frequencies within these 
ethnic groups was limited. 
 
4.6 Mutation analysis by Gap-PCR for the detection of deletional forms of alpha 
thalassaemia 
Two independent multiplex Gap-PCR assays (as discussed in Chapter 2) provided an 
essential screening tool for the rapid detection of a range of common alpha thalassaemia 
deletions in the heterogeneous referral population found within the North West of 
England, especially for the diagnosis of compound heterozygous patient cases. 
 
The Liu et al multiplex Gap-PCR protocol (discussed in Chapter 2, Section 3.3) failed to 
provide a true multiplexed assay as the original protocol could not be reliability replicated 
and all three multiplex PCR reactions required individual optimisation. Subsequently the 
Chong et al based assay (discussed in Chapter 2, Section 3.4) was employed as the 
primary screening assay for the detection of alpha thalassaemia deletions. A separate assay 
was set up based on the Eng et al protocol for the detection of the --BRIT deletion in 
selected patients. The Chong et al assay and the Eng et al assay were optimised using the 
same PCR kit system, therefore for ease of use in a diagnostic setting they were 
incorporated into the same SOP document. 
 
Deletional alpha thalassaemia was found in a variety of ethnicities, with the highest 
frequency reported in patients from SEA and Black ethnic groups. This genotypes showed 
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the strongest correlation between patients‟ stated ethnicity and deletion found. The alpha 
plus α-3.7 and alpha zero --SEA deletions were found at the highest prevalence in our referral 
population. This can be explained not only by the large proportion of referrals from Black 
and SEA ethnic groups but also the high incidence of the --SEA deletion in Chinese 
populations and the α-3.7 deletion in Black African populations, especially as its co-
inheritance with sickle cell haemoglobin offers a selective advantage against malaria. The 
alpha zero --BRIT deletion was almost exclusively found in patients of White British 
origin and the --MED deletion exclusively in Mediterranean patients. Conversely, all five 
cases of the triplicated alpha genotype were in a variety of ethnic groups, reflecting the 
heterogeneity of the alpha thalassaemia disorders. This supports the findings of a study by 
Fisher et al (2003) which highlights the possible implications of not detecting underlying 
triplicated alpha thalassaemia when only a targeted mutational screening approach is used 
in complex ethnic populations. Four of these cases were found in the compound 
heterozygous state with a beta thalassaemia allele, whilst the other case was found in a 
young White British male who had been referred with anaemia with a persistently low 
MCV. This genotype alone was not sufficient to explain his phenotype and further HBB 
MLPA analysis was performed, the findings of which are discussed further in Section 
4.12b below. 
 
Deletional Hb H disease was detected in a total of 5 patients, 3 of these were found in 
patients of SEA origin and was commonly caused by the genotypes: --SEA/-α3.7 and --
SEA/-α4.2, as would be expected in this ethnic group. The other two cases were found in an 
Arabic patient with the genotype --MED/-α3.7 and a White British patient with the 
genotype --BRIT/-α3.7. 
 
4.6.1 Summary of Gap-PCR analysis for the detection of deletional alpha 
thalassaemia. 
Data on different deletional alpha thalassaemia genotypes obtained by Gap-PCR analysis 
on 324 patient referrals shows that the genotypes found correlated well with the patients 
stated ethnicity (as shown in Chapter 3, Figure 3.5) and supports reported findings in the 
general literature. 
 
The highest prevalence of alpha plus thalassaemia was found in individuals of Black-
African and Asian-Indian origin, caused by the -α3.7 deletion. When a two gene deletion 
121 
 
was found in these ethnic groups, the genotype was always caused by a single gene 
deletion on each chromosome i.e. homozygosity for the alpha plus -α3.7 deletion (-α3.7/-
α3.7). As expected there were no cases of alpha zero thalassaemia found in the either the 
Black or Asian ethnic groups, as the literature reports this is extremely uncommon. 
Deletional alpha plus thalassaemia was also reported in three patients of SEA origin in 
which the -α4.2 deletion was common, although this deletion was also reported in one 
patient of Asian origin and one of Black origin. 
 
As expected, alpha zero thalassaemia was found in those ethnic groups which are 
traditionally identified to be at highest risk, such as SEA, in which two genes are deleted 
from each chromosome by either of the following genotypes: --SEA,--FIL and --MED. 
Unexpectedly, there was one case of the compound heterozygous genotype -α3.7/-α4.2 in a 
SEA patient, who had been referred for query alpha zero thalassaemia. One further similar 
case has also been reported since the completion of this study. This demonstrates the 
importance of Gap-PCR analysis in order to distinguish the genotypes in those MED or 
SEA individuals where both α+ and α0 thalassaemia are common. 
 
Interestingly, there was a large proportion (22%, n=8) of alpha thalassaemia found in the 
White ethnic group. In which five of these cases with alpha zero thalassaemia had the --
BRIT deletion. One further case had Hb H disease caused by the co-inheritance of this --
BRIT deletion with the –α3.7 deletion. The reported prevalence of these disorders within 
White ethnic groups serves to highlight the importance of incorporating this Gap-PCR 
assay into our spectrum of diagnostic tests, in order to detect this British deletion which 
appears to originate in the North-West of England. 
 
The mutational data presented above reflects the overall high frequency of carriers for 
alpha thalassaemia found throughout the world. This is evident within this study by the 
high incidence of deletional alpha thalassaemia reported in a wide variety of ethnic 
groups. The –α20.5 deletion was not detected in any of the patient referrals, this may be due 
to the small proportion referrals received from Mediterranean patients. 
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4.7 Mutation screening by DNA sequencing of HBA1 and HBA2 for the detection of 
non-deletional forms of alpha thalassaemia 
Traditionally, screening for non-deletion forms of alpha thalassaemia using PCR based 
sequencing techniques was not routinely performed in diagnostics laboratories. This is 
partly because non-deletional forms of alpha thalassaemia are relatively uncommon and 
there are inherent problems associated with the amplification of the HBA1 and HBA2 
genes due to their sequence homology and the GC-richness of their gene sequences. A 
robust and reliable sequencing protocol was developed within the MDC which allowed 
routine DNA sequencing of the alpha globin genes in a proportion of patient referrals. 
 
In this study, heterozygosity for five different types of non-deletional alpha thalassaemia 
mutations was found in a small proportion (n=6) of patients, the majority of which were 
reported in the alpha-2 globin gene. Three of these mutations; IVS-I donor site (-5nts), 
IVS1-5 (G>A) and IVS1-117 (G>A) result in aberrantly spliced RNA which partially 
explains their alpha thalassaemia phenotype presentation. In the other mutation; Cd19 (del 
G), the single nucleotide deletion results in a frame shift introducing a premature stop 
codon at codon 48. Premature stop codons are often associated with an increased 
degradation of the mutant RNA transcript (nonsense mediated RNA decay) which again 
would explain the alpha thalassaemia phenotype associated with this mutation. In the Poly 
A (-AA) mutation the two nucleotide deletion within polyadenylation site results in an 
extended RNA transcript due to inefficient transcription termination and subsequently 
results in a thalassaemic phenotype. It has been reported that these mutational mechanisms 
found within the polyadenylation site on the HBA2, which result in an extended transcript 
may also interfere with and downregulate the expression of HBA1 on the same 
chromosome (Harteveld, C.L et al: 1994 and Weatherall and Clegg: 2001). 
 
Of the six patients in which a non-deletional form of alpha thalassaemia was found, the 
highest incidence (n=4) was found those patients of Asian ethnicity, with the two 
remaining cases reported in the SEA and Black ethnic groups.  
 
Literature reports that non-deletional forms of alpha thalassaemia are traditionally found at 
highest incidence within Middle Eastern populations, especially in Saudi Arabia, but this 
was not reflected from the distribution of mutations found within our referral population, 
despite the relatively large proportion (n=15) of Arabic patient referrals received. 
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Furthermore the unexpected high incidence of these mutations found in Asian patients 
may just be a reflection of the large number of referrals received from this ethnic group. 
These findings are still significant, as none of these mutations would have normally been 
expected in this ethnic group. Such mutations may have not been detected if an „ethnic-
led‟ screening approach was used, especially as in four of these patient cases their 
phenotype did not suggest the presence of an underlying non-deletional α-thalassaemia 
mutation. 
 
4.7.1 Summary of DNA sequencing of HBA1 and HBA2 for the detection of non-
deletional forms of alpha thalassaemia 
Despite the low frequency of non-deletional forms of alpha thalassaemia found within our 
referral population, the findings from this study highlight the advantages of employing a 
comprehensive screening programme that includes DNA sequencing of the α-globin 
genes. DNA sequencing proved especially valuable in this group of patients as many 
presented with complex phenotypes, therefore it was not possible accurately assess their 
alpha thalassaemia status, as a result these mutations may be easily overlooked by 
phenotypic screening alone.  
 
Subsequently, the true population frequency of non-deletional forms of alpha thalassaemia 
are likely to be underestimated, especially those affecting the HBA1 gene, as it is widely 
recognised that those associated with the HBA2 lead to a more marked reduction of α-
globin production. None of these patients within this had co-inherited a deletional form of 
alpha thalassaemia but in those ethnic groups where alpha zero thalassaemia is common it 
is important to identify these compound heterozygote genotypes, especially those 
mutations within the HBA2 Poly A signal as they belong to a group of non-deletional 
mutations that can interact to produce severe Hb H disease or even Hb H hydrops fetalis, 
in which prenatal diagnosis is indicated. 
 
4.8 Mutation screening by DNA sequencing of HBB for the detection of point 
mutations associated with beta thalassaemia. 
Direct DNA sequencing of the beta globin gene provided an essential and reliable 
screening assay for the heterogeneous patient population found within the North West of 
England. A single-pass detection analysis could be performed in order to detect point 
mutations associated with beta thalassaemia and haemoglobin variants. After the initial 
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primer design had been done in order to amplify the three sections of the essentials regions 
of HBB, no further assay optimisation was needed. 
 
The beta thalassaemia disorders are extremely heterogeneous at the genetic level, with 
more than 200 causative mutations described in a wide range of ethnic groups. Within this 
study a total of 308 patients had their beta globin genes sequenced. Within the North West 
of England referral population a total of 20 different mutations causing beta thalassaemia 
were found in 72 patient cases (note this figure does not include those mutations resulting 
in a haemoglobin variant). The most common mutation found was IVS I-5 (G>C) (16%), 
followed by codon 8/9 (+G) (15%), Minus 88 (C>T) (14%). The three mutations, Codon 
41/42 (−TTCT), Codon39 (C>T) and CAP+1 (A>C) all comprised 8%. 
 
The severity of beta thalassaemia mutations found was analysed. The largest proportion of 
patients (45%, n=33) had a mutation that would be associated with a clinically significant 
beta zero thalassaemia genotype. A further 34% (n=25) of patients had a beta mutation 
that was associated with mild beta plus thalassaemia, and the smallest proportion of 
patients (21%, n=15) had a mutation classified as severe beta plus thalassaemia. 
 
The highest prevalence of beta thalassaemia was found in patients of Asian origin, 
comprising nearly half (49%, n=36) of all beta thalassaemia mutations detected. Within 
this ethnic group the mutations found at highest frequency was the frame shift mutation 
Codon 8/9 (+G) and the splice site mutation IVS1-5 (G>C), both of which are reported in 
Asian Indian ethnic groups. These two mutations collectively comprised nearly half of all 
beta thalassaemia cases within this ethnic group, which would explain the highest 
frequency of β0 and severe β+ mutations found in patients of Asian ethnicity. Conversely, 
these figures may just reflect the large number of Asian patient referrals received and the 
smaller number of referrals received from other ethnic groups, as the Asian ethnic group 
also had the highest frequency of mild β+ mutations.  
 
Homozygosity for a further four beta thalassaemia mutations were found in six patients of 
Asian origin, the codon 39 (C>T), IVS1-110 (G>A), codon 5 (del CT) and IVS2-1 (G>A), 
all of which are normally reported in Mediterranean regions. Additionally, DNA 
sequencing detected the CAP+1 mutation in five patients of Asian ethnicity, which would 
have required more extensive targeted mutation screening in order to detect this mutation 
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if the ethnic led approach was employed as it is rarely found in Asian ethnicities. 
Furthermore, detection of this mutation by DNA sequencing was also helpful as many of 
the patients with this genotype were referred with borderline HbA2 levels. 
 
Furthermore, the minus 88 (C>T) promoter mutation was detected in 4 patients of Asian 
Pakistani origin, three of whom were homozygotes. This would be expected within the 
Asian ethnic group, but in those individuals belonging to the Indian sub-group rather than 
the Pakistani sub-group. The larger proportion of individuals within the North West 
population from the Pakistani Asian ethnic sub-group, rather than the Indian subgroup did 
not seem to affect the range of beta thalassaemia mutations found. 
 
The second highest prevalence of beta thalassaemia was found in the Black ethnic group, 
comprising 15% (n=11) of all beta thalassaemia mutations detected. The minus 88 (C>T) 
promoter mutation was found at highest prevalence (n=5) within this ethnic group. This 
would be expected as published beta thalassaemia distribution maps (such as in Chapter 1, 
Figure 1.7) show that Africa has an extremely high prevalence of mild beta thalassaemia 
promoter mutations -29 (A>G) and -88 (C>T) which are associated with particularly high 
levels of Hb F (see Chapter 1, Section 1.4.2). This accounts for the large proportion of 
relatively mild β-thalassaemia cases found in Black African patients (Weatherall, D.J and 
Clegg, J.B:2001). 
 
It has also been reported that compound heterozygosity for mild β-thalassaemia and Hb S 
is relatively common in this ethnic group, resulting in a less severe phenotype than an 
interaction with β0-thalassaemia. Despite the high frequency of Hb S (n=42) found in this 
study (highlighted in Chapter 3, Section 6.2), only a small number of cases (n=2) of 
compound heterozygosity for mild β-thalassaemia/Hb S was found. 
 
The detection of the -88 (C>T) beta thalassaemia mutation and other beta thalassaemia 
mutations which are rare in the indigenous population of the UK, highlights the effects of 
immigration to a non-thalassaemia endemic country and the subsequent racial 
heterogeneity found. 
 
β0 thalassaemia was found in two individuals of Black ethnicity, caused by the frame shift 
mutation codon 39 (C>T) and the initiation codon (A>G) mutation respectively, both of 
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which would not normally be expected to be found within this ethnic group. The initiation 
codon (A>G) mutation is reported to be associated with particularly high HbA2 levels 
(Bain, B: 2006) which was consistent with that found (6.3%) in the affected patient in this 
study.  
 
A beta thalassaemia mutation was found in 10% (n=7) of patients from the SEA ethnic 
group. The mutations codon 41/42 (-TTCT) and IVS2-654 (C>T) were both found in three 
patient cases and the IVS1-5 (G>C) mutation was found in the remaining patient. All three 
of these mutations are associated with a severe phenotype and would normally be expected 
in patients belonging to this ethnic group. None of these 7 affected patients had their 
phenotype ameliorated by the co-inheritance of deletional alpha thalassaemia. 
 
Despite the large proportion (21%) of SEA patients received for genetic testing within the 
North West referral population, a higher frequency of beta thalassaemia diagnoses would 
have been expected to be observed, as literature reports that beta thalassaemia is also most 
commonly found around the Mediterranean and South East Asia, as well as India and 
Africa. The very small number of referrals received from patients of Mediterranean origin 
account for the low frequency observed of some of the beta thalassaemia alleles such as 
the IVS1-110 (G>A) and IVS1-(-1) G>C). 
 
A further three cases of beta thalassaemia were found in patients of Arabic origin, caused 
by two different frame shift mutations, in which a small deletion within HBB results in a 
premature stop codon. Two patients were heterozygous for codon 5 (del CT), and their 
phenotype was further aggravated by the co-inheritance of the alpha gene duplication, 
resulting in beta thalassaemia intermedia. One patient was homozygous for codon 8 (del 
AA) resulting in beta thalassaemia major. None of the beta thalassaemia mutations 
reported within this ethnic group would have been expected, as they are normally reported 
in those individuals of Mediterranean origin, therefore „ethnic-led‟ mutation screening 
within this ethnic group would have been less effective. 
 
Significantly, there were a total of 5 cases of beta thalassaemia reported in patients of 
White ethnic origin, an ethnic group in which beta thalassaemia is considered rare. None 
of the four mutations detected in these individuals had been reported in White British 
populations.  Of these 5 cases, 2 patients were heterozygous for a clinically significant 
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mutation, codon 39 (C>T) which is associated with β0 thalassaemia. This mutation creates 
a stop codon at codon 39, resulting in premature termination of translation. Another 
patient was heterozygous for the severe β+ mutation IVSII-654 (C>T). This mutation 
creates a new donor splice site specificity, leading to the accumulation of mis-spliced 
mRNA which then translates into a highly unstable β–chain variant with a dominant 
negative effect. This has been suggested to be the cause of the unusually severe disease 
seen in patients heterozygous for this mutation. The affected patient‟s phenotype was 
consistent with these findings, as he had marked hypochromia and microcytosis, with a 
particularly high HbA2 level of 3.8%. 
 
The remaining two patients were heterozygous for mutations found near or within the Poly 
A signal of the beta globin gene; the +1570 (from the CAP site) T>C nucleotide 
substitution, which is 12 nucleotides 5' to the poly A site and the Poly A (-AT del) 
mutation. Both of these mutations result in a mild beta plus thalassaemia phenotype as it 
has been reported that an intact Poly A signal is not essential for correct cleavage of the 
mRNA transcript. Interestingly, the patient with the +1570 T>C mutation presented with a 
normal HbA2 level of 3.1%, even though this mutation is normally associated with a HbA2 
level of between 4.8 and 6.4%. 
 
4.8.1 Summary of mutation screening by DNA sequencing of HBB for the detection 
of point mutations associated with beta thalassaemia. 
The data above reflects the heterogeneity of the beta thalassaemia disorders found within a 
variety of ethnic groups within the North West referral population and supports the 
findings of a study by Henderson, S et al (2009), in which the haemoglobinopathy 
mutations found in the UK can be divided into two groups; those very rare ones that are 
specific to individuals of white British origin, such as those with a dominant β-
thalassaemia phenotype, or more often those that are commonly observed in specific 
ethnic groups from the countries in which thalassaemia is prevalent  (i.e. Mediterranean, 
Asian Indian, Southeast Asian, and Africa). 
 
It is the effect of immigration from thalassaemia endemic regions which poses a challenge 
for the molecular screening of β-thalassaemia mutations within the UK. Studies have 
shown that the UK was found to have the largest number of distinct mutations (n=68) 
compared to other countries (Henderson, S et al: 2009). It is therefore not possible to 
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perform a quick ethnic-led screen for the detection of the common mutations in this 
heterogeneous population. The current study indicates that an ethnic-led, targeted mutation 
screening strategy may miss up to 34% (n=57) of beta mutations in our referral 
population. This suggests that diagnosis of beta thalassaemia in heterogeneous populations 
is best performed using methods such as direct DNA sequencing in order to detect the 
diverse panel of mutations likely to be encountered. 
 
4.9 Mutation analysis by Gap-PCR for the detection of deletional forms of HPFH and 
δβ disorders 
The Gap-PCR protocol used, adapted from Craig, R.A et al: 1994 (as detailed in Chapter 
2, Section 4) provided a reliable and robust method for the molecular detection of the 
deletions associated with either the HPFH or δβ-thalassaemia disorders. The KAPA2G 
DNA polymerase PCR kit worked reliably, but this laboratory assay required extensive 
optimisation from the original protocol. It could not be multiplexed as each of the nine 
individual, deletion specific, PCR reactions required different concentrations of MgCl2 
and different annealing and extension times. All mutations detected were confirmed either 
by external genetic analysis or MLPA, although due to lack of positive control samples the 
following deletions could not validated: Spanish (δβ)o, Sicilian (δβ)o, Asian-Indian 
Gγ(Aγδβ)0 Inversion/Deletion A and B and Turkish (δβ)o Inversion/Deletion A and B. This 
did not hamper any patient diagnoses as the HPFH and δβ disorders are relatively easy to 
identify by phenotypic screening due to their relative increase in Hb F levels and absence 
of any additional haematological changes in HPFH heterozygotes. The findings in this 
study correlate with general literature that reports these deletions tend to show 
geographical and racial clustering. Therefore where the ethnicity of the patient was 
known, it was used as a guide in choosing the appropriate Gap-PCR assay(s). 
 
Only a small proportion (3%, n=9) of all patient diagnoses were heterozygous for either a 
HPFH or δβ deletion. The HPFH-2 deletion was the most commonly reported deletion as 
it was found in 5 patient cases. The remaining 4 patient cases had either the HPFH-1, 
HPFH-3, Hb Lepore or Chinese δβ deletion. Seven of the nine cases had a deletion that 
would be expected within the patients‟ ethnic group, including HPFH-1 and 2 deletions in 
black ethnic groups, HPFH-3 in an Indian patient and Chinese δβ in a patient of Chinese 
origin. The remaining two patients had a deletion that would not normally be expected 
within their ethnic group, including a HPFH-2 deletion in a patient of Mediterranean 
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origin and Hb Lepore in a patient of Bangladeshi origin, although in this latter case it is 
difficult to accurately correlate the patient‟s ethnicity to the genotype as there are three 
different molecular varieties of Hb Lepore (Hb Lepore Washington/ Boston, Baltimore 
and Hollandia) that are indistinguishable by phenotype, of which only Hb Lepore 
Hollandia has been reported in Bangladeshi populations. 
 
None of the above nine cases were co-inherited with a beta thalassaemia mutation, but 3 
patients were compound heterozygous for the HPFH-2 deletion and the –α3.7 deletion and 
either the Hb S or Hb C variant, which is in agreement with general literature that suggests 
these combinations tend to be restricted to either the HPFH-1 or HPFH-2 deletions. 
 
The ability to distinguish between HPFH and δβ-thalassaemia rapidly using Gap-PCR 
methodology proved useful in the antenatal context in three patient cases in which the 
partner was found to be either heterozygous for β-thalassaemia or the βS variant. 
Furthermore, detection of HPFH deletions by this methodology helped to diagnose and 
differentiate those severe genotypes associated with sickle cell disease from those mild 
genotypes associated with HPFH deletions.  
 
4.9.1 DNA sequencing of the 5‟ region of HBG2 (GGamma) for the detection of the 
Xmn I
 
restriction site polymorphism and point mutations associated with non-
deletional forms of HPFH. 
DNA sequencing of the 5‟ region of the HBG2 (Gγ) gene was originally set up for the 
detection of the Xmn I polymorphism in patients in which it may serve to ameliorate their 
genotype i.e. those with beta thalassaemia intermedia, major or the βS variant, as it is 
thought to only have a minimal effect on the synthesis of Hb F in normal individuals (See 
Chapter 1, Section 1.4.3). This assay also detected the promoter point mutations within 
HBG, found between minus 175 and minus 202 nucleotides (relative to the CAP site) that 
are associated with non-deletional forms of HPFH (as described in Chapter 1, Section 
1.4.3).  
 
Heterozygosity for the Xmn I polymorphism was detected in a total of 20 patient cases (as 
discussed in Chapter 3, Section 8) all with a wide variety of associated genotypes. Six of 
these patients had the βS variant, including one case that had sickle cell disease in the 
presence of a particularly raised haemoglobin F level of 20.8%, suggesting a HPFH 
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mutational mechanism was involved. DNA sequencing revealed that this individual was 
homozygous for the Xmn I polymorphism, therefore contributing to her high Hb F levels. 
The remaining cases are not discussed further due to the reported limited effect of 
heterozygosity for this polymorphism on thalassaemia genotypes.  
 
Homozygosity for the Xmn I polymorphism was detected in 5 patient cases with a beta 
thalassaemia mutation. Two cases were found in unrelated patients of Asian origin who 
were homozygous for the β+ IVS1-5 (G>C) and β0 IVS2-1 (G>A) mutations respectively. 
Interestingly, a study by Ho et al (1998) showed that there was a strong association of this 
polymorphism within Asian Indian populations with the β0 IVS1-1 (G>T) mutation. The 
presence of the polymorphism in these two cases may have helped to ameliorate their beta 
thalassaemia major genotype to beta thalassaemia intermedia. Due to the limited number 
of patient samples analysed within this study, together with the limited clinical 
information available on some patients, it was not possible to truly asses the modulating 
effect of this polymorphism in our referral population, which was further compounded by 
the diverse range of beta genotypes found. 
 
Heterozygosity for the minus 202 (C>G) HPFH point mutation (HBG2:c.-255 C>G) was 
found in a male Black African patient, who had been referred with a Hb S level of 47% 
and a Hb F level of 21.7%. This mutation has been previously described in Black patients 
resulting in a HPFH phenotype (Collins, F, S et al: 1984 and Huisman, T.H.J et al: 1975, 
Hb Variant database). As the literature supports, this compound heterozygous genotype 
does not result in a marked anaemia as the patient only had slightly reduced MCV and 
MCH values. 
 
4.9.2 Summary of results obtained by DNA sequencing of the 5‟ region of HBG2 for 
the detection of Xmn I
 
restriction site polymorphism and point mutations associated 
with non-deletional forms of HPFH. 
Findings from the phenotypic analysis of individuals within this study support the view 
that the regulation of Hb F production is a complex subject area, and the variation of Hb F 
levels observed between patients is yet to be fully understood (Chapter 1, Section 1.4.3). 
The degree to which Hb F was elevated varied widely between patients, even between 
those members of the same family or those with the same mutation. Some of this variation 
may be explained by the different haplotypes of the chromosome carrying the allele, such 
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as the βS variant (as described in Chapter 1, Section 1.4.4), other factors linked to the β-
globin cluster are known to affect gamma gene expression such as the Xmn I 
Gγ 
polymorphism and non-deletional point mutations within HBG2. Therefore detection of 
these sequence changes may be useful in a research context as they could serve as a 
prognostic factor in those patients with sickle cell anaemia or β-thalassaemia or for 
therapeutic purposes in order to predict a patients‟ response to hydroxycarbamide therapy.  
 
It is also worth mentioning that in this study only those sequence changes associated with 
non-deletional forms of 
Gγ HPFH and not Aγ HPFH were analysed, as the same mutations 
have been reported in the same position 5‟ within these two genes, due to their sequence 
homology. Other genetic factors known to segregate independently of the β-globin cluster 
could also account for some of the variability of Hb F observed (as mentioned in Chapter 
1, Section 1.4.3). 
 
4.10 Mutation screening by DNA sequencing of HBB, HBA1 and HBA2 for the 
detection of variant haemoglobins. 
DNA sequencing of the alpha and beta globin gene detected a wide range of haemoglobin 
variants within the study population, including those variants commonly associated with 
disease such as haemoglobins S, C and E, but there are also rarer haemoglobin variants 
that do not always result in a clinically significant haemoglobinopathy. 
 
The suspected presence of a structural haemoglobin variant was provided by either HPLC 
or IEF phenotypic screening, clinical or family history or from peripheral blood film 
examination with evidence of haemolysis. In this study, characterisation of variant 
haemoglobins by DNA sequencing was essential for distinguishing between apparently 
identical variant phenotypes and also to confirm the genetic identity of variable 
phenotypes, including the differentiation of relatively benign genetic interactions from 
those that result in disease, for example differentiating Hb E homozygosity from Hb E/β 
thalassaemia. 
 
4.10.1 Clinically significant variants detected by DNA testing that result in disease 
The variants discussed in this section include those variant haemoglobins, detected by 
DNA sequencing of HBB, of clinical relevance as outlined by the Antenatal and Newborn 
screening programme including haemoglobins S, C, D-Punjab, E, Lepore and O-Arab. 
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There are no haemoglobin variants reported within the alpha globin genes that must be 
detected in this context. 
 
Primary identification of these variants was based solely on the phenotypic screening by 
HPLC and in some circumstances secondary screening by IEF, further genetic testing was 
requested in those patient cases where a definitive diagnosis was needed. Haemoglobins S, 
E, D-Punjab and C were found in 22% (n=71) of all patient referrals. No patient diagnoses 
were made with the genotype Hb O-Arab, even though it would have been expected within 
our referral population group as it has been reported in a variety of ethnic groups, although 
at low frequencies. 
 
 4.10.1a βS variant 
The Hb S variant was found at highest frequency (n=42) within our referral population. It 
was mainly detected in those patients of Black ethnicity (79%, n=33) with a further six 
cases found in the Asian Indian ethnic group. The two remaining cases were each found in 
the Mediterranean and Mixed ethnic groups. The ethnic group was not stated in the 
remaining sickle case. The distribution of the Hb S variant observed in this study would be 
expected as is most commonly reported throughout African, Mediterranean and Indian 
regions. An even higher frequency of this variant may have been diagnosed if the North-
West of England referral population comprised a larger proportion of patients from 
Mediterranean regions. 
 
Extensive DNA analysis on 13 patients with the βS variant helped to differentiate those 
with a clinically significant phenotype, caused by the interaction with other thalassaemic 
genotypes e.g. β-thalassaemia, from those with a mild phenotype caused by an interaction 
of an ameliorating genotype e.g. HPFH or alpha thalassaemia. This proved especially 
valuable in the 12 antenatal cases referred. DNA analysis of these 13 patients revealed that 
4 were homozygous for Hb S resulting in sickle cell anaemia and 6 patients were 
compound heterozygous for sickle-cell and β-thalassaemia. Of these, three patients had a 
mild β+ mutation, one patient had a severe β+ mutation and two had a β0 mutation. The 
remaining three patients had the compound heterozygous genotype Hb S/HPFH, in which 
their raised levels of Hb F may have served to ameliorate their phenotype. 
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There was a remarkable degree of clinical heterogeneity (obtained from the reason for 
referral information supplied) observed between all sickle patients, which is in agreement 
with general literature that highlights the highly variable clinical course of sickle cell 
disease. There is often very limited information to explain this observation. As already 
highlighted above in Section 4.5, a large number of sickle patients (n=20) had a deletional 
form of α-thalassaemia, which may serve to ameliorate their phenotype, although some 
studies still debate the significance of this interaction, suggesting that the overall effect of 
the co-inheritance of α-thalassaemia with Hb S is minimal (Steinberg et al 1984 and Vyas 
et al 1988). 
 
The clinical heterogeneity observed, especially between different ethnic groups, may also 
be partly explained due to the heterogeneity of the β-thalassaemia mutations co-inherited 
with this variant. It is well recognised that Africans with the βS variant have a mild clinical 
course due to the elevated levels of Hb F associated with the co-inheritance of mild beta 
promoter mutations. Interestingly, in this study there were two African sickle-cell trait 
individuals that presented with a particularly severe phenotype. One patient reportedly 
suffered from severe pain crisis and an additional sickling haemoglobin variant was 
suspected, but DNA sequencing eliminated this. The other patient had been receiving 
multiple transfusions even though they only had sickle cell trait and the IVS1-5 (G>A) 
alpha mutation. Furthermore, an Asian patient who was also receiving regular blood 
transfusions was found to have the genotype βS/IVS1-110 (G>A), which conflicts with 
case reports of this interaction in Mediterranean populations which suggests that it is only 
associated with a mild clinical course. 
 
DNA studies also helped to clarify those patients who presented with complex phenotypic 
results whereby additional bands were observed on HPLC, such as when the βS variant is 
co-inherited with the α-G-Philadelphia variant, which was encountered in 3 cases. Another 
patient of African origin who was referred for characterisation of an additional variant 
found co-eluting with haemoglobin HbA2, was identified to be homozygous for the HBA2 
gene variant Hb Fort Worth. There is limited clinical information in this interaction, but it 
has been reported to show thalassaemic properties and may result in microcytosis. DNA 
studies also helped to eliminate underlying beta thalassaemia in this case as it was not 
possible to accurately quantify the amount of HbA2. 
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DNA sequencing also detected the beta gene variant Hb City of Hope in a Black African 
patient who had been referred for sickle cell and query underling iron deficiency/ alpha 
thalassaemia. This additional variant was „silent‟ on HPLC as it co-migrates with 
haemoglobin A. Again, there was limited data on the clinical effects of this interaction. 
 
There were no cases of sickle cell disease caused by the interaction of haemoglobin S with 
haemoglobins C, D-Punjab or O-Arab. 
 
4.10.1b βE variant 
Hb E, which is associated with a thalassaemic phenotype, was found in only a small 
proportion (5%, n=16) of all diagnoses, but it was found in the largest variety of ethnic 
groups, including 5 in SEA patients, five Asian patients and two in patients of mixed 
ethnic origin (one Asian and White European and one White British and Thai). The ethnic 
group was not stated in the remaining 4 cases. 
 
DNA studies on this group of patients was especially valuable in order to provide a 
definitive diagnosis, as there is huge clinical variability in the range of conditions 
associated with Hb E disorders (as highlighted in Chapter 1, Section 1.4.4). Compound 
heterozygosity for βE and either α0-thalassaemia or β0-thalassaemia is not uncommon due 
to the high frequency of these alleles found within Thai, South East Asian and Indian 
populations.  
 
DNA analysis is a vital tool in order to differentiate between the different Hb E disorders 
as Hb E co-migrates with HbA2 on HPLC. It is difficult to distinguish by phenotypic by 
screening alone homozygous E patients (a asymptomatic condition) which is of no clinical 
significance, from those compound heterozygous cases of Hb E/β-thalassaemia (resulting 
in a more severe clinical picture). Therefore it is not surprising that the largest proportion 
of these patient referrals (n=10) were for clarification of their ambiguous phenotypic 
screen where underlying beta thalassaemia was suspected.  
 
HBB DNA sequencing of these 16 patients revealed that nine had homozygosity for Hb E. 
Compound heterozygosity for Hb E and a β-thalassaemia allele was only found in one 
patient of Asian origin, who had the rare β-chain variant Hb Monroe, which is also 
associated with a thalassaemic phenotype. This interaction is not only rare in general but 
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particularly within the patient‟s ethnic group as Hb Monroe is usually reported within 
Black ethnic groups. Due to the limited amount of literature on this interaction, its clinical 
consequence is unclear. 
 
The remaining six patients were referred from high risk ethnic groups in which underlying 
α-thalassaemia was suspected due to their low percentage of Hb E. Of these, two patients 
had the alpha zero --SEA deletion, one of whom was of mixed ethnicity, three patients had 
the alpha plus –α3.7 deletion, including a homozygous case found in a patient of SEA 
origin, and one patient, of Malaysian origin had the Poly A (-AA) non-deletional alpha 
thalassaemia mutation which is normally reported in Indian populations. 
 
Even though there were no cases identified in this study, Hb E is commonly found in the 
same population groups in which α0 thalassaemia and alpha chain haemoglobin variants 
occur, for example Hb Constant Spring in SEA. These compound heterozygous states can 
result in particularly severe forms of Hb H disease and are therefore important to identify 
by employing a comprehensive DNA testing strategy.  
 
4.10.1c β D-Punjab variant 
The Hb D-Punjab variant was found in 3% (n=10) of all diagnoses. As expected it was 
reported at highest frequency (n=8) in patients of Asian Pakistani ethnicity, as generally 
reported.  It does not commonly occur in those of Asian Indian ethnicity. The two other 
cases were in patients of White British origin which is in agreement with reports that it 
exists at low prevalence amongst Caucasian populations within England.  
 
Again, DNA sequencing provided a valuable tool for definitive diagnosis in this group of 
patient, as phenotypic screening by HPLC was unable to identify the exact variant within 
the „D/G window‟. In this antenatal context it was important to distinguish Hb D-Punjab 
from other alpha or beta chain variants with lesser clinical significance.  
 
DNA sequencing revealed homozygosity for Hb D-Punjab in two patient cases, which 
would only result in a mild clinical phenotype, and heterozygosity in 6 patient cases. 
Compound heterozygosity for Hb D-Punjab and beta thalassaemia was detected in two 
patients, one with the IVS1-5 (G>C) mutation and one with the codon 15 (G>A) mutation, 
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which was also co-inherited with a non-deletional alpha mutation (Poly A -AA). These 
results confirm general findings that this variant tends to be co-inherited with β0 
thalassaemia mutations.  
 
4.10.1d βC variant 
All 3 cases of this variant were found in patients from the Black ethnic group. One patient 
had a common compound heterozygous genotype Hb C/β+ thalassaemia caused by the -88 
(C>T) mutation. The other two cases showed compound heterozygosity with the HPFH-2 
deletion. This interaction is commonly reported in patients with Hb C, as both of these 
genotypes usually occur in African populations. 
 
Despite the large number of patient referrals received from Black ethnic groups, only a 
small number of patients were diagnosed with the Hb C genotype, therefore meaningful 
conclusions cannot be drawn. However, the findings above support general literature 
reports stating that this group of disorders tend to present with mild clinical manifestations 
mainly in African populations, due to the association with mild beta thalassaemia 
promoter mutations such as -88 (C>T) and HPFH deletions.  
 
4.10.1 Summary of clinically significant beta chain variants detected by DNA testing 
that result in disease. 
There was a strong correlation observed between those patients with a clinically 
significant haemoglobin variant and their stated ethnicity, which would be expected due to 
their high frequency found throughout the world. Even though phenotypic screening by 
HPLC and IEF alone are sufficient to identify these haemoglobin variants, DNA 
sequencing provides a vital tool in differentiating their homozygous states (e.g. Hb EE) 
from their compound heterozygous states with a β-thalassaemia mutation (e.g. Hb E/β+ or 
β0-thalassaemia), all of which result in very different clinical disorders, the latter of which 
is associated with a more severe clinical phenotype. Characterisation of the exact 
genotype, by DNA sequencing is vital in order to accurately predict the genetic risk to 
offspring in those „at risk‟ antenatal couples. Furthermore this may serve to relieve any 
unnecessary worry by differentiating those clinically significant disorders from those 
benign disorders. 
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4.10.2 Rare variants detected by DNA sequencing of the alpha and beta globin genes 
There are a further group of rarer haemoglobin structural variants that may either be 
associated with a form of thalassaemia or may be clinically „silent‟. The identification of 
these haemoglobin variants is often presumptive as it is based on their electrophoretic 
mobility on HPLC, family history or ethnicity or by other clinical characteristics presented 
by the individual. This section evaluates the merits of identifying the wide range of 
variants found within our study at the molecular level by DNA sequencing, not only in 
relation to their clinical significance, but also because of their common co-inheritance with 
the thalassaemia disorders within the same populations. 
 
The Antenatal and Newborn screening programme does not generally indicate DNA 
testing on those patients with haemoglobin variants, apart from those clinically significant 
ones mentioned in Section 4.10.1. However, BCSH genetic guidelines for the diagnosis of 
significant haemoglobinopathies (Ryan, K et al: 2010) indicate that haemoglobinopathy 
investigations may also encompass those clinical disorders in which there is an 
unexplained anaemia, splenomegaly, haemolysis, polycythaemia or cyanosis, with normal 
oxygen saturation. These disorders may be caused by the synthesis of an abnormal 
haemoglobin variant in which the causative mutation causes destabilisation of the 
haemoglobin tetramer. The varying properties of an abnormal haemoglobin variant 
determine the nature of the actual clinical manifestations and may encompass those 
variants that are associated with either an unstable protein structure or altered oxygen 
affinity, i.e. increased or decreased, or those associated with a thalassaemic phenotype.  
 
Therefore the significance of the detection of these haemoglobin variants by DNA 
sequencing within this study are discussed in the following sections below, in terms of 
their clinical manifestations and the globin chain in which they are found. 
 
In this study a total of 82 patients were referred for DNA analysis for a suspected 
haemoglobin variant that had either been detected by HPLC or for the reasons mentioned 
above (therefore the variants discussed in this section exclude those clinically significant 
variants discussed in Section 4.10.1 that can be provisionally identified by phenotypic 
screening).  
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In a large proportion (71%, n=58) of referrals in which a haemoglobin variant was 
suspected, the variant haemoglobin could not be positively identified by phenotypic 
screening alone and further genetic analysis by DNA sequencing was needed in order to 
provide a definitive diagnosis. 
 
In a smaller proportion (23%, n=19) of cases, phenotypic screening by HPLC was 
sufficient to identify the variant, although in eight of these patient cases this provisional 
identification of the variant was aided by the family history i.e. the same haemoglobin 
variant had been previously reported in another family member. 
 
In a further two patient cases, DNA testing revealed an alternative mutation mechanism 
i.e. a mutation resulting in a haemoglobin variant was not found. One patient, who had 
been referred for query α-thalassaemia and a possible variant of 1.9% co-eluting with 
haemoglobin F was diagnosed with β+ thalassaemia and homozygous α+ thalassaemia, 
further external genetic testing reported a „probable δ-chain variant‟. One patient who was 
referred in order to exclude a haemoglobin M variant due to her clinical presentation of 
methaemoglobinaemia was diagnosed with β+ thalassaemia.  
 
One further patient was diagnosed with a novel mutational mechanism, resulting in a 
haemoglobin variant within codon 11 of HBA2 (HBA2:p.Lys11Glu). No genetic 
abnormality was detected in the remaining two patients (as included in Chapter 3, Figure 
3.18). One of these patients, who had been referred for explanation of his compensative 
haemolytic anaemia, was found to have an alternative clinical disorder (pyruvate kinase 
deficiency). The other patient, who had been referred with a „flat HbA2 peak‟ detected on 
HPLC, was suspected to have a HbA2 variant, but no further DNA analysis was requested 
as these variants are reported not be of any clinical significance. 
 
Furthermore, DNA sequencing on a further eight patient referrals identified a haemoglobin 
variant that was completely silent on HPLC, and included the HBB variant Hb City of 
Hope (discussed below in Section 4.10.2a) and the HBA variants: Hb Evanston, Hb 
Fontainebleau, Hb Constant Spring, Hb Quong Sze and Hb Seal Rock (discussed below in 
Section 4.10.2b).  
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4.10.2a: Beta chain (HBB) haemoglobin variants detected by DNA sequencing. 
A larger proportion of beta chain haemoglobin variants were found by DNA sequencing 
than alpha chain variants. Additionally, a significantly larger proportion of patients had a 
haemoglobin variant genotype (n=96) than had a beta thalassaemia genotype (n=63).  
 
Excluding those variant haemoglobins already mentioned in Section 4.10.1, a further 20 
different beta chain haemoglobin variants were detected in 36 individuals within a variety 
of ethnic groups. Further investigation of these 20 variants within published literature 
demonstrated that 10 of them, found in 50% (n=18) of patients, were associated with a 
completely normal clinical presentation, i.e. the variant globin chains are still capable of 
forming viable haemoglobin tetramers and the variant haemoglobin molecule is 
synthesised at a normal rate when compared to Hb A. These variants include: Hb Alamo, 
Hb Alperton, Hb Camden, Hb City of Hope, Hb D-Iran, Hb OSU-Christiansborg, Hb J-
Bangkok, Hb K-Woolwich, Hb Pyros and Hb South Florida. The data is inconclusive with 
the latter variant as there have been no functional studies reported. The mutational 
mechanism in this variant affects the first codon of HBB resulting an elongated β-globin 
chain suggesting it could potentially affect the quaternary protein structure, but both 
patient cases in which this variant was found presented with red cell indices within their 
normal range. 
 
A further 10 haemoglobin variants were detected in the remaining 50% (n=18) of patients 
which were considered to be of clinical significance, either because of their inability to 
form stable haemoglobin tetramers, or because the tetramers they form are synthesised at a 
reduced rate resulting in a thalassaemic phenotype caused by the imbalanced α:β globin 
chain ratio. These are discussed below according to their clinical classification: 
 
Unstable haemoglobin variants 
Unstable haemoglobin variants are caused by the inability of the mutated globin chains to 
combine to form stable, viable haemoglobin tetramers, even though they are synthesised at 
a normal rate (as highlighted in Chapter 1, Section 1.4.4). Unlike the thalassaemia 
disorders, these haemoglobin variants tend to follow an autosomal dominant pattern of 
inheritance and present as a dominant form β-thalassaemia. They result in severe 
haemolytic anaemia caused by the precipitation of the excess of variant globin chains 
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within red cell precursors. Therefore affected individuals are almost exclusively 
heterozygotes.  
 
The largest number of characterised unstable haemoglobins (see Hb Variant database) 
affect β-globin chains. This probably reflects the more pronounced clinical effects that 
such β-globin chain variants would have on half of the total haemoglobin formed 
compared to those found on the α-globin chains which only affect a quarter the total alpha 
chains formed and are likely to be overlooked and therefore underreported. 
 
For the purposes of this study, Hb Monroe (IVS-I (-1) G>C) was included in the 
discussion of this group of variants, even though it is commonly considered as 
thalassaemic variant. Hb Monroe was detected in three patients, two of which were found 
in an Asian Antenatal couple. This highly unstable variant is reported to result in 
transfusion-dependent β-thalassaemia major when inherited in the homozygous state. In 
this study there was only one case of compound heterozygosity in which Hb Monroe was 
co-inherited with Hb E. Furthermore, two patients who were heterozygous for Hb Monroe 
may have had their phenotype ameliorated by the coinheritance of α+ thalassaemia. 
 
In the heterozygous state, the severity of disease caused by unstable haemoglobin variants 
is variable. They may be associated with reticulocytosis and mild to moderate haemolytic 
anaemia as a result of the unbalanced globin synthesis caused by the  alteration in the 
relative amounts of α and β globin mRNA (Rieder, R.F and James, G.W: 1976). These 
clinical symptoms may become more pronounced when exacerbated under conditions of 
oxidative stress, such as particular drugs or viral infections. At the severe end these 
unstable variants can mimic symptomatic forms of β-thalassaemia, which is well 
documented in the case of Hb Leiden (Lie-Injo et al 1977), in which compound 
heterozygosity with β0-thalassaemia in a Chinese patient had severe haemolytic anaemia. 
 
A further six different unstable variants were detected in a total of eight patients referrals, 
they include Hb Bushwick, Hb Hofu, Hb J-Guantanamo, Hb Tyne, Hb Köln and Hb 
Leiden. Hb Köln and Hb Leiden are also associated with an increased oxygen affinity, 
which usually leads to polycythaemia, but here their dominant clinical feature is 
haemolysis due to their highly unstable nature. They are therefore primarily categorised as 
unstable, rather than high-affinity, variants.  
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In this group of eight patient referrals received, reticulocytosis was not a prominent feature 
and their MCV values were not significantly increased, which supports general literature 
reports that these variants often result as a well-compensated mild haemolytic anaemia and 
do not always result in a thalassaemic picture (Hoyer, J.D et al: 1999). Therefore, despite 
the highly unstable nature of these variants, phenotypic screening may not always 
highlight these properties, and therefore their potential clinical significance. Furthermore, 
these unstable variants tend to present at very low percentages on HPLC, for example, the 
Hb Köln variant was found at only 7.5%. These highly unstable variants may be easily 
missed or mistaken for a benign alpha chain variant. 
 
Interestingly, the two patients in whom the Hb Köln and Hb Leiden variants were detected 
showed no evidence of an expected polycythaemia as their haemoglobin levels were 11.0 
g/dL in the female patient with Hb Leiden and 14.4 g/dL in the male patient with Hb Köln, 
although this latter patient case did show evidence of haemolysis with an MCV of 113 fL.  
 
High-affinity haemoglobin variants 
There was a further subgroup of rare but clinically significant haemoglobin variants 
detected within our referral population, in which the underlying mutational mechanism 
results in haemoglobin variants with increased oxygen affinity when compared to the 
normal haemoglobin A molecule. They are of clinical interest as they tend to present with 
haemoglobin levels above the normal range and usually lead to polycythaemia (Bain, B: 
2006). In reality the actual haemoglobin levels can be highly variable between patients, as 
encountered in this study, as the degree of shift of the oxygen dissociation curve may 
influence the final haemoglobin levels. 
 
A total of three high-affinity haemoglobin variants: Hb Old Dominion, Hb Olympia and 
Hb Malmö were detected in 7 patient cases referred for the detection of an abnormal 
variant with signs of polycythaemia, as they all had Hb levels above or within the upper 
range of normal levels. 
 
Heterozygosity for Hb Malmö was found in four Asian Pakistani family members. Initially 
the parents were referred as an antenatal couple with an unknown „haemoglobin J variant‟ 
of 47.6% and 45.9%, respectively, detected on HPLC, with normal red cell indices but 
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with evidence of mild polycythaemia as their respective haemoglobin levels were 15.1 and 
16.4 g/dL. The findings from subsequent DNA analysis highlighted the potential 
implication for the next generation in this family, given the possibility of their offspring 
inheriting homozygosity for this variant. Again, these high-affinity variants are usually 
reported in the heterozygous state, there is very limited data on the consequence of a 
homozygous genotype. Available literate suggests that, even though polycythaemia rarely 
requires treatment, in vivo these variants may be associated with fetal hypoxia 
(Weatherall, D.J and Clegg, J.B: 2001) due to the impaired oxygen transfer to the fetus. 
However, none of these findings have been reported in vitro. DNA analysis of the two 
male offspring found that they were both heterozygous for Hb Malmö, with haemoglobin 
levels of 15.7 and 14.6 g/dL at 7 and 8 years of age respectively. 
 
Correlation of rare beta chain haemoglobin variants with stated ethnicity: 
The highest frequency of rare beta chain haemoglobin variants was found in individuals of 
Asian (n=12) origin, followed by those of White (n=8) ethnicity. When the patients stated 
ethnicity was compared to their beta genotype, as represented in Chapter 3, Figure 3.16, it 
shows that a large proportion (61%, n=59) of patients with a haemoglobin variant 
genotype had a variant haemoglobin that would be expected within their ethnic group. 
This strong correlation can be accounted for by the large number of sickle haemoglobins 
reported in patients of Black ethnicity. Therefore, when the clinically significant variants 
are omitted, this correlation is much weaker, only 13% (n=12) of all patients with a 
haemoglobin variant genotype had a rare variant that would be expected within their 
ethnic group. For example, only four out of the 12 Asian patients had a rare variant that 
would be normally expected within this ethnic group. Furthermore, all three cases of the 
Hb Monroe variant were found in this ethnic group, which is normally expected in Black 
ethnic groups. Additionally, only half of those patients of white ethnicity had a rare variant 
that would normally be expected within this ethnic group. 
 
Summary of rare HBB haemoglobin variants detected by DNA sequencing: 
The identification of these HBB variants by DNA sequencing was important in some cases 
as there are a subset that cannot be separated by HPLC and in some cases may even mask 
underlying β-thalassaemia trait as they elute within the HbA2 window. In this study they 
included: Hb D-Iran, Hb Spanish Town and Hb OSU-Christiansborg. Furthermore, DNA 
analysis was an essential tool for the differentiation of those variants that elute within the 
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„D-window‟ on HPLC, such as Hb G-Norfolk, Hb G-Philadelphia and Hb D-Punjab, the 
latter of which must be identified as part of the antenatal screening guidelines. 
 
The frequency of rare beta chain haemoglobin variants found within individuals of Asian 
ethnicity is significant as this is an ethnic group in which consanguinity is not uncommon, 
giving rise to the possibility of homozygosity for these variants.  Depending on the nature 
of these variants they may have clinical consequences, such as in the Hb Malmö scenario 
outlined above. Additionally, only DNA sequencing was capable of detecting the high 
affinity variant Hb Köln, as it elutes within the Hb A window on HPLC. Again, 
homozygosity for this variant may result in a severe haemolytic anaemia. 
 
The data presented above contrasts with discussion around DNA screening guidelines that 
suggest the detection of abnormal haemoglobin variants by DNA sequencing creates 
„noise‟ for screening programmes and that there is little clinical value in their detection 
and identification. Within our referral population, 50% of the rare beta chain variants 
detected have an altered protein structure and may be considered to be of clinical 
significance, especially in the antenatal context due to their possible interactions with β-
thalassaemia. This, coupled with the poor correlation observed between patients‟ ethnicity 
and the variant found, indicates that our screening methodologies employed are of clinical 
benefit. The detection of these rare HBB variants may help to inform clinical management 
and monitoring of a patient, although their identification would not form an essential part 
of a PND screening service. 
 
4.10.2b Alpha chain haemoglobin variants detected by DNA sequencing of HBA1 and 
HBA2. 
Direct DNA sequencing of HBA1 and HBA2 detected 33 different alpha chain variant 
haemoglobins in 16% (n=53) of all patient referrals (Chapter 3, Figure 3.8). Surprisingly, 
nearly an equal number of haemoglobin variant cases were detected within HBA1 (n=30) 
and HBA2 (n=29). This is unexpected because general literature tends to only report those 
variants within HBA2 which are deemed to be of greater clinical significance. The clinical 
significance of each of these variants detected is discussed further in this section. 
 
The variants found at highest frequency within our referral population were all found 
within HBA1 and include Hb G-Philadelphia (n=5), Hb Manitoba (II) (n=4), Hb Q-India 
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(n=4) followed by Hb Stanleyville II (n=3). The remaining 29 variants were found at low 
frequency in a variety of cases and ethnic groups. 
 
The relatively high frequency of Hb G-Philadelphia and Hb Stanleyville II, all of which 
were found in the Black or mixed Black ethnic groups within our referral population, is 
expected due to the overall large proportion of Black patient referrals received and the 
common co-inheritance of Hb G-Philadelphia in cis with –α3.7 or with βS. Hb Manitoba II, 
normally reported in British and Italian populations, was found in two individuals of 
Mixed ethnicity (Indian and French), and unexpectedly in two individuals of Asian 
ethnicity. Hb Q-India was unexpectedly found in one SEA patient but was also found in 
three Asian individuals, which is more consistent with published reports. 
 
Despite literature reports suggesting that a large proportion of haemoglobin variants found 
within the alpha globin genes are of no clinical significance, a surprisingly large 
proportion of alpha variants detected within our referral population were associated with 
some form of clinical disease. From the wide range (n=33) of alpha chain variants 
detected within this study it would be expected that only a very small proportion of these 
variants would be of any clinical significance, but in fact only 45% (n=15) of the different 
variants detected, found in within 40% (n=21) of cases were associated with a clinical 
abnormality. 
 
Furthermore, even though two of these variants (Hb G-Philadelphia and Hb Q-Thailand) 
are reported on the Hb variant database as having normal functional protein properties and 
therefore a normal clinical presentation, they are most commonly found in the compound 
heterozygous state with an alpha thalassaemia deletion (–α3.7 and –α4.2 respectively), as 
found in all seven patient cases within this study. When Hb G-Philadelphia is found in 
trans with -α3.7 deletion, this interaction can increase the relative proportion of the variant, 
from the usual 30-35% to around 45%, and therefore reinforce any associated clinical 
phenotype. It was not possible to determine the mode of inheritance of this variant in the 
five reported cases, due to the co-inheritance of Hb S in three cases and homozygosity for 
–α3.7 in two cases, but all of these genetic interactions resulted in a distinct microcytosis 
and hypochromia.  
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Within this study, heterozygosity for Hb Q-Thailand was found in trans with the -α4.2 
deletion in two individual antenatal Chinese patients, as reflected by the high quantity of 
the variant detected (30.8 and 30%, respectively), again resulting in mild microcytosis and 
hypochromia. Unfortunately there was no phenotypic information available on their 
respective partners. 
 
In one further case, the alpha chain variant (HBA2:pLys127Glu) was found in a White 
Irish patient referred for an unknown variant of 18.8% detected on HPLC, however, it was 
not possible to assess the clinical significance of this variant due to limited case reports. 
  
The remaining 14 clinically significant alpha chain variants detected within 38% (n=20) 
of these patients are discussed below. They are all associated with a change in protein 
structure and are associated with either a thalassaemic phenotype or haemolytic anaemia, 
caused by the resultant unstable protein structure of the variant or polycythaemia caused 
by the increased oxygen affinity of the variant. 
 
Alpha chain haemoglobin variants causing a thalassaemic phenotype: 
Four different variants (Hb Constant Spring, Hb Seal Rock, Hb Quong Sze and Hb 
Evanston) found in six patients within our referral population are classified, according to 
the Hb variant database, as a non-deletional form of alpha thalassaemia as heterozygotes 
for these variants have an α-thalassaemia phenotype with a chronic haemolytic anaemia 
(see Chapter 1, Section 1.4.4). This phenotype is mostly due to the alteration of the tertiary 
structure of the haemoglobin molecule in which the resultant highly unstable haemoglobin 
tetramer precipitates within the red cells. 
 
Definitive diagnosis of this class of variants by mutation detection, in this case DNA 
sequencing, in our patient cohort was vital as this is the only current technique, apart from 
mass spectrometry, in which the presence of such variants can be reliably demonstrated. 
Detection of these highly unstable alpha chain haemoglobin variants by HPLC can be 
unreliable. Rather than forming discrete bands at around 25%, as usually found in carriers 
for alpha chain variants (Chapter 1, Section 1.4.4), they are rapidly degraded and may go 
undetected, for example heterozygotes for the Hb Constant Spring variant  have ~1% of 
Hb Constant Spring in their red blood cells (Bain, B (2006). Of all six cases in which this 
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class of variant was found, phenotypic screening by HPLC failed to detect the variant 
haemoglobin, and only by performing DNA sequencing analysis were they detected. 
 
Compound heterozygosity for these unstable variants with a deletional form of α+ or α0 
thalassaemia, commonly found within the SEA population groups, tend to result in 
particularly severe forms of Hb H disease compared to those caused by deletional 
compound heterozygous genotypes (Chapter 1, Section 1.4.4) as they are associated with a 
dominant mode of inheritance. Homozygosity for the most severe variants may even be 
incompatible with life (Weatherall, D.J and Clegg, J.B: 2001). DNA studies on one SEA 
patient, who had been referred for possible Hb H disease, with an MCV of 74 fL and an 
MCH of 18.0 pg and a fast band detected on HPLC, confirmed that they did have Hb H 
disease caused by the compound heterozygous genotype --SEA/αQSα. Unexpectedly, this 
patient had a less marked hypochromic and microcytic anaemia in comparison to those 
five patients with deletional forms of Hb H diseased in this study. 
 
DNA analysis on another female patient, of unknown ethnicity, who had been referred 
with microcytic indices (MCV 77 fL and MCH 25.2 pg) and a possible HbA2 variant of 
1.8%, showed that she was compound heterozygous for Hb Seal Rock and -α3.7 deletion, 
resulting in a mild form of Hb H disease. 
 
These genetic interactions are important to diagnose within the antenatal context, as the 
two cases discussed here highlight.  Both reports of the Hb Constant Spring variant in this 
study had been referred as part of an „at risk‟ antenatal couple. One individual with this 
variant had been referred as part of a Chinese antenatal couple, with possible alpha 
thalassaemia (MCV 78 fL and MCH 26.5 pg). DNA studies on their partner revealed 
heterozygosity for the α0 --SEA deletion. Offspring of this couple therefore have a 1 in 4 
risk of inheriting Hb H disease caused by the interaction of these genotypes. The second 
patient with Hb Constant Spring had been referred as part of a Thai antenatal couple for 
possible alpha thalassaemia (MCV 77.8 fL and MCH 25.7 pg), with no variant detected by 
HPLC. DNA studies on their partner, who had been referred with suspected Hb E with a 
raised HbA2 level of 21.7% (MCV 67.1 fL and MCH 21.5 pg), revealed heterozygosity for 
the α0 --SEA deletion and heterozygosity for the βE variant. Offspring of this couple have 
a 1 in 4 chance of inheriting the genotype: --/αCSα, ββE which is associated with a 
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phenotype similar to Hb H disease. The literature reports that such genetic interactions are 
common in Thai and SEA populations.  
 
Hb Evanston was detected in one patient of unknown ethnicity who had been referred for 
query β or δβ-thalassaemia (MCV 63.2 fL and MCH 21.2 pg) with a raised HbA2 of 4.2% 
and Hb F of 18.0%. Extensive DNA analysis of this patent also revealed heterozygosity 
for severe β+ thalassaemia, caused by the mutation IVS1-5 (G>C). Interestingly, Hb 
Evanston is found on the HBA1 gene and is not only associated with a thalassaemic 
phenotype but also with increased oxygen affinity. It is rapidly destroyed and is not 
detectable on HPLC. There are limited case reports of this interaction, but unlike 
deletional forms of alpha thalassaemia, this alpha genotype is unlikely to ameliorate the 
beta genotype. Further DNA sequencing of the 
Gγ gene showed this patient was 
heterozygous for the Xmn I polymorphism, which might account for their high Hb F level, 
but this effect tends to be only observed under conditions of erythropoietic stress, which 
the patient‟s raised RBC count (6.80 x1012/L) indicates. Further genetic analysis by HBB 
MLPA was not performed as this patient was unlikely to carry a deletional type of HPFH 
or δβ because their Hb A was too high (14.4 g/dL) for this genotype combination. This 
case reflects the importance of extensive DNA analysis in clarifying the exact genotype in 
those patients presenting with complex phenotypic screening results.  
 
Unstable haemoglobin variants 
A further group of three different unstable alpha chain variants: Hb Setif, Hb Spanish 
Town and Hb Manitoba types I and II, which are classified together as they both lead to 
the same protein defect, were detected in seven cases from our referral population. These 
variants alter the tertiary structure of the haemoglobin molecule and can result in a chronic 
haemolytic anaemia. Unexpectedly this clinical picture was only observed in those 
individuals with the Hb Manitoba (Type II) variant, found within HBA1, in which all of 
these patients had borderline to reduced red cell indices. 
 
The individual with Hb Manitoba (Type I), found on HBA2, presented with a higher 
percentage (15.7%) of variant than those with the Type II variant. This is consistent with 
literature reports that state variants within HBA2 tend to present at a higher proportion (see 
Chapter 1, Section 1.4.4) than those within HBA1 due to their differential transcription 
rates. Unexpectedly, unlike those patients with the Type I variant, this patient presented 
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with normal red cell indices. It may be expected that this variant type would be associated 
with a more pronounced clinical picture due to the higher proportion of protein production 
from the HBA2 gene. 
 
Interestingly another unstable variant which was detected in one patient by DNA 
sequencing and was not detected on HPLC was Hb Riccarton. This variant is unlike those 
unstable variants discussed above in that it belongs to a group that are so highly unstable 
they undergo very rapid post synthetic degradation and are unable to form haemoglobin 
tetramers. This means there is no associated loss of normal β chains as they remain in 
excess within the red cells and the clinical presentation is normal. This correlated with the 
phenotype of the affected White British male as the Riccarton variant was not detected on 
HPLC and their red cell indices were normal. DNA sequencing was important in this case 
as this patient had been referred as part of an „at risk‟ antenatal couple in which his 
Chinese origin partner had a raised Hb A2 level of 3.6%, although DNA analysis failed to 
detect an underlying mutation in this case.  
 
Again, as with the unstable beta chain variants, it is important that these unstable abnormal 
haemoglobins are diagnosed by DNA sequencing as the resultant unstable proteins cannot 
be detected by HPLC screening and they may be associated with an alpha thalassaemia 
phenotype. 
 
High affinity haemoglobin variants 
A further five alpha chain variants with an increased oxygen affinity were detected in six 
cases (Hb Chesapeake, Hb Dunn, Hb Linwood, Hb Toulon and Hb West-One), in a variety 
of ethnic groups. These variants are associated with erythrocytosis, interestingly, two of 
which (Hb Toulon and Hb Chesapeake) were found within HBA1. 
 
Hb Chesapeake, was detected in one patient of unknown ethnicity who had been referred 
for DNA studies for the identification of an unknown haemoglobin variant of 22.5%. This 
variant is also reported to be mildly unstable, as well as being associated with mild 
erythrocytosis; this was evident within this patients phenotype as she had normal red cell 
indices and a RBC of 4.95 (x10
12
/L). 
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The two cases of Hb Linwood were found in a SEA family, in which the antenatal couple 
had been referred for genetic analysis from the phenotypic screening results obtained. One 
partner with Hb Linwood was referred for an unknown variant detected at 27.3%. Their 
partner was referred for possible alpha thalassaemia (MCV 59 fL and  MCH 17.8 pg). 
DNA analysis revealed heterozygosity for the α0 --SEA deletion. There was limited data 
on the possible clinical phenotype associated with this potential interaction. Subsequent 
DNA analysis of their child showed that he had inherited heterozygosity for Hb Linwood. 
This variant is reported to have an increased oxygen affinity and is associated with 
reticulocytosis, therefore offspring of this couple are likely to have marked erythrocytosis. 
Both individuals in this family with the Hb Linwood variant had Hb levels at the high end 
of normal range (14.5% and 14.8% respectively). 
 
Summary of rare haemoglobin variants detected by DNA sequencing of HBA1 and 
HBA2: 
This study detected an unexpectedly high proportion of alpha chain variants within our 
referral population, a surprisingly large number of which were not completely clinically 
benign as they result in an altered protein structure. This is contradictory to literature 
reports that suggests the majority of alpha chain variants do not result in a clinical disorder 
and therefore do not warrant identification by DNA studies in the antenatal context. 
 
The pathophysiology of some of the variants identified in this study was similar to that 
found in the thalassaemia disorders, and because they are frequently co-inherited together 
with different forms of thalassaemia, DNA sequencing provided a vital tool for their 
identification, especially with those that cannot be detected by phenotypic screening alone 
due their highly unstable nature. Their identification proved especially valuable in those 
patients who presented with a microcytic and hypochromic phenotype where Gap-PCR 
had failed to detect an alpha deletional mutation mechanism. 
 
Even though in some DNA diagnostic laboratories it is not always possible to identify 
alpha chain variants due to methodology restraints, and the antenatal screening programme 
states that it is not always of potential clinical significance to do so, the cases discussed 
above highlight the wide range of clinical conditions associated with these variants, 
including those which may result in particularly severe forms of Hb H disease. There 
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remain some variants which are important to identify by DNA sequencing in the antenatal 
context, and potentially even for PND purposes in isolated cases. 
 
4.11 Summary of mutation screening by DNA sequencing of HBA1 and HBA2 for the 
detection of all point mutations associated with alpha thalassaemia and haemoglobin 
variants. 
Routine DNA sequencing of HBA1 and HBA2 provided an important diagnostic screening 
tool, as a wide range of non-deletional alpha thalassaemia mutations and haemoglobin 
variants were detected within a variety of ethnic groups from the North West of England 
referral population, the clinical significance, or otherwise, of which has been discussed 
above. Out of all of these patient cases, in which a point mutation was found within either 
of the alpha globin genes, only 53% (n=31) had an alpha genotype that would be expected 
in their stated ethnic group and 37% (n=22) had an alpha genotype not normally 
associated with their ethnic group. In the remaining 10% (n=6) of cases the patients‟ 
ethnicity was not stated (See Chapter 3, Figure 3.9). Therefore DNA sequencing of the 
essential regions of the alpha-globin genes indicates that a “first pass” ethnic led mutation 
screening strategy may miss up to 47% of alpha genotypes analysed. 
 
A wide range of HBA variants were detected within this study by DNA sequencing, not all 
of which result in a clinically significant disease. It is widely reported in literature that a 
proportion of these variants, especially when co-inherited with a deletional form of α-
thalassaemia result in severe forms of Hb H hydrops fetalis, a publication by Viprakasit, V 
et al (2001) highlights a case of Hb H hydrops fetalis syndrome caused by the interaction 
of two common α-thalassaemia genotypes --MED/αTSaudiα. HBA variants found within this 
study that could potentially result in a similar severe phenotype include Hb Constant 
Spring, Hb Quong Sze, Hb Seal Rock and Poly A (del AA). This contrasts with the 
antenatal screening programme, which states that these variants do not warrant further 
genetic analysis within the antenatal or PND context because they do not cause severe 
disease in the fetus. Furthermore, many of these variants are silent on HPLC due to their 
highly unstable nature and can therefore only be identified, in the heterozygous state, by 
performing DNA analysis. Therefore broader mutation detection by DNA sequencing of 
HBA could be used to identify such genetic interactions and enable counselling for 
potentially severe forms of Hb H disease. 
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4.12 MLPA analysis for the detection and confirmation of deletional forms of alpha 
and beta thalassaemia. 
Once established and validated, MLPA proved to be a useful assay for the detection of 
rare or previously uncharacterised deletions and duplications affecting either the alpha or 
beta globin gene clusters (Chapter 2, Section 6.0). In this study MLPA was applied to 
those individuals in whom alternative methodologies had failed to detect a causative 
mutation. 
 
Initial intensive optimisation of both the HBA (P140-B2) and HBB (P102-B1) MLPA kits 
was required. This assay was validated using known positive and negative control samples 
in which the sample had either been genotyped within the MDC using alternative 
methodologies or externally by MLPA analysis. Once these assays had been validated 
strict quality control criteria relating to data obtained from analysed samples was always 
adhered to (Chapter 2, Section 6.4), in which samples with a standard deviation score 
exceeding 0.1 were rejected. MLPA was also used in this study to confirm and validate 
those HPFH and δβ-thalassaemia samples that were genotyped using the Craig, R.A et al 
(1994) Gap-PCR protocol. Furthermore, when the interpretation of the expected probe 
heights was unavailable for certain deletions from MRC Holland, the characteristic 
reduced probe height pattern observed in known positive controls  was recorded to aid 
future deletion characterisation, such as Hb Lepore and Chinese δβ-thalassaemia. 
 
4.12a HBA MLPA 
HBA MLPA analysis was mainly used for the confirmation of a normal alpha genotype 
and to exclude rarer forms of deletional α-thalassaemia in those patients in which 
alternative methodologies did not found a causative mutation and their phenotype did not 
correlate. This approach was very useful in order to comprehensively genotype two „at 
risk‟ antenatal couple cases, discussed below, and to accurately predict the risk to their 
offspring for genetic counselling purposes. 
 
The first couple, of Filipino origin, had both been referred for query alpha thalassaemia.  
Gap-PCR analysis on the partner revealed heterozygosity for the South East Asian α0-
thalassaemia deletion, which was consistent with his phenotype (MCV of 66.3 fL and 
MCH of 21.0 pg). In contrast, the normal results obtained by extensive DNA analysis of 
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the female was insufficient to explain her phenotype (MCV of 72.2 fL and MCH of 23.1 
pg). Further HBA MLPA analysis revealed a normal probe pattern, therefore excluding a 
rare form of deletional alpha thalassaemia. Given the preliminary nature of our MLPA 
assay development, confirmatory analysis by the National Reference Laboratory for 
Haemoglobinopathies was requested.  This confirmed our findings and it was concluded 
that iron deficiency was the underlying cause of her microcytosis and hypochromia. This 
couple were therefore not at risk of having a child affected with Hb Bart‟s Hydrops Fetalis 
syndrome. 
 
The second couple, both of Chinese origin, had been referred as the partner had query 
alpha thalassaemia with an MCV of 71 fL and MCH of 22.4 pg, in which subsequent Gap-
PCR analysis revealed heterozygosity for the South East Asian α0-thalassaemia deletion. 
The female was referred for query β-thalassaemia, with a HbA2 of 5.5%, an MCV of 64 fL 
and a MCH of 20.1pg. It was therefore of clinical importance to exclude underlying alpha 
thalassaemia in this patient, which HBA MLPA helped to do. DNA sequencing of her β-
globin genes confirmed a diagnosis of severe β+ thalassaemia trait, caused by the IVSII-
654 (C>T) mutation. 
 
HBA MLPA analysis on selected patients within our referral population did not detect any 
additional deletional mechanisms that had not already been identified by existing 
methodologies such as Gap-PCR, including any rare or novel deletions. This reflects the 
effectiveness of a multiplex Gap-PCR protocol for the detection of the common deletional 
causes of alpha thalassaemia.  HBA MLPA analysis performed on a young Caucasian male 
patient subsequent to the completion of this study, detected a deletion within the 
regulatory region of his α-globin gene cluster (HS-40) which would result in a marked 
decrease in the transcription rate of the α-globin genes on that chromosome. These 
findings correlated with the patient‟s microcytic, hypochromic phenotype (MCV: 53 fL, 
MCH: 18.2 pg) as his triplicated alpha genotype alone, did not (as discussed in Section 4.6 
above and Chapter 3, Section: 9.5). 
 
4.12b HBB MLPA 
Even though deletional forms of β-thalassaemia are reported to comprise a relatively rare 
group of disorders, as found in this study as only two cases were reported, these types of  
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beta thalassaemia account for nearly 20% of all β-thalassaemia alleles within the Punjab 
region of India (Mikula, M et al: 2011), with the 619 bp deletion reported to be the second 
most common cause of β-thalassaemia in Gujarat, India (Colah et al: 2010) (Chapter 1, 
Section 1.4.2). Their identification in areas that have a diverse immigrant population such 
as the North West of England is important, as unlike the common point mutations which 
can be associated with either a β0 or β+ thalassaemia phenotype, large deletional forms 
always result in β0 thalassaemia, therefore their identification is important for those 
antenatal couples considering prenatal diagnosis.  In addition, fine scale mutation analysis 
by DNA sequencing is likely to miss beta gene deletions as the presence of the intact copy 
will mask their existence on sequence traces.   
 
Within our referral population only two deletional forms of beta thalassaemia were found 
in two cases. Even though these deletions were detected by the National Reference 
Laboratory, due to the unavailability of HBB MLPA within the MDC at the time (Chapter 
3, Section 9.6), these cases were easily highlighted by their characteristic phenotype, as 
deletional forms of β-thalassaemia tend to show significantly higher levels of haemoglobin 
HbA2 and occasionally F. Therefore, external testing was requested in these cases when 
the severity of the phenotype was discrepant from the genotype identified with the MDC.   
 
One case of the Afghan 909 bp β° deletion (which removes the 5‟ end of HBB) was found 
in a male patient of unknown ethnicity who had been referred for β-thalassaemia with a 
very high proportion of HbA2 (7.4%), Hb F (9.5%), an MCV of 71 fl and an MCH of 21.5 
pg. This phenotypic presentation is expected, as these 5‟ HBB deletions tend to show a 
characteristic increase in haemoglobin F as the 5‟ regulatory region of HBB is deleted. 
 
The one case of the 619 bp β° deletion (which removes the 3‟ part of HBB, including part 
of intron-2, exon 3 and a segment of DNA 3' to the termination codon) was found  in a 
female patient of Asian Indian origin, which is expected as it is normally found in Indian 
or Asian populations. She had been referred as part of an antenatal couple for possible β-
thalassaemia with a significantly raised HbA2 level of 5.3%, MCV of 64 fl and an MCH of 
20.3 pg. Her Hb F level of 1.7% was not significantly raised as this level could be 
explained by pregnancy. This patient‟s phenotype was consistent with case reports of this 
deletion, in which 3‟ deletions affecting HBB do not show an increase in haemoglobin F 
because the 5‟ regulatory region is not deleted. This couple were not at risk of having an 
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affected child with a clinically significant haemoglobinopathy as the partner only had an 
alpha plus (–α3.7) deletion. 
 
A further three cases of deletional forms of thalassaemia found within our referral 
population associated with the δβ-thalassaemia disorders, which remove both the δ- and β-
genes. Again these deletional mechanisms were initially detected by HBB MLPA 
performed by Oxford (Chapter 3, Section 11.6), but were highlighted within the MDC due 
to their characteristic raised haemoglobin F levels.  
 
The Indian 32 kb, 
GγAγ(δβ)0 deletion was found in an antenatal female patient of Asian 
Indian ethnicity, referred for query δβ-thalassaemia or HPFH, with a raised Hb F level of 
19.2% and a normal Hb A2 of 2.3%, she also had microcytic and hypochromic indices 
with an MCV of 77 fl and an MCH of 25.7 pg. This patient‟s phenotype was consistent 
with other reports concerning this mutation and subsequent screening of her partner 
revealed a normal phenotype. 
 
The two cases of the Black 12 kb δβ° deletion were found in two female siblings referred 
for possible δβ-thalassaemia (as in their mother). Both had marked microcytic and 
hypochromic indices and elevated haemoglobin F levels of 15.2% and 15.8% respectively, 
and haemoglobin A2 levels within the normal range. Their phenotype was consistent with 
case reports of this deletion with the co-inheritance of α-thalassaemia. 
 
A further 6 cases of deletional forms of thalassaemia were detected by HBB MLPA 
analysis performed at Oxford, including rare, uncharacterised HPFH and δβ-thalassaemia 
deletions. This demonstrates that MLPA can be a useful tool for the detection of deletions 
in the α or β-globin clusters genes with no prior knowledge of breakpoints of the deletions, 
providing a useful DNA screening tool in appropriate cases. Once HBB MLPA had been 
established and validated within the MDC laboratory, it was useful in those cases where 
DNA sequencing was uninformative.  MLPA analysis helped to differentiate those 
patients with the Hb SS genotype from Hb S/HPFH or Hb S/δβ-thalassaemia. This was 
especially helpful in patients with the Arab-Indian sickle haplotype (Chapter 1, Section 
1.4.4) or those with only homozygous polymorphisms detected within the β-globin gene 
by DNA sequencing, possibly indicating the presence of a whole or partial deletion of one 
allele. 
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HBB MLPA was also used within the MDC for the analysis of two suspected cases of εγδβ 
thalassaemia (Chapter 3, Section 11.5), in which initial extensive genetic screening by 
existing methodologies had failed to detect a causative mutation. HBB MLPA analysis 
helped to exclude εγδβ-thalassaemia in a young Caucasian male patient case, in whom 
only the triplicated alpha genotype had been found (but as highlighted in Section 4.12a, 
subsequent HBA MLPA analysis detected an additional deletional mechanism). The 
second patient, who was a white British female, showed a characteristic reduced probe 
pattern (See Chapter 3, Section 11.5 and Figure 3.19) which was indicative of group I 
εγδβ-thalassaemia (which removes the entire β-globin cluster), therefore explaining this 
patient‟s clinical presentation of severe neonatal anaemia. 
 
Even though the εγδβ-thalassaemia disorders are rare, their detection and characterisation 
by HBB MLPA is useful as it can be used as an elimination tool for the proportion of 
patients who present with unexplained hypochromia and microcytosis and normal Hb A2 
levels in which an α-thalassaemia genotype was not found.  It would also be impractical to 
detect this group of disorders by Gap-PCR methodologies since their molecular 
heterogeneity is broad, as they can be caused by at least 15 known deletional mechanisms 
(Rooks, H et al: 2005). 
 
Furthermore, MLPA is a useful tool for the diagnosis of those thalassaemic conditions 
which may be caused by deletions within the upstream regulatory elements of either the α-
globin gene cluster (HS-40) or the β-globin gene cluster (β-LCR), as other methodologies 
may indicate that the globin genes are intact, but would fail to indicate as to whether or not 
they are actively transcribing and synthesising globin chains on that chromosome (as 
demonstrated from the male Caucasian patient case discussed in Section 4.12a with the 
HS-40 deletion and the white British female discussed earlier in this Section with εγδβ-
thalassaemia). 
 
4.12.1 Summary of HBA and HBB MLPA analysis 
MLPA is a useful screening tool for the detection of deletions within HBA and HBB, 
although it does not allow the user to map the exact boundaries of a deletion. Identifying a 
deletional mechanism by MLPA analysis is important in the antenatal context for the 
accurate genetic counselling of couples, especially for those conditions in which prenatal 
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diagnosis may be indicated. It is important that a haemoglobinopathy DNA diagnostic 
service employs such gene dosage based methodologies that can detect changes in the 
relative quantity of copy numbers, as alternative fine scale assay methodologies such as 
DNA sequencing cannot always detect those complex genetic abnormalities associated 
with the interaction of  α and β-thalassaemia. 
 
4.13 Patients in which no causative mutation was detected by the DNA screening 
methodologies employed within MDC. 
In a proportion of patient referrals (13%, n=41), no causative mutation was detected using 
the laboratory screening methods outlined in Chapter 2, or the genotype detected within 
the MDC was insufficient on its own to account for the patients‟ phenotype. (Chapter 3, 
Section 11.0).  As already outlined (Chapter 3, Figure 3.18), the largest proportion (34%, 
n=14) of these patients were those who had been referred as part of an antenatal couple in 
which extensive DNA testing on both partners was beneficial in accurately assessing the 
risk to the offspring, especially in those presenting with a borderline HbA2 level in which 
the other partner had β-thalassaemia.  
 
DNA analysis for the exclusion of a thalassaemia disorder was requested in a proportion 
of patients and young children where it was deemed to be of clinical interest i.e. in those 
where it was not possible to exclude underlying iron deficiency, especially in those not 
responding to iron therapy, or those in which ZPP levels were unreliable (as they can often 
be falsely elevated in some cases of thalassaemia), or in order to avoid further invasive 
clinical testing. 
This group of patients also included those urgent antenatal cases in which one partner had 
borderline red cell indices and there was insufficient time to trial a course of iron therapy. 
Of this group of patients 12% (n=5) were diagnosed with iron deficiency either from the 
exclusion diagnosis by DNA or by their low serum ferritin levels. The two other cases, 
with suspected εγδβ-thalassaemia, which comprised 5% these patient cases, have already 
been discussed above (Section 4.12b). This deletional mechanism was not initially 
detected due to the unavailability of HBB MLPA at that time. 
The remaining 11 patient cases have been previously highlighted (Chapter 3, Section 11.0) 
and included those with other underlying clinical conditions, a novel mutation, or their 
phenotype remained unexplained despite confirmatory genetic testing by the National 
Reference Laboratory for Haemoglobinopathies. 
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4.14 Patients referred to the National Reference Laboratory for 
Haemoglobinopathies for further genetic testing - indicating further service 
development within the MDC. 
Within this study there were a total of 12 cases in which no mutation was detected using 
the panel of tests employed within the MDC at the time, where subsequent DNA analysis 
by the National Reference Laboratory for Haemoglobinopathies detected a causative 
mutational mechanism (Chapter 3, Section 11.6). 
 
Of these 12 patient cases, five consisted of four different deletional genotypes, which have 
already been discussed above in Section 4.12b, and included deletional β-thalassaemia or 
novel δβ-deletional mechanisms that could not be detected or confidently characterised 
within the MDC due to the unavailability of HBB MLPA at that time. Our current testing 
regime would now be able to detect these deletional mechanisms since the establishment 
of HBB MLPA. A further five cases included rare or unidentified forms of HPFH or δβ-
thalassaemia which were also detected by HBB MLPA (highlighted in Chapter 3, Section 
11.6). Again, these genotypes can now be detected using our current testing regime. In one 
further case, in whom the National Reference Laboratory reported to be either normal or to 
have some form of εγδβ0 thalassaemia could be diagnosed in the same manner as those 
cases discussed above in Section 4.12b. 
 
In the remaining one patient case, who was reported by the National Reference Laboratory 
as having a probable δ-chain variant, further DNA analysis or assay development would 
not be worthwhile, as δ-chain variants are not clinically significant. 
 
4.14.1 Future service developments 
As well as MLPA, which is relatively cumbersome and does not map deletions with a high 
degree of accuracy, detection of the deletional forms of β-thalassaemia can be achieved by 
using a Gap-PCR based methodology (provided that the deletional breakpoints are 
known), which could then be used alongside current methodologies to act as an 
independent confirmatory technique. A future service development for the MDC 
diagnostic service would be the development of a Gap-PCR method for the detection of 
the following β0 thalassaemia deletions which all occur at significant frequencies to 
warrant their identification: Indian 619 bp, Black 1393 bp, Afghan 909 bp, Filipino ~45 kb 
and the Indian 32 kb deletion. 
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In order to provide a pre natal diagnostic service, where speed of diagnosis is very 
important, it would be prudent to consider the development of a panel of rapid assays 
which could be used as independent confirmatory techniques. An obvious candidate for 
this would be rapid testing for the Hb S mutation and a panel of common beta zero 
mutations found in our local referral population.  Techniques such as ARMS-PCR may be 
suitable for this purpose.  
 
Furthermore, the development of mass spectrometry would be useful for the positive 
identification of haemoglobin variants. A large proportion of variants can be identified by 
this technique as mass spectrometry can determine if the variant is on either the α- or β-
globin chain and can also estimate the proportion of the variant. Further analysis may also 
enable prediction of the possible amino acid substitution based on the observed change in 
mass of the variant. This technique may eliminate the need for DNA sequencing in those 
cases which cannot be positively identified by HPLC and would also be useful for the 
detection of fusion gene variants such as Hb Kenya. The disadvantage of this technique is 
the initial cost, as the apparatus is very expensive and the data interpretation of the results 
requires considerable experience. Whilst it would be useful in an antenatal context, it 
would not, in the conventional approach, replace genetic PND investigation. 
 
4.15 Summary and conclusions of mutation detection strategy employed versus 
ethnic led mutation screening for the North West referral population 
Within most populations, a large proportion of carriers for alpha and/or beta thalassaemia 
will have a common subset of mutations which are strongly associated with their ethnic 
group, followed by a smaller proportion exhibiting rarer mutations. Therefore, the strategy 
for identifying α- and β-thalassaemia mutations within many diagnostic laboratories is 
based on this knowledge of the spectrum of expected common, and less common but still 
relatively frequent, mutations expected to be found within the ethnic group of the 
individual. This „ethnic-led‟ PCR based screening approach should therefore detect a large 
proportion of mutations, eliminating the need to perform DNA sequence analysis on every 
case.  
 
Recently, a number of literature reports have highlighted the increasing racial 
heterogeneity of the UK population, in which the spectrum of haemoglobinopathy 
mutations found has significantly increased (see Chapter 1, Section 1.3). This large 
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molecular heterogeneity poses challenges for diagnostic laboratories which must be able 
identify this wide range of mutations which will be present within ethnically diverse 
populations, as well as rare mutations which can present in any population. The referral 
population served by the Molecular Diagnostics Centre at Manchester Royal Infirmary 
represents a diverse ethnic mix.  Therefore, in order to achieve a high mutation detection 
rate in such a heterogeneous population, a comprehensive mutation screening approach is 
required. This diagnostic screening approach was employed within the MDC by using 
multiplex Gap-PCR, DNA sequencing and MLPA methodologies in order to detect the 
wide range of mutations likely to be present within the North-West of England. 
 
Results obtained from DNA sequencing of HBB identified 44 different types of non-
deletional mutations, which comprised of 20 that cause β-thalassaemia and 24 that are 
associated with variant haemoglobins. Furthermore, DNA sequencing of HBA1 and HBA2 
also identified 38 different types of non-deletional mutations, which comprised a small 
proportion of five that result in a non-deletional form of α-thalassaemia and 33 that are 
associated with variant haemoglobins. The variety of alpha and beta chain haemoglobin 
variants detected in this study is an important observation since our referral population is 
comprised mainly of individuals of Asian ethnicity, an ethnic group in which 
consanguinity is not uncommon. Subsequently this may serve to increase the frequency at 
which homozygosity for certain haemoglobin variants occurs, even though these 
homozygous genotypes are considered to be rare in the general population. These may 
have potential implications for any future offspring in which some circumstances may 
result in clinically significant disorders, such as the Hb Malmö case discussed in Section 
4.10.2a. 
 
DNA sequencing proved a useful assay for the detection of a proportion of haemoglobin 
variants that could not be detected or positively identified by HPLC analysis, including 
those HBB variants that tend to co-elute within the Hb A or Hb A2 windows or those HBA 
variants that are so unstable are undetectable at the protein level. 
 
A broad spectrum of mutations were detected within our referral population by DNA 
sequencing, resulting in a wide range of genetic interactions between different alpha and 
beta thalassaemia associated alleles,  reflecting the complex molecular heterogeneity of 
these disorders. 
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A compound heterozygous genotype (i.e. a mutation in both the α and β-globin chains) 
was found in 17% (n=55) of all patient diagnoses made, and included cases where the α:β 
globin chain ratio was imbalanced by their co-inheritance, including cases in which β-
thalassaemia was aggravated by the co-inheritance of triplicated alpha thalassaemia.  In 
contrast, there were cases in which the individual‟s phenotype was ameliorated by the co-
inheritance of deletional alpha thalassaemia, particularly α0 thalassaemia.  
 
Such gene-gene interactions between different alleles often made it difficult to accurately 
interpret patients‟ clinical phenotype, such as in those cases with β-thalassaemia that had 
been masked by co-inheritance with 
0 
thalassaemia, resulting in the normalisation of their 
red cell indices. DNA sequencing in these cases helped to clarify their genotypes, which 
was especially valuable in those antenatal couples where both partners had thalassaemic 
red-cell changes but with normal HbA2 levels.  This was important in order to assess their 
risk of having a child affected with Hb Bart‟s hydrops syndrome.  
 
The frequency and distribution of the haemoglobinopathy mutations detected within our 
referral population, by employing a broad mutation detection approach, was then 
correlated with patients‟ stated ethnicity using previously published mutation frequencies. 
The strength of this correlation varied between the different genotypes: there was a strong 
correlation observed between patients‟ stated ethnicity and those with a deletional form of 
alpha thalassaemia (detected by Gap-PCR) in which a large proportion (82%, n=108) of 
patients had a deletion which would be expected within their ethnic group. This 
correlation was less pronounced in those patients that had a mutation within HBA1 or 
HBA2 (including variant haemoglobins) detected by DNA sequencing, as 53% (n=31) of 
patients in this group had an alpha genotype that would be expected in their ethnic group.  
There was a stronger correlation in those patients that had a non-deletional mutation 
within HBB (including variant haemoglobins) detected by DNA sequencing, in which 66% 
(n=111) of patients had a beta genotype that would be expected within their ethnic group. 
When this group of patients were analysed further, the correlation between patients‟ 
ethnicity and beta genotype found was less pronounced in those with a haemoglobin 
variant genotype than those with a  β-thalassaemia genotype, in which 61% (n=59) and 
73% (n=46) respectively had a mutation which would normally be expected within their 
ethnic group. 
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In conclusion, the results obtained from DNA sequencing of the essential regions of HBA1 
and HBA2 indicates that a “first pass” ethnic led targeted mutation screening strategy may 
miss up to 47% of alpha point mutation genotype cases analysed, whilst a similar ethnic 
led strategy for HBB may miss up to 34% (n=57) of all beta genotype cases analysed. 
This, together with the large spectrum of alpha point mutations detected and the 
significant number of complex alpha and beta genotype interactions found, indicates that a 
comprehensive mutational screening approach, using multiplex Gap-PCR, DNA 
sequencing and MLPA is appropriate to detect the mutation spectrum found within the 
heterogeneous populations of the North-West of England, or in any other ethnically 
diverse populations. 
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Appendices: 
 
Appendix 1: Table of parental carrier state combinations that give rise to the risk of 
a fetus with significant sickle cell disease or β-thalassaemia: 
 
 
Obtained from: NHS SCT screening programme: Handbook for Laboratories September 
2009 (http://sct.screening.nhs.uk). 
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Appendix 2: Testing algorithm for laboratory screening in high prevalence areas: 
 
RF=Report format: (laboratory report formats as recommended by the NHS SCT 
screening programme) 
Obtained from: NHS SCT screening programme: Standards for the linked Antenatal and 
Newborn Screening Programme. Second Edition. October 
201.(http://sct.screening.nhs.uk). 
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Appendix 3: HBB genomic DNA sequence with primer locations. 
 
The forward and reverse primer binding sites are indicated in red, for each of the three 
separate amplification products of HBB (the common N13 tail sequences have not been 
included). Exonic sequences are highlighted in CAPITAL letters and intronic sequences in 
lower case (HBB: NM_000518.4). 
 
HBB Fragment-1 
actcctaagccagtgccagaagagccaaggacaggtaCGGCTGTCATCACTTAGACCTCACCCTGT
GGAGCCACACCCTAGGGTTGGCCAATCTACTCCCAGGAGCAGGGAGGGCAGGAGCCAGGGCTGGGC
ATAAAAGTCAGGGCAGAGCCATCTATTGCTTACATTTGCTTCTGACACAACTGTGTTCACTAGCAA
CCTCAAACAGACACCATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGC
AAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAGgttggtatcaaggttacaagacagg
tttaaggagaccaatagaaactgggcatgtggagacagagaagactcttgggtttctgataggcac
tgactctctctgcctattggtctattttcccacccttagGCTGCTGGTGGTCTACCCTTGGACCCA
GAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTAAGGTGAA
GGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACCTGGACAACCTCAAGGG
CACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGGgt
gagtctatgggacccttgatgttttctttccccttcttttctatggttaagttcatgtcataggaa
ggggagaagtaacagggtacagtttagaatgggaaacagacgaatgattgcatcagtgtggaagtc
tcaggatcgtttt 
 
HBB Fragment-2 
tttctttccccttcttttctatggttaagttcatgtcataggaaggggagaagtaacagggtacag
tttagaatgggaaacagacgaatgattgcatcagtgtggaagtctcaggatcgttttagtttcttt
tatttgctgttcataacaattgttttcttttgtttaattcttgctttctttttttttcttctccgc
aatttttactattatacttaatgccttaacattgtgtataacaaaaggaaatatctctgagataca
ttaagtaacttaaaaaaaaactttacacagtctgcctagtacattactatttggaatatatgtgtg
cttatttgcatattcataatctccctactttattttcttttatttttaattgatacataatcatta
tacatatttatgggttaaagtgtaatgttttaatatgtgtacacatattgaccaaatcagggtaat
tttgcatttgtaattttaaaaaatgctttcttcttttaatatacttttttgtttatcttatttcta
atactttccctaatctctttctttcagggcaataatgatacaatgtatcatgcctctttgcaccat
t 
 
HBB Fragment-3 
tggaatatatgtgtgcttatttgcatattcataatctccctactttattttcttttatttttaatt
gatacataatcattatacatatttatgggttaaagtgtaatgttttaatatgtgtacacatattga
ccaaatcagggtaattttgcatttgtaattttaaaaaatgctttcttcttttaatatacttttttg
tttatcttatttctaatactttccctaatctctttctttcagggcaataatgatacaatgtatcat
gcctctttgcaccattctaaagaataacagtgataatttctgggttaaggcaatagcaatatttct
gcatataaatatttctgcatataaattgtaactgatgtaagaggtttcatattgctaatagcagct
acaatccagctaccattctgcttttattttatggttgggataaggctggattattctgagtccaag
ctaggcccttttgctaatcatgttcatacctcttatcttcctcccacagCTCCTGGGCAACGTGCT
GGTCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGGCTGCCTATCAGAA
AGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTCCA
ATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCC
TTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAAtgatgtatttaaattatt
tctgaatattttactaaaaagggaatgtgggaggtcagtgcatttaaaacataaaga 
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Appendix 4: HBG2 genomic DNA sequence with primer locations. 
 
The forward and reverse primer binding sites are indicated in red for the HGB2 gene 
amplification products (the common N13 tail sequences have not been included). Exonic 
sequences are highlighted in CAPITAL letters and intronic sequences in lower case 
(HBG2: NM_000184.2). 
 
HBG Fragment 
 
cagccagcacatacacttatccagtgataaatacacatcatcgggtgcctacatacatacctgaat
ataaaaaaaatacttttgctgagatgaaacaggcgtgatttatttcaaataggtacggataagtag
atattgaagtaaggattcagtcttatattatattacataacattaatctattcctgcactgaaact
gttgctttataggatttttcactacactaatgagaacttaagagataatggcctaaaaccacagag
agtatattcaaagataagtatagcacttcttatttggaaaccaatgcttactaaatgagactaaga
cgtgtcccatcaaaaatcctggacctatgcctaaaacacatttcacaatccctgaacttttcaaaa
attggtacatgctttaactttaaactacaggcctcactggagctacagacaagaaggtgaaaaacg
gctgacaaaagaagtcctggtatcttctatggtgggagaagaaaactagctaaagggaagaataaa
ttagagaaaaattggaatgactgaatcggaacaaggcaaaggctataaaaaaaattaagcagcagt
atcctcttgggggccccttccccacactatctcaatgcaaatatctgtctgaaacggtccctggct
aaactccacccatgggttggccagccttgccttgaccaatagccttgacaaggcaaacttgaccaa
tagtcttagagtatccagtgaggccaggggccggcggctggctagggatgaagaATAAAAGGAAGC
ACCCTTCAGCAGTTCCACACACTCGCTTCTGGAACGTCTGAGGTTATCAATAAGCTCCTAGTCCAG
ACGCCATGGGTCATTTCACAGAGGAGGACAAGGCTACTATCACAAGCCTGTGGGGCAAGGTGAATG
TGGAAGATGCTGGAGGAGAAACCCTGGGAAGgtaggctctggtgaccaggacaagggagggaagga
aggaccctgtgcctggcaaaagtccaggtcgcttctcaggatttgtggcaccttctgactgtcaaa
ctgttcttgtcaatctcacagGCTCCTGGTTGTCTACCCATGGACCCAGAGGTTCTTTGACAGCTT
TGGCAACCTGTCCTCTGCCTCTGCCATCATGGGCAACCCCAAAGTCAAGGCACATGGCAAGAAGGT
GCTGACTTCCTTGGGAGATGCCATAAAGCACCTGGATGATCTCAAGGGCACCTTTGCCCAGCTGAG
TGAACTGCACTGTGACAAGCTGCATGTGGATCCTGAGAACTTCAAGgtgagtccaggagatg 
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Appendix 5: HBA1 and HBA2 genomic DNA sequence with primer locations 
 
The forward and reverse primer binding sites are indicated in red, for each of the HBA1 
and HBA2 gene amplification products (the common N13 tail sequences have not been 
included). Exonic sequences are highlighted in CAPITAL letters and intronic sequences in 
lower case (HBA1: NM_000558.3 and HBA2: NM_000517.4.HBA1). 
 
gtggagggtggagacgtcctggcccccgccccgcgtgcacccccaggggaggccgagcccgccgcc
cggccccgcgcaggccccgcccgggactcccctgcggtccaggccgcgccccgggctccgcgccag
ccaatgagcgccgcccggccgggcgtgcccccgcgccccaagcataaaccctggcgcgctcgcggc
ccggcACTCTTCTGGTCCCCACAGACTCAGAGAGAACCCACCATGGTGCTGTCTCCTGCCGACAAG
ACCAACGTCAAGGCCGCCTGGGGTAAGGTCGGCGCGCACGCTGGCGAGTATGGTGCGGAGGCCCTG
GAGAGgtgaggctccctcccctgctccgacccgggctcctcgcccgcccggacccacaggccaccc
tcaaccgtcctggccccggacccaaaccccacccctcactctgcttctccccgcagGATGTTCCTG
TCCTTCCCCACCACCAAGACCTACTTCCCGCACTTCGACCTGAGCCACGGCTCTGCCCAGGTTAAG
GGCCACGGCAAGAAGGTGGCCGACGCGCTGACCAACGCCGTGGCGCACGTGGACGACATGCCCAAC
GCGCTGTCCGCCCTGAGCGACCTGCACGCGCACAAGCTTCGGGTGGACCCGGTCAACTTCAAGgtg
agcggcgggccgggagcgatctgggtcgaggggcgagatggcgccttcctcgcagggcagaggatc
acgcgggttgcgggaggtgtagcgcaggcggcggctgcgggcctgggccctcggccccactgaccc
tcttctctgcacagCTCCTAAGCCACTGCCTGCTGGTGACCCTGGCCGCCCACCTCCCCGCCGAGT
TCACCCCTGCGGTGCACGCCTCCCTGGACAAGTTCCTGGCTTCTGTGAGCACCGTGCTGACCTCCA
AATACCGTTAAGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCC
TCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCAgcctgtgtgt
gcctgagttttttccctcagcaaacgtgccaggcatgggcgtggacagcagctgggacacacatgg
ctagaacctctc 
 
HBA2 
gtggagggtggagacgtcctggcccccgccccgcgtgcacccccaggggaggccgagcccgccgcc
cggccccgcgcaggccccgcccgggactcccctgcggtccaggccgcgccccgggctccgcgccag
ccaatgagcgccgcccggccgggcgtgcccccgcgccccaagCATAAACCCTGGCGCGCTCGCGGG
CCGGCACTCTTCTGGTCCCCACAGACTCAGAGAGAACCCACCATGGTGCTGTCTCCTGCCGACAAG
ACCAACGTCAAGGCCGCCTGGGGTAAGGTCGGCGCGCACGCTGGCGAGTATGGTGCGGAGGCCCTG
GAGAGgtgaggctccctcccctgctccgacccgggctcctcgcccgcccggacccacaggccaccc
tcaaccgtcctggccccggacccaaaccccacccctcactctgcttctccccgcagGATGTTCCTG
TCCTTCCCCACCACCAAGACCTACTTCCCGCACTTCGACCTGAGCCACGGCTCTGCCCAGGTTAAG
GGCCACGGCAAGAAGGTGGCCGACGCGCTGACCAACGCCGTGGCGCACGTGGACGACATGCCCAAC
GCGCTGTCCGCCCTGAGCGACCTGCACGCGCACAAGCTTCGGGTGGACCCGGTCAACTTCAAGgtg
agcggcgggccgggagcgatctgggtcgaggggcgagatggcgccttcctctcagggcagaggatc
acgcgggttgcgggaggtgtagcgcaggcggcggctgcgggcctgggccgcactgaccctcttctc
tgcacagCTCCTAAGCCACTGCCTGCTGGTGACCCTGGCCGCCCACCTCCCCGCCGAGTTCACCCC
TGCGGTGCACGCCTCCCTGGACAAGTTCCTGGCTTCTGTGAGCACCGTGCTGACCTCCAAATACCG
TTAAGCTGGAGCCTCGGTAGCCGTTCCTCCTGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCCTC
CTTGCACCGGCCCTTCCTGGTCTTTGAATAAAGTCTGAGTGGGCAGCAgcctgtgtgtgcctgggt
tctctctatcccggaatgtgccaacaatgg 
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Appendix 6: Details of SALSA MLPA P140-B2 HBA probemix, with their 
corresponding chromosomal positions: 
 
 
* The 339 nt probe is not entirely specific and will be replaced in the future. Samples that are homozygous 
for the alpha-3.7 deletion do not give any signal for 8 out of 9 probes that are deleted. The 339 nt probe 
however does give a (reduced) signal on such samples. 
† The 142 & 166 nt probes detect both HBA1 and HBA2. 
¥ SNP rs35557 could influence the probe signal of the 220 nt probe. In case of apparent deletions, it is 
recommended to sequence the region targeted by this probe. Population frequency is not known. 
± SNP rs2362746 influences the 160 nt probe signal. This probe is located at a 1 nt difference between the 
HBA1 and HBA2 intron sequence. We recommend ignoring apparent deletions of only this probe. 
 
(Description version 22; 24/12/2011. Obtained from MRC-Holland: www.mlpa.com). 
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Appendix 7: Details of SALSA MLPA P102-B1 HBB probemix, with their 
corresponding chromosomal positions: 
 
 
* New in version B1 (from lot 0508 onwards) 
§ The 214 nt probe will only give a signal when the sickle cell-specific point mutation (rs334) is present. 
° The 166 nt and 399 nt probes have been reported to be variable. 
† Please disregard apparent copy number changes detected only by the 436 HBG2 exon 3 probe. In the 
sequence detected by this probe (17 nt after the stop codon), there is only a single nucleotide difference 
between the HBG1 and HBG2 gene. Due to their close proximity (5 kb), it is likely that the HBG2 sequence 
at this position in some healthy individuals is changed in a HBG1 sequence (and vice versa) due to gene 
conversion, without any consequences. 
(Description version 14; 24/08/2011. Obtained from MRC-Holland: www.mlpa.com) 
Appendix 8: Raw table of all patient information and mutational data 
PATIENT INFORMATION DNA MUTATION DATA  
Patient 
M
/F 
Ethnicity 
Clinical reason for 
referral  
α-
multiple 
Gap-PCR  
HBB Sequencing 
HBA1/HBA2 
Sequencing 
Xmn 
External DNA 
analysis 
MDC 
Further 
Analysis 
1 M Any other Beta thal ?severity αα/ααα Cd 8/9 (+G) No mutation       
2 F Any Other: Chilean Abnomal variant -IVF αα/αα Hb Hofu No mutation       
3 F ARABIC: A/O Oman ? Alpha zero α
-3.7
/α
-3.7
 No mutation n/a       
4 M ARABIC: A/O Oman ? Alpha zero α
-3.7
/α
-3.7
 No mutation n/a       
5 F ARABIC: Iranian ?Alpha/HbH αα/ααα Cd5 (del CT) (Het) No mutation Het -158     
6 
F ARABIC: Iranian 
?HbH. HbF=9.2. ↑ for 
age 
αα/ααα Cd5 (del CT) (Het) No mutation Het -158     
7 M ARABIC: Iranian ?alpha α
-3.7
/α
-4.2
 No mutation n/a       
8 
M ARABIC: Iranian 
?silent α-thal trait. HbA2 
1.9 
αα/αα No mutation No mutation       
9 M ARABIC: Iranian ? Alpha thal αα/α
-3.7 
 No mutation No mutation       
10 M ARABIC: Iraq Beta thal major αα/αα Cd8 (del AA:Homo)  No mutation       
11 F ARABIC: Iraq Unknown variant 19.9% αα/αα No mutation Hb Q-Iran       
12 M ARABIC: Iraq ?alpha thal αα/αα No mutation No mutation       
13 
M ARABIC: Kurdish Alpha thal (non-del) 
--MED/α
-
3.7
  
No mutation n/a       
14 M ARABIC: Kurdish Hb variant 16.5% αα/αα No mutation Hb Setif       
15 
F ARABIC: Kurdish 
IVF-α chain variant ? G-
Pest 
αα/αα No mutation Hb Kudistan        
16 
F 
ARABIC: Other 
(Middle Eastern) 
↑HbA2. Norm indicies αα/αα No mutation 
Cd146 (3'UTR 
G>A) 
Poly-
369,309 
    
17 
F 
ARABIC: Other (Saudi 
Arabia) 
Unknown variant 13.9% αα/αα  No mutation Hb Dunn       
18 M ASIAN Beta thal ?β° or β+ αα/αα IVS1-5 (G-C) n/a Het -158     
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19 
M ASIAN 
?δβ thal.HbA2=4.4% 
HbF=18.5% 
αα/α
-3.7 
 Minus 88 (C-T) No mutation Het-158     
20 F ASIAN HbA2 4% ?mild beta αα/αα CAP+1 (A-C) No mutation       
21 F ASIAN ?HbE abnormal variant αα/αα Hb D-Iran No mutation       
22 M ASIAN HbDD/HbDβ thal α
-3.7
/α
-3.7 
 Hb D-Punjab (Homo)  n/a       
23 F ASIAN HbEE/HbE/B-thal αα/αα  HbEE No mutation       
24 M ASIAN ?βthal major(trace HbA) αα/αα IVS1-5 (G>C) Homo n/a       
25 F ASIAN Beta thal ?β° or β+ αα/αα IVS1-5 (G-C) n/a       
26 F ASIAN ?Alpha or δβ thal αα/αα No mutation No mutation       
27 M ASIAN Alpha thal αα/αα  No mutation No mutation       
28 F ASIAN  HbEE/E Beta thal n/a HbEE n/a       
29 
F ASIAN: Any Other ?alpha thal αα/αα No mutation 
IVS1donor.det 
5nts(TGAGG) 
      
30 
M ASIAN: Any Other 
A-typical thal M.I raised 
HbF 
αα/αα  No mutation No mutation   Normal/εγδβ°   
31 F ASIAN: Bangladeshi HbE and ?alpha thal αα/αα HbAE No mutation       
32 M ASIAN: Bangladeshi HbEE/E/B--thal αα/αα HbEE n/a       
33 F ASIAN: Bangladeshi ?B-thal at risk couple αα/αα  IVS1-5 (G-C) No mutation       
34 M ASIAN: Bangladeshi ?Hb Lepore. ANC couple αα/αα  No mutation No mutation   Hb Lepore Hb Lepore 
35 F ASIAN: Indian HbAS ?alpha αα/αα HbAS n/a Het -158     
36 F ASIAN: Indian ?HbAS ?alpha αα/αα HbAS No mutation Het -158     
37 M ASIAN: Indian F/Sonly ?HbS/b-thal αα/αα HbAS and Cd8/9 (+G) n/a Het -158     
38 F ASIAN: Indian F/Sonly ?HbS/b-thal αα/αα HbAS and Cd8/9 (+G) n/a Het -158     
39 
M ASIAN: Indian ?Beta thal major αα/αα IVS1-5 (G-C) (Homo) Cd19 (del G) 
Homo-
158  
    
40 F ASIAN: Indian ?Beta  αα/αα CAP+1 (A-C) No mutation       
41 F ASIAN: Indian BTT-PND failed αα/αα Cd 39 (C-T) No mutation       
42 M ASIAN: Indian BTT-PND failed αα/αα Cd 39 (C-T) No mutation       
43 F ASIAN: Indian Known β-thal.α-genetics αα/αα  Cd 39 (C-T) No mutation       
44 F ASIAN: Indian ?Hb Manitoba αα/αα  No mutation Hb Manitoba II       
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45 M ASIAN: Indian ?Beta thal couple αα/αα Cd 41/42 (-TTCT) No mutation       
46 M ASIAN: Indian ?B
+
/
o
thal (Partner HbD) αα/αα Cd 5 (del CT) No mutation       
47 F ASIAN: Indian ?Beta thal couple αα/αα Cd 8/9 (+G) No mutation       
48 M ASIAN: Indian ?Beta thal trait αα/αα Cd 8/9 (+G) No mutation       
49 M ASIAN: Indian Beta thal. + or 0 αα/αα  Cd 8/9 (+G) No mutation       
50 M ASIAN: Indian ? Alpha+ αα/α
-3.7
 n/a n/a        
51 M ASIAN: Indian Beta thal HbA2=5% αα/α
-3.7 
 IVS1-5 (G-C) No mutation       
52 F ASIAN: Indian Hb Manitoba αα/αα No mutation Hb Manitoba II       
53 F ASIAN: Indian 
?Hb variant 24.6%.Hb Q-
India αα/α
-3.7 
 
No mutation 
Hb Q-India 
      
54 
F ASIAN: Indian IVF-variant 17.9% Q-India αα/αα No mutation Hb Q-India       
55 F ASIAN: Indian ?Variant. 17% αα/αα No mutation Hb Q-India       
56 F Asian: Indian ?δβ/HPFH. HbF19.2% M.I αα/αα No mutation n/a   Indian 32kb   
57 
F ASIAN: Indian Beta ?Alpha αα/αα No mutation n/a   Indian 619bp del 
Not 
detected 
58 F ASIAN: Indian Hb variant HbA2 peak αα/αα No mutation No mutation       
59 F ASIAN: Indian ?HPFH HbF 28% αα/αα No mutation No mutation   HPFH-3 HPFH-3 
60 
F 
ASIAN:Indian (Sri-
Lanka)  
Indeterminate HbA2  αα/αα CAP+1 (A-C) No mutation       
61 F 
ASIAN:Indian (Sri-
Lanka)  
?Hb variant. ?Shape of A 
peak αα/αα Hb Alperton 
No mutation       
62 
M 
ASIAN:Indian (Sri-
Lanka)  
? Alpha α
-3.7
/α
-3.7
 No mutation n/a       
63 
F ASIAN: Other 
?thal intermedia HbH 
bodies  
αα/αα HbAE and Hb Monroe  No mutation 
Homo-
158 
    
64 F ASIAN: Other HbSS or S/βthal.Multi Tx αα/αα HbAS/IVS1-110 (G-A) No mutation       
65 F ASIAN: Other (Afgan) Hb D/G variant αα/αα  Hb D-Punjab No mutation       
66 M ASIAN: Other (Afgan) Hb D/G variant αα/αα  Hb D-Punjab No mutation       
67 
M ASIAN: Other (Afgan) Hb variant (shoulder pk) αα/αα  No mutation 
Santa 
Barnabas 
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68 F ASIAN: Pakistan ?b-thal intermedia αα/αα Cd 8/9 (+G) No mutation       
69 F ASIAN: Pakistan β-thal inter.(HbF 59%) αα/αα Minus 88 (C-T) Homo No mutation       
70 
F ASIAN: Pakistani 
HbSS/HbS/Beta thal or 
HPFH 
αα/αα  HbSS No mutation 
Homo-
158 
    
71 M 
ASIAN: Pakistani 
No  HbA. 100% HbF αα/α
-3.7 
 IVS2-1 (G>A) (Homo) 
No mutation 
Homo-
158  
    
72 F ASIAN: Pakistani β-thal.rpt sample αα/αα CAP+1 (A-C) No mutation       
73 F ASIAN: Pakistani B-thal trait α
-3.7
/α
-3.7 
 CAP+1 (A-C)  n/a       
74 F ASIAN: Pakistani b-thal trait αα/αα Cd 41/42 (-TTCT) n/a       
75 M ASIAN: Pakistani B-Thal αα/αα Cd 41/42 (-TTCT) n/a       
76 M ASIAN: Pakistani ?Beta thal/ααα αα/ααα Cd 8/9 (+G) n/a       
77 F ASIAN: Pakistani Beta thal/intermedia αα/αα Cd 8/9 (+G) No mutation       
78 M ASIAN: Pakistani Beta thal αα/αα Cd 8/9 (+G) No mutation       
79 F ASIAN: Pakistani B-thal intermedia αα/αα  Cd 8/9 (+G) No mutation       
80 F ASIAN: Pakistani Hb variant 54.7% αα/α
-3.7
 Hb Camden No mutation       
81 
F ASIAN: Pakistani HbDD/HbD/Bthal αα/αα 
Hb D-Punjab/IVS1-
5G>C 
No mutation       
82 F ASIAN: Pakistani Hb variant (39.4%) αα/α
-3.7 
 Hb D-Iran n/a       
83 F ASIAN: Pakistani Hb variant ?D Iran αα/αα Hb D-Iran No mutation       
84 M ASIAN: Pakistani ?Hb D trait αα/α
-3.7
 Hb D-Punjab IVS2-55 poly       
85 F ASIAN: Pakistani ?HbE trait. 24% αα/αα Hb D-Punjab No mutation       
86 F ASIAN: Pakistani Hb D/G ?D disease α
-3.7
/α
-3.7 
 Hb D-Punjab (Homo) n/a       
87 
F ASIAN: Pakistani HbDD/HbDβ thal αα/αα 
Hb D-Punjab/Cd15 
G>A 
Poly A (del AA)        
88 M ASIAN: Pakistani Hb J variant αα/α
-3.7
 Hb Malmo No mutation       
89 F ASIAN: Pakistani Hb J variant αα/αα Hb Malmo No mutation       
90 
M ASIAN: Pakistani 
variant 46.7% parents Hb 
Malmo 
αα/αα Hb Malmo No mutation       
91 
M ASIAN: Pakistani 
variant 45.9% parents Hb 
Malmo 
αα/α
-3.7 
 Hb Malmo IVS2-55 poly       
92 F ASIAN: Pakistani ?B-thal αα/α
-3.7
 Hb Monroe -42 poly n/a        
177 
 
93 M ASIAN: Pakistani ANC partner.?B-thal αα/-α
4.2
  Hb Monroe -42 poly n/a        
94 
F ASIAN: Pakistani 
? Non-deletional alpha 
thal 
αα/αα Normal n/a    
No mutation: 
Normal HbF/A2. 
Unlikely B-thal  
  
95 F ASIAN: Pakistani ?thal intermedia/major αα/αα Minus 88 (C-T) Homo IVS1-117 (G-A)       
96 
F ASIAN: Pakistani 
?thal intermedia/major 
(Tx) 
αα/αα Minus 88 (C-T) Homo No mutation       
97 F ASIAN: Pakistani ?Hb J variant (19.5%) αα/αα No mutation Hb J-Meerut       
98 M ASIAN: Pakistani B-thal trait ? Normal αα/αα No mutation n/a       
99 
F ASIAN: Pakistani 
HbF 5.4% (husband 
βtrait) 
αα/αα No mutation n/a   
Non-del HPFH 
unidentified 
  
100 F ASIAN: Pakistani ?Alpha thal/Fe def  αα/α
-3.7 
 No mutation No mutation       
101 F ASIAN: Pakistani ?alpha thal αα/α
-3.7 
 No mutation No mutation       
102 
F ASIAN: Pakistani Hb variant 14.4% αα/αα No mutation 
Hb 
Fontainebleau 
      
103 F ASIAN: Pakistani Indeterminate HbA2 αα/αα No mutation No mutation       
104 F BLACK: African Raised HbF α
-3.7
/α
-3.7
 Minus 88 (C-T) n/a Het -158     
105 
M BLACK: African ANC HbAS αα/αα HbAS n/a 
Het 6nt 
del 
    
106 
M BLACK: African ?HbS/HPFH αα/αα HbSS No mutation 
Poly:-
369,309.
-158 
    
107 M BLACK: African HbC.?SAT/δβthal αα/α
-3.7 
 HbCC No mutation Poly-309 HPFH 1 or 2 HPFH.2  
108 
M BLACK: African 
HbA2 variant 
1.9%.HbF1.7% 
α
-3.7
/α
-3.7
 Minus 29 (A-G) n/a 
Het-
309/-
378(C>T) 
Prob chain 
variant 
  
109 
M BLACK: African ANC HbAS α
-3.7
/α
-3.7
 HbAS n/a 
Het-369+ 
Homo-
309 
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110 
F BLACK: African ANC HbAS=33.5% αα/α
-3.7
 HbAS n/a 
hom 6nt 
del-307 
A-G 
    
111 
F BLACK: African ?HbS/HPFH/δβ αα/α
-3.7 
 HbSS (?Hemi) No mutation 
Homo 
poly-
309+-
369.  
HbS/α
3.7
HPFH/δ
β deletion un-i.d 
  
112 
M BLACK: African HBAS/Beta thal αα/αα Hb AS/Minus 88 (C-T) No mutation 
Homo-
309 
    
113 
M BLACK: African 
?HbS/HPFH/δβ 
HbS47%.HbF21.7% 
αα/α
-3.7 
 HbAS No mutation 
Minus 
202(C>G) 
HPFH 
    
114 
F BLACK: African ANC HbAS αα/αα HbAS n/a 
Minus 
369 and -
309 
    
115 F BLACK: African ?βthal trait/intermedia αα/αα Cd 39 (C-T) No mutation       
116 F BLACK: African IVF-Unknown Hb 49.8% αα/αα Hb Camden No mutation       
117 
F BLACK: African 
Abnormal Hb:fast band 
40% 
αα/αα Hb J-Guantanamo No mutation       
118 
F BLACK: African ?Hb Stanleyville αα/αα n/a 
Hb 
Stanleyville-II 
      
119 M BLACK: African ANC HbAS-M.I α
-3.7
/α
-3.7
 HbAS n/a        
120 F BLACK: African HbAS and ?alpha αα/α
-3.7
 HbAS n/a       
121 F BLACK: African ANC.HbAS αα/α
-3.7
 HbAS n/a        
122 F BLACK: African ANC.HbAS αα/α
-3.7
 HbAS n/a        
123 
F BLACK: African ? Hb Variant ?G-Phil αα/αα Normal 
Hb 
Stanleyville-II 
      
124 M BLACK: African HbAS n/a HbAS Homo +832       
125 F BLACK: African HbAS n/a HbAS n/a       
126 M BLACK: African HbAS n/a HbAS n/a       
127 M BLACK: African ANC.HbAS αα/α
-3.7
 HbAS n/a        
128 F BLACK: African HbAS/Alpha αα/α
-3.7
 HbAS No mutation       
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129 F BLACK: African ?HbS/G-Philadelphia αα/α
-3.7 
 HbAS G-Philadelphia       
130 F BLACK: African HbS/HbS/G-Phil αα/α
-3.7 
 HbAS G-Philadelphia       
131 F BLACK: African HbAS at risk couple αα/αα HbAS n/a       
132 M BLACK: African HbAS at risk couple αα/αα HbAS n/a        
133 F BLACK: African HbAS-at risk couple αα/αα HbAS n/a        
134 M BLACK: African HbAS-at risk couple αα/αα HbAS n/a        
135 
F BLACK: African 
HbAS with severe pain 
crisis?α-variant 
αα/α
-3.7 
 HbAS No mutation       
136 
M BLACK: African 
HbAS. Multiple 
Tx.HbS=7% 
αα/αα HbAS IVS1-5 (G-A)       
137 
M BLACK: African Variant@HbA2/Alpha αα/α
-3.7
 HbAS/Minus 83poly 
Fort 
Worth:Homo 
      
138 M 
BLACK: African 
HbAS+?α-thal/Fe def αα/αα 
HbAS/ Hb City of 
Hope 
No mutation       
139 M BLACK: African ?Sickle/beta thal αα/αα HbSS IVS2-55 poly       
140 F BLACK: African Beta thal/intermedia αα/α
-3.7 
 Int Codon (A-G) IVS2-55 poly       
141 F BLACK: African abnormal variant αα/αα No mutation Hb Buffalo       
142 M BLACK: African Hb D/G. 42.2% α
-3.7
/α
-3.7 
 No mutation G-Philadelphia       
143 M BLACK: African Hb variant. ?Hb D/G α
-3.7
/α
-3.7 
 No mutation G-Philadelphia       
144 F BLACK: African Hb variant (HbA2 19.3%) αα/αα No mutation Hb Toulon       
145 
M BLACK: African Variant@HbA2/Alpha αα/αα  Minus 83poly (G-A) 
Fort 
Worth:Homo 
      
146 M BLACK: African ?α-zero partner of above α
-3.7
/α
-3.7
 No mutation n/a       
147 F BLACK: African Abnormal variant 21.6% αα/αα n/a Hb Matsue-Oki       
148 
F BLACK: African Hb variant:23.6% ?α-thal αα/αα No mutation 
Hb Stanleyville 
II 
      
149 
F BLACK: African 
?α not at risk-not sent 
Oxford 
α
-3.7
/α
-3.7
 No mutation n/a       
150 M BLACK: African ?Unstable Hb variant αα/α
-3.7 
 No mutation No mutation       
151 
F BLACK: African HPFH/δβ αα/αα No mutation No mutation   
δβ trait rare 
novel del 
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152 
F 
BLACK:Afro-
Caribbean 
?alpha α
-3.7
/α
-3.7 
 No mutation n/a       
153 
M 
BLACK:Afro-
Caribbean 
?HbS/Beta thal αα/αα  HbAS/Minus 88 (C-T)  No mutation       
154 
F BLACK: British ?δβ-mother is δβ-trait αα/-α
4.2
  No mutation No mutation 
Het -158, 
-309 (A-
G) 
12Kb Black- β   
155 
F BLACK: British ?δβ-mother is δβ-trait αα/αα No mutation No mutation 
Homo-
158 
12Kb Black- β   
156 M BLACK: British HbAS/?alpha (HbS20%) α
-3.7
/α
-3.7
 HbAS n/a       
157 F BLACK: British Bthal trait αα/αα IVS2-849 (A-G) No mutation       
158 
M BLACK: Caribbean ?C/βthal αα/αα Minus-88 (C-T)/HbAC IVS2-55 poly Het-309     
159 
F BLACK: Caribbean Hb SS, persistent ↑HbF αα/α
-3.7 
 HbAS No mutation Het-368 
?Form of HPFH 
del 
HPFH.2  
160 F BLACK: Caribbean BTT (partner HbAS) αα/αα  Cd 24 (T-A) No mutation       
161 F BLACK: Caribbean C Beta ? Exisiting thal  αα/αα Hb CC n/a   HPFH 1 or 2 HPFH.2  
162 F BLACK: Caribbean HbS 25% ?Alpha M.I αα/α
-3.7
 HbAS No mutation       
163 F BLACK: Caribbean Mother of X αα/α
-3.7 
 HbSS  No mutation       
164 F BLACK: Caribbean BTT-considering PND αα/α
-3.7 
 Minus 29 No mutation       
165 F BLACK: Caribbean ↑Hb A2. Normal indicies αα/α
-3.7 
 Minus 88 C>T(Homo) No mutation       
166 
F BLACK: Caribbean ?HPFH HbF 11.6% αα/αα No mutation n/a   
Non-del HPFH γ-
gene 
(unidentified) 
No 
mutation 
167 F BLACK: Caribbean Var:14.8% co-elute HbA2 αα/αα  No mutation Spanish Town       
168 M BLACK: Caribbean ?β (M.I HbF 23.1%) αα/αα No mutation No mutation   HPFH-1 or 2 HPFH 2 
169 M BLACK: Carribean ?δβ/HPFH αα/α
-3.7 
 No mutation No mutation Het-158   HPFH.1 
170 F BLACK: Carribean ?HbJ variant 42.7% αα/αα  Hb Alamo No mutation       
171 
M 
MEDITERRANEAN: 
Greek 
ANC-? Beta αα/αα Minus-87 (C>G) No mutation 
Homo-
158 
    
172 F MED: Greek /Turkish ?Alpha thal αα/--MED  No mutation No mutation       
173 M MED: Greek Cypriot Raised HbA2 and F αα/α
-3.7 
 IVS1-110 (G-A) No mutation       
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174 F MED: Other (Bulgaria) ?Hb variant αα/αα No mutation Hb O-Padova       
175 M 
MED: Other 
(Portugal) ?δβ/HPFH (Partner HbAS) αα/αα 
No mutation No mutation     
HPFH.2 
176 F MED: Turkish HbAS+Poly A alpha thal αα/αα HbAS No mutation       
177 F MIXED: Afro/E.U HbD/S and Hb X detected αα/α
-3.7 
 HbAS G-Philadelphia       
178 F MIXED: Asian/E.C HbEE/E Beta thal αα/αα HbEE No mutation       
179 
F 
Mixed: Black 
Caribbean 
β variant ? Osu 
Chistiansborg 
αα/α
-3.7
 Hb Osu Christiansborg n/a        
180 F MIX: British/Pakistani BTT/HPFH αα/αα  Minus 88 (C-T:Homo) n/a       
181 F MIX: British+Pakistan Hb variant 16.2% αα/αα No mutation Hb West One       
182 F MIX: Chinese/Afro ?Alpha and beta αα/--SEA  No mutation No mutation       
183 F MIX: Chinese/British Thal trait. ?Alpha zero αα/--SEA  No mutation No mutation       
184 F MIX: English/Thai Hb A/E and ?α-zero thal αα/--SEA  HbAE No mutation       
185 M MIX: Half Chinese Alpha zero αα/--SEA No mutation n/a       
186 F MIX: Indian/French ?Hb Manitoba αα/αα  No mutation Hb Manitoba II       
187 M MIX: Indian/French ?Hb Manitoba αα/αα  No mutation Hb Manitoba II       
188 
M 
MIX:Middle 
E/Chinese 
?B, partner HbAS/?alpha αα/αα No mutation No mutation       
189 
F MIX: Part chinese 
B-thal. LWH HbA24.1 
(MRI 3.6%) 
αα/αα 
Unknown: Cd133 (G-
C)  
Poly+861 (A-G)       
190 F MIX: UK/Ital/Spanish Unknown variant 45.7% αα/αα Hb Old Dominion No mutation       
191 
F MIX:White/Chinese Hb variant 16.8% ?HbD/G αα/αα  No mutation Hb G-Norfolk       
192 
F NOT STATED 
?Homozygous E (71%) 
(HbF 7%) 
αα/αα HbEE 
Hb 
Fontainebleau 
Het -158     
193 M NOT STATED °/HbH-3 mth follow up αα/--SEA No mutation No mutation Het -158     
194 
F NOT STATED ?b=thal/ Normal red cell αα/αα No mutation Poly+861 (A-G) 
Het-158/ 
-317 
(G>A) 
    
195 
M NOT STATED ?δβ thal (HbF 18%) αα/αα IVS1-5 (G-C) Hb Evanston 
Hetero-
158/ -
408 
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196 F Not Stated ?M haemoglobin αα/αα Minus 56 (G>C) No mutation Het-158     
197 F NOT STATED Hb variant unknown αα/αα n/a Hb Chesapeake       
198 
F NOT STATED ?HPFH/Beta  αα/α
-3.7 
 
CAP+1 (A-C)/IVS1-5 
(G-C) 
No mutation       
199 F NOT STATED Hb variant unknown αα/αα n/a Hb J-Meerut       
200 F NOT STATED ?Abnormal Hb (37.2%) αα/αα Hb D-Iran No mutation       
201 F NOT STATED ?Hb D-Iran αα/αα Hb D-Iran No mutation       
202 M NOT STATED ?Alpha thal αα/--FIL n/a n/a       
203 F NOT STATED Abnormal Variant αα/αα Hb K-Woolwich No mutation       
204 F Not Stated ?Hb variant  24.8% αα/αα Hb Leiden n/a       
205 M Not Stated ?Hb Olympia αα/αα Hb Olympia n/a       
206 F NOT STATED Abnormal Variant 50% αα/αα Hb Pyrgos No mutation       
207 
M NOT STATED 
Hb variant ?flat A pk 
guthrie 
αα/αα  Hb Tyne No mutation       
208 F NOT STATED Hb variant :27% α
-3.7
/α
-3.7
 HbAE n/a       
209 
F NOT STATED 
Hb S only on 
HLPC(69.4%).HbF 20.0% 
α
-3.7
/α
-3.7 
 HbAS/IVS1-5 (G-C) n/a       
210 F NOT STATED HbE/β Thal αα/αα HbEE n/a       
211 F NOT STATED HbEE/Eβ-thal αα/αα HbEE  n/a        
212 F  NOT STATED HbF 14.2% α
-3.7
/α
-3.7 
 IVS1-5 (G-C) n/a       
213 M NOT STATED ?beta thalassaemia αα/αα IVS2-1 (G-A) n/a       
214 
F NOT STATED 
Hb variant. No 
HbA2.?Manitoba 
αα/αα n/a 
Hb Manitoba 
(I) 
      
215 F NOT STATED ? Alpha αα/α
-3.7
 No mutation n/a       
216 M NOT STATED ?alpha. Persis. low MCV αα/α
-3.7
 No mutation No mutation       
217 
M NOT STATED 
Nomal (not sent) ANC 
partner 
αα/αα No mutation No mutation       
218 M NOT STATED ? Alpha    αα/αα No mutation No mutation       
219 
M NOT STATED 
?Pyruvate def.?Unstable 
variant 
αα/αα No mutation Poly+861 (A-G)       
220 F NOT STATED ?HbA2 variant. M.I αα/α
-3.7 
 No mutation Hb Seal Rock       
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221 
M NOT STATED Raised HbA2+HbF αα/αα  No mutation No mutation   
Afghan 909bp β° 
del 
  
222 M NOT STATED alpha thal α
-3.7
/α
-3.7 
 No mutation n/a       
223 M NOT STATED HbA2 1.8% αα/α
-3.7 
 No mutation No mutation       
224 F SEA ?HbEE (96.3%E) αα/α
-3.7
 HbEE No mutation       
225 F SEA Abnormal variant 19.7% αα/αα No mutation Hb Q-India       
226 F SEA ?Alpha αα/αα No mutation No mutation       
227 M SEA ?alpha zero αα/αα No mutation Hb Quong Sze       
228 M SEA: Chinese ?alpha zero αα/--SEA No mutation No mutation Het -158     
229 F SEA: Chinese Beta thal carrier αα/αα Cd 41/42 (-TTCT) n/a        
230 M SEA: Chinese ?Beta/underlying alpha αα/αα Cd 41/42 (-TTCT) No mutation       
231 F SEA: Chinese Beta thal αα/αα Cd 41/42 (-TTCT) No mutation       
232 F SEA: Chinese HbH disease --SEA/
-4.2
 n/a n/a       
233 F SEA: Chinese Alpha zero αα/--SEA n/a n/a       
234 F SEA: Chinese ?Alpha zero αα/--SEA  n/a n/a       
235 F SEA: Chinese Hb variant (43.5%) αα/αα Hb J-Bangkok n/a       
236 M SEA: Chinese βthal (rule out  α-thal) αα/αα IVS2-654 (C-T) No mutation       
237 F SEA: Chinese βthal (rule out  α-thal) αα/αα  IVS2-654 (C-T) No mutation       
238 F SEA: Chinese βthal/ thal αα/αα IVS2-654 (C-T) No mutation       
239 F SEA: Chinese ?Hb variant  30.8% αα/-α
4.2
  No mutation Hb Q-Thailand       
240 
F SEA: Chinese 
?Hb variant Q-
Thailand:30% 
αα/-α
4.2
  No mutation Hb Q-Thailand       
241 M SEA: Chinese ?Hb variant: HbG αα/αα No mutation Hb Ube-4       
242 M SEA: Chinese ?Alpha   αα/--SEA n/a No mutation       
243 M SEA: Chinese ?alpha thal αα/--SEA  n/a No mutation       
244 F SEA: Chinese ?alpha zero carrier αα/--SEA  n/a No mutation       
245 M SEA: Chinese ?Alpha thal αα/--SEA  n/a No mutation       
246 F SEA: Chinese ?Alpha at risk couple αα/-α
4.2
  n/a No mutation       
247 
M SEA: Chinese ?HPFH ?ANC couple αα/αα No mutation n/a   Chinese-δβ°  
Chinese-
δβ° 
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248 F SEA: Chinese HbH disease --SEA/
-3.7
 No mutation n/a       
249 F SEA: Chinese ?alpha zero/Hb variant αα/--SEA No mutation No mutation       
250 M SEA: Chinese Alpha thal (Son HbH) αα/--SEA No mutation No mutation       
251 M SEA: Chinese ?Alpha (Father) αα/--SEA  No mutation No mutation       
252 F SEA: Chinese ?alpha (Daughter) αα/--SEA  No mutation No mutation       
253 F SEA: Chinese ?Alpha αα/--SEA  No mutation No mutation       
254 M SEA: Chinese ?Alpha zero thal αα/--SEA  No mutation No mutation       
255 F SEA: Chinese ?Alpha thal (HbA2 2.6%) αα/--SEA  No mutation No mutation       
256 F SEA: Chinese ?Alpha thal αα/--SEA  No mutation No mutation       
257 F SEA: Chinese Conf of alpha zero αα/--SEA  No mutation No mutation       
258 F SEA: Chinese ?Alpha α
-3.7
/α
-4.2
 No mutation n/a       
259 
M SEA: Chinese ?alpha partner of X αα/αα  No mutation 
Constant 
Spring 
      
260 F SEA: Chinese Alpha thal (Son HbH) αα/α
-3.7
 No mutation No mutation       
261 F SEA: Chinese ?Alpha thal αα/α
-3.7 
 No mutation IVS1-55 poly       
262 
M SEA: Chinese ?Hb Variant 29.2% αα/α
-3.7 
 No mutation 
Hb G27G-
Honolulu 
(Homo) 
      
263 F SEA: Chinese Unknown variant 27.3% αα/αα No mutation Hb Linwood       
264 
M SEA: Chinese 
Hb variant 23.5 % (mum 
Hb Linwood) 
αα/αα No mutation Hb Linwood       
265 F SEA: Chinese ?HbH αα/--SEA  No mutation Hb Quong Sze       
266 F SEA: Chinese ?B-thal borderline HbA2 αα/αα  No mutation No mutation       
267 F SEA: Chinese alpha thal αα/--SEA No mutation No mutation       
268 M SEA: Chinese thal αα/--SEA No mutation No mutation       
269 F SEA: Filipino ?Hb variant@42.8% (IVF) αα/αα Hb J-Bangkok No mutation       
270 F SEA: Filipino HbH --SEA/
-3.7
 No mutation n/a       
271 M SEA: Filipino ? Alpha thal αα/--FIL No mutation n/a       
272 M SEA: Filipino ?Alpha (Daughter HbH) αα/--FIL  n/a No mutation       
273 F SEA: Filipino ?Alpha (Daughter HbH) αα/α
-3.7 
 n/a No mutation       
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274 M SEA: Filipino ?alpha zero couple αα/--SEA No mutation No mutation       
275 F SEA: Filipino ?alpha thal αα/--SEA  No mutation No mutation       
276 F SEA: Filipino ?alpha thal α
-3.7
/α
-3.7 
 No mutation n/a       
277 F SEA: Filipino ?alpha zero couple αα/αα  No mutation No mutation   No mutation   
278 F SEA: Indonesian ?Alpha zero αα/--SEA  No mutation No mutation       
279 F SEA: Indonesian miscarriage ?α-zero αα/α
-3.7
 No mutation No mutation       
280 
F SEA: Malaysian ?alpha zero/HbE αα/αα Hb AE  
PolyA: 
AATAA>AATA 
(AA del) 
      
281 M 
SEA: Malaysian 
Beta thal ?underlying α-
thal αα/αα IVS1-5 (G>C) 
No mutation       
282 F SEA: Malaysian ?Alpha zero αα/--SEA  n/a No mutation       
283 M SEA: Malaysian ?Alpha αα/--SEA  No mutation No mutation       
284 F SEA: Malaysian ?Alpha thal αα/αα No mutation No mutation       
285 F 
SEA: Other 
(Mongolia) 
?HPFH HbF 12.9 αα/αα 
No mutation n/a   
Non-del HPFH γ-
gene 
(inidentified) 
No 
mutation 
286 
F SEA: Thai ?EE/Eβ thal and ?αzero α
-3.7
/α
-3.7
 HbEE  n/a 
Het -
158/-
406A-G 
    
287 F SEA: Thai ?HbE (22.6%) αα/--SEA Hb AE  No mutation       
288 F SEA: Thai HbEE αα/αα Hb EE No mutation       
289 
M SEA: Thai ↑HbA2 (ANC partner) αα/αα No mutation 
Constant 
Spring 
      
290 F SEA: Thai Alpha thal αα/--SEA No mutation No mutation       
291 M SEA: Thai ?Alpha thal αα/--SEA  No mutation No mutation       
292 F SEA: Vietnamese ?Alpha zero   αα/--SEA  No mutation No mutation       
293 M WHITE: Caucasian ?alpha aquired/hered. αα/αα No mutation No mutation       
294 F WHITE: English ?Hb Le Lamentin (23.3%) αα/αα n/a Hb Brugg       
295 M WHITE: English B-thal/HPFH (HbF 9.4) αα/αα Cd 39 (C-T) No mutation       
296 M WHITE: English ?Beta thal trait αα/αα Cd 39 (C-T) No mutation       
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297 
F WHITE: English 
?Hb var: 34.8%.Hb 
Bushwick 
αα/αα  Hb Bushwick No mutation       
298 
F WHITE: English 
?Hb var:37.2%.Hb 
Bushwick 
αα/αα  Hb Bushwick No mutation       
299 F WHITE: English ?Hb D-punjab αα/αα Hb D-Punjab n/a       
300 
F WHITE: English 
?Hb D-Punjab 37.6% 
(antenatal) 
αα/αα Hb D-Punjab No mutation       
301 
M WHITE: English 
variant ?Hb Koln 7.5%. 
↑MCV+MCH 
αα/αα Hb Koln No mutation       
302 F WHITE: English Hbvar43.6%.Old Dom αα/αα Hb Old Dominion No mutation       
303 
F WHITE: English ?Hb Osu Christiansborg αα/α
-3.7
 Hb Osu Christiansborg IVS2-55 poly         
304 
M WHITE: English 
?Hb J Oxford. 
PartnerHbAS 
αα/αα Hb South Florida No mutation       
305 F WHITE: English Abnormal variant 8.2% αα/αα  Hb South Florida No mutation       
306 F WHITE: English ?Hb Tyne (as in father) αα/αα Hb Tyne No mutation       
307 M WHITE: English sister has HbH disease  α
-3.7
/--
BRIT
 n/a n/a       
308 M WHITE: English ?beta thal/MDS αα/αα IVS2-654 (C-T)         
309 F WHITE: English ?Hb Le Lamentin (23.6%) αα/αα No mutation Hb Brugg       
310 
M WHITE: English 
?variant LWH-split A pk 
(norm:MRI) 
αα/αα No mutation Hb Riccarton       
311 F WHITE: English mother has HbH disease αα/--BRIT No mutation n/a       
312 F WHITE: English ?alpha thal αα/--BRIT No mutation No mutation       
313 M WHITE: English ?BRIT alpha αα/--BRIT No mutation No mutation       
314 F WHITE: English ?alpha BRIT thal αα/--BRIT No mutation No mutation   αα/--BRIT αα/--BRIT 
315 M WHITE: English ?BRIT Alpha αα/--BRIT No mutation Poly IVS2-55   αα/--BRIT αα/--BRIT 
316 F WHITE: English Alpha thalassaemia αα/αα No mutation Poly+861 (A-G)       
317 
M WHITE: English 
?Alpha-pers. 
↓MCV+MCH 
αα/αα  No mutation No mutation       
318 F WHITE: English ↓MCV unresponsive Fe αα/αα  No mutation No mutation       
319 F WHITE: English ↑HbA2. Norm red cell αα/αα  No mutation No mutation       
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320 M WHITE: English ?alpha thal αα/ααα No mutation No mutation       
321 M WHITE: English ?alpha thal αα/αα +1570 (T>C. 5' Poly A) No mutation       
322 F WHITE: English b-thal αα/αα  Poly A (-AT del) No mutation       
323 
F 
WHITE: English 
(WIGAN) 
?Hydrops, severe alpha αα/αα No mutation Poly+861 (A-G)       
324 M WHITE: European ?delta beta αα/αα No mutation No mutation   No mutation   
325 F WHITE: European ?α-thal/Fe deficiency  αα/αα No mutation Poly+861 (A-G)       
326 F WHITE: Irish ?Hb variant 22.3% αα/αα n/a Hb J-Toronto       
327 
F WHITE: Irish ?Hb variant (18.8%) αα/αα No mutation 
Codon 127 (A-
G) variant 
      
328 F WHITE:N.European ?Hb variant 25.9% αα/αα No mutation No mutation       
 
         
          HBA Sequencing key:   
      n/a denotes neither HBA1 or HBA2 sequencing was performed 
     Black text: denotes changes found within HBA2 
      Red text: denotes changes found within HBA1 
      
n/a: denotes HBA2 not amplififed to due to homo/cmp htz for -α+ deletion  
     
 
